



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
---------------	-------------	----------------------	---------------------

08/170,344 03/30/94 KAST

W D45113TFM

EXAMINER

MINNIFIELD, N

ART UNIT

PAPER NUMBER

13

COOPER & DUNHAM
30 ROCKEFELLER PLAZA
NEW YORK, NY 10112

18N1/0823

AUG 28 1995

1813

DATE MAILED:

08/23/95

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

☐ This application has been examined ☒ Responsive to communication filed on

4-07-95
5-15-95

☐ This application is not responsive to communication filed on

RECEIVED

A shortened statutory period for response to this action is set to expire 3 month(s), 0 days from the date of this letter.
Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

AUG 23 2004

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

- ☐ Notice of References Cited by Examiner, PTO-892.
- ☒ Notice of Draftsman's Patent Drawing Review, PTO-948.
- ☐ Notice of Art Cited by Applicant, PTO-1449.
- ☐ Notice of Informal Patent Application, PTO-152.
- ☐ Information on How to Effect Drawing Changes, PTO-1474.
- ☐

OFFICE OF PETITIONS

Part II SUMMARY OF ACTION

1. ☒ Claims 1-2, 4-22, 24 are pending in the application.

Of the above, claims _____ are withdrawn from consideration.

2. ☒ Claims 3 have been cancelled.

3. ☐ Claims _____ are allowed.

4. ☒ Claims 1-2, 4-22, 24 are rejected.

5. ☐ Claims _____ are objected to.

6. ☐ Claims _____ are subject to restriction or election requirement.

7. ☐ This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes.

8. ☐ Formal drawings are required in response to this Office action.

9. ☐ The corrected or substitute drawings have been received on _____. Under 37 C.F.R. 1.84 these drawings are ☐ acceptable; ☐ not acceptable (see explanation or Notice of Draftsman's Patent Drawing Review, PTO-948).

10. ☐ The proposed additional or substitute sheet(s) of drawings, filed on _____, has (have) been ☐ approved by the examiner; ☐ disapproved by the examiner (see explanation).

11. ☐ The proposed drawing correction, filed _____, has been ☐ approved; ☐ disapproved (see explanation).

12. ☐ Acknowledgement is made of the claim for priority under 35 U.S.C. 119. The certified copy has ☐ been received ☐ not been received ☐ been filed in parent application, serial no. _____; filed on _____.

13. ☐ Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.

14. ☐ Other

EXAMINER'S ACTION

BEST AVAILABLE COPY

Art Unit: 1813

Part III DETAILED ACTION

Response to Amendment

15. Applicants' amendments filed April 17, 1995 and May 14, 1995 are acknowledged and have been entered. Claim 3 has been cancelled. Claims 1, 2, and 16-21 have been amended. Claims 1, 2, 4-22, and 24 are now pending in the present application. All prior rejections are withdrawn with the exception of those discussed below.

16. The text of the 35 U.S.C. Code not included in this Office Action can be found in the prior Office Action.

17. The information disclosure statement filed January 4, 1994 fails to comply with 37 CFR § 1.98(a)(3) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the content of the information, of each patent listed that is not in the English language. It has been placed in the application file, but the information referred to therein has not been considered as to the merits. Applicants state (April 17, 1995) that a substitute IDS will be filed, however it has not been received.

18. The objection to the specification and rejection of claims 1, 2, 4-22, and 24 under 35 U.S.C. § 112, first paragraph (i.e. lack of an enabling disclosure) is maintained. This rejection is maintained for essentially the same reasons as the rejection of claims 1-22 and 24 under this statutory provision, as set forth in paragraphs 17 and 18 of the last Office action. Applicants' arguments filed April 17, 1995 have been fully considered but they are not deemed to be persuasive.

Art Unit: 1813

The specification is objected to under 35 U.S.C. § 112, first paragraph, as failing to provide an adequate written description of the invention and failing to adequately teach how to make and/or use the invention, i.e. failing to provide an enabling disclosure. The disclosure is enabled for nonapeptide sequences from the E6 or E7 genes of HPV16 or HPV18, and MHC Class I molecules as specifically taught in the specification. The specification has not provided sufficient evidence of a method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition. Matlashewski et al. discloses that HPV18 proteins (E6 gene) maybe diagnostically useful since the proteins have been identified in specific human cancers, however the methods as claimed in this invention are not known in the art. Accordingly, amendment of the claims to what is supported in the specification or filing of evidence in the form of a Rule 132 declaration providing factual evidence supporting the broad range claims is suggested.

A disclosure in an application, to be complete, must contain such description and details as to enable any person skilled in the art or science to which it pertains to make and use the invention as of its filing date, In re Glass, 181 USPQ 31; 492 F.2d 1228 (CCPA 1974). While the prior art setting may be mentioned in general terms, the essential novelty, the essence of the invention, must be described in such details, including proportions and techniques where necessary, as to enable those persons skilled in the art to make and utilize the invention.

Specific operative embodiments or examples of the invention must be set forth. Examples and description should be of sufficient scope as to justify the scope of the claims. Where the constitution and formula of a compound is stated only as probability and speculation, the disclosure is not sufficient to support claims identifying the compound by such composition or formula. A disclosure involving a new chemical compound or composition must teach persons skilled in the art how to make the

Art Unit: 1813

compound. Incomplete teachings may not be completed by reference to subsequently filed applications.

The instant specification invites the skilled artisan to experiment. The factor which must be considered in determining undue experimentation are set forth in *Ex parte Forman* 230 USPQ 546. The factors include 1) quantity of experimentation necessary, 2) the amount of guidance presented, 3) the presence or absence of working examples, 4) the nature of the invention, 5) the state of the prior art, 6) the predictability of the art and the 7) breath of the claims. With regard to factors three and six, it is noted that there are no working examples or support for in vivo efficacy of the active ingredients in a method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition, or peptides from any HPV that bind to MHC Class I molecules. Such is not seen as sufficient to support the breath of the claims, wherein the scope of the claims encompasses how to prepare a peptide from any of the listed HPV proteins (or any other HPV protein) wherein the peptide binds to any human MHC Class I molecule. It is noted that Law requires that the disclosure of an application shall inform those skilled in the art how to use applicant's alleged discovery, not how to find out how to use it for themselves., see *In re Gardner et al.* 166 USPQ 138 (CCPA 1970).

Applicants have argued that the specification is enabled and have cited *Ruppert et al.*, *Kast et al.*, *Feltkamp et al.*, *Vitiello et al.*, and *Ressing et al.* as support to demonstrate enablement, however it is noted that the specification must be enabled as of its filing date. Prior art references that were published after Applicants' effective filing date (5-5-92) cannot be used to rebut prima facie case of nonenablement under 35 USC 112. *In re Glass*, 181 USPQ 31; 492 F.2d 1228 (CCPA 1974).

Applicants have argued that it would be unethical to demonstrate HPV treatment in humans, however the Examiner has not suggested such a demonstration. Applicants have not demonstrated treatment of HPV in animal models. With regard

Art Unit: 1813

to the method of prophylactic or therapeutic treatment, it appears that the specification is a paper protocol. The specification does not show any therapy or prophylactic treatment, only in vitro studies; no animal studies using the peptides to demonstrate prophylactic or therapy treatment that would correlate to human efficacy have been set forth in the specification.

Applicants have argued that Kast et al. (1991, PNAS 88:2283-2287 and 1991, Immunol. Letters 30(2):229-232) show that one of skill in the art would readily understand from these references how to make and use the claimed invention. Kast et al. (1991, PNAS) disclose the immunization of synthetic peptides of Sendai virus, not HPV. Further, Kast et al. (1991, Immunol. Letters) does disclose the use of peptide vaccination, however the use of HPV peptides is not discussed. HPV is discussed with regard to using "... cultured human CTL for immunotherapy of virus-induced tumors" (p. 229). Furthermore, the reference discloses that there are several unanswered questions regarding peptide vaccination as a novel immnuotherapeutic or preventive approach in man (summary; p. 230, col. 2).

In response to Applicant's argument that Matlashewski et al. does not include certain features of Applicant's invention, the limitations on which the Applicant relies (i.e., peptides that bind in the groove on top of an MHC Class I molecule) are not stated in the claims. Therefore, it is irrelevant whether the reference includes those features or not.

19. The rejection of claims 1, 2, 4, 7, 8, 11, 13, and 15-23 under 35 U.S.C. § 102(b) as anticipated by, or in the alternative, under 35 U.S.C. § 103 as obvious over Schoolnik et al. is maintained. This rejection is maintained for essentially the same reasons as the rejection of claims 1-22 and 24 under this statutory provision, as set forth in paragraph 24 of the last Office action. Applicants' arguments filed April 17, 1995 have been fully considered but they are not deemed to be persuasive.

Art Unit: 1813

Schoolnik et al. discloses synthetic peptides from HPV that are useful in the diagnosis and therapy of conditions associated with HPV infection (abstract; p. 9, l. 10-18; claims). Schoolnik et al. teaches the preparation of peptides from HPV16 (E6 and E7) or other HPV proteins useful to raise antibodies for diagnostic, protective (i.e. prophylactic), and therapeutic purposes and vaccines, as well as various mode of administration (p. 3, l. 1-39; p. 5, l. 28-50; p. 4, l. 27 to p. 5, l. 24; p. 7, l. 47 to p. 8, l. 8).

It is noted that the claims recite a peptide comprising an amino acid sequence from a protein of E6 or E7 of HPV 16 or HPV 18.

The teachings of Schoolnik et al. anticipates the claimed invention by disclosing a peptide from a HPV protein wherein the peptide binds to a MHC Class I molecule, and a method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition. The compositions and methods disclosed in Schoolnik et al. are believed to inherently possess properties which anticipates the claimed invention or if they are not the same the composition and methods, the HPV peptides (and compositions) and methods of treatment as disclosed by Schoolnik et al. would none the less render the claims obvious because it possesses the components necessary to prepare a peptide from HPV and methods of treatment as claimed in the instant application. Binding of MHC Class I molecules via T-cell activation is an inherent part of the process of generating an immunogenic response in a mammal. Since the Office does not have the facilities for examining and comparing applicants' method for preparation of a HPV peptide and methods of treatment of the prior art, the burden is on applicant to show a novel or unobvious differences between the claimed product and the product of the prior art (i.e., that the peptide, composition, and method of use of the prior art does not possess the same material structural and functional characteristics of the claimed composition and methods of preparation).

Art Unit: 1813

See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

In response to Applicant's argument that Schoolnik et al. does not include certain features of Applicant's invention, the limitations on which the Applicant relies (i.e., peptides have to fit snugly in the groove of HLA Class I molecule; pockets in the groove; specific anchor residues) are not stated in the claims. Therefore, it is irrelevant whether the reference includes those features or not.

It is noted that the use of prior art published after Applicants' effective filing date can not be used rebut rejections.

20. The following new rejection has not been necessitated by the amendment.

21. Claims 5, 6, 8, 10, 12, and 14 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims are indefinite for being in improper Markush format. The Office recommends the use of the phrase "selected from the group consisting of..." with the use of the conjunction "and" rather than "or" in listing the species. See MPEP 706.03(Y).

22. No claims are allowed.

23. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is (703) 305-3394. The examiner can normally be reached on Monday-Thursday from 7:00 AM-4:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christine M. Nucker, can be reached on (703) 308-4028. The fax phone number for this Group is (703) 305-7939.


Serial Number: 08/170344

-8-

Art Unit: 1813

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

N. M. Minnifield
August 21, 1995


HAZEL F. SIDBERRY
PRIMARY EXAMINER
GROUP 1800

FORM PTO-892
(REV. 2-92)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

SERIAL NO.

8/170344

GROUP ART UNIT

1813

ATTACHMENT
TO
PAPER
NUMBER

13

NOTICE OF REFERENCES CITED

APPLICANT(S)

Kast et al.

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
A							
B							
C							
D							
E							
F							
G							
H							
I							
J							
K							

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS	PERTINENT SHTS. DWG.	PP. SPEC.
L									
M									
N									
O									
P									
Q									

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

R	Kast et al. 1991. Immunization efficacy of virus-derived peptide... Immunol. Letters. 30 229-232
S	Kast et al. 1991. Protection against lethal viral infection by... PNAS 88 2283-2287.
T	
U	

EXAMINER

DATE

8/21/95

* A copy of this reference is not being furnished with this office action.
(See Manual of Patent Examining Procedure, section 707.05 (a).)

8170344

NOTICE OF DRAFTSPERSON'S PATENT DRAWING REVIEW

PTO Draftpersons review all originally filed drawings regardless of whether they are designated as formal or informal. Additionally, patent Examiners will review the drawings for compliance with the regulations. Direct telephone inquiries concerning this review to the Drawing Review Branch, 703-305-8404.

The drawings filed (insert date) 3/30/94 are:

A. ☒ not objected to by the Draftsperson under 37 CFR 1.84 or 1.152.

B. ☒ objected to by the Draftsperson under 37 CFR 1.84 or 1.152 as indicated below. The Examiner will require submission of new, corrected drawings when necessary. Corrected drawings must be submitted according to the instructions on the back of this Notice.

1. DRAWINGS. 37 CFR 1.84(a): Acceptable categories of drawings:

Black ink. Color.

☐ Not black solid lines. Fig(s) _____

☐ Color drawings are not acceptable until petition is granted.

2. PHOTOGRAPHS. 37 CFR 1.84(b)

☐ Photographs are not acceptable until petition is granted.

3. GRAPHIC FORMS. 37 CFR 1.84 (d)

☐ Chemical or mathematical formula not labeled as separate figure. Fig(s) _____

☐ Group of waveforms not presented as a single figure, using common vertical axis with time extending along horizontal axis. Fig(s) _____

☐ Individuals waveform not identified with a separate letter designation adjacent to the vertical axis. Fig(s) _____

4. TYPE OF PAPER. 37 CFR 1.84(c)

☐ Paper not flexible, strong, white, smooth, nonshiny, and durable. Sheet(s) _____

☐ Erasures, alterations, overwritings, interlineations, cracks, creases, and folds not allowed. Sheet(s) _____

5. SIZE OF PAPER. 37 CFR 1.84(f): Acceptable paper sizes

21.6 cm. by 35.6 cm. (8 1/2 by 14 inches)

21.6 cm. by 33.1 cm. (8 1/2 by 13 inches)

21.6 cm. by 27.9 cm. (8 1/2 by 11 inches)

21.0 cm. by 29.7 cm. (DIN size A4)

☐ All drawing sheets not the same size. Sheet(s) _____

☐ Drawing sheet not an acceptable size. Sheet(s) _____

6. MARGINS. 37 CFR 1.84(g): Acceptable margins:

Paper size

21.6 cm. X 35.6 cm. (8 1/2 X 14 inches)	21.6 cm. X 33.1 cm. (8 1/2 X 13 inches)	21.6 cm. X 27.9 cm. (8 1/2 X 11 inches)	DIN Size A4
T 5.1 cm. (2")	2.5 cm. (1")	2.5 cm. (1")	2.5 cm.
L .64 cm. (1/4")	.64 cm. (1/4")	.64 cm. (1/4")	2.5 cm.
R .64 cm. (1/4")	.64 cm. (1/4")	.64 cm. (1/4")	1.5 cm.
B .64 cm. (1/4")	.64 cm. (1/4")	.64 cm. (1/4")	1.0 cm.

Margins do not conform to chart above.

Sheet(s) _____

☐ Top (T) ☐ Left (L) ☐ Right (R) ☐ Bottom (B)

7. VIEWS. 37 CFR 1.84(h)

REMINDER: Specification may require revision to correspond to drawing changes.

☐ All views not grouped together. Fig(s) _____

☐ Views connected by projection lines. Fig(s) _____

☐ Views contain center lines. Fig(s) _____

Partial views. 37 CFR 1.84(h)(2)

☐ Separate sheets not linked edge to edge.

☐ View and enlarged view not labeled separately.

☐ Fig(s) _____

☐ Long view relationship between different parts not clear and unambiguous. 37 CFR 1.84(h)(2)(ii)

☐ Fig(s) _____

Sectional views. 37 CFR 1.84(h)(3)

☐ Hatching not indicated for sectional portions of an object.

☐ Fig(s) _____

☐ Hatching of regularly spaced oblique parallel lines not spaced sufficiently. Fig(s) _____

☐ Hatching not at substantial angle to surrounding axes or principal lines. Fig(s) _____

☐ Cross section not drawn same as view with parts in cross section with regularly spaced parallel oblique strokes.

☐ Fig(s) _____

☐ Hatching of juxtaposed different elements not angled in a different way. Fig(s) _____

Alternate position. 37 CFR 1.84(h)(4)

☐ A separate view required for a moved position.

☐ Fig(s) = Descriptive matters dx

Modified forms. 37 CFR 1.84(h)(5)

☐ Modified forms of construction must be shown in separate views. Fig(s) _____

8. ARRANGEMENT OF VIEWS. 37 CFR 1.84(i)

☐ View placed upon another view or within outline of another.

☐ Fig(s) _____

☐ Words do not appear in a horizontal, left-to-right fashion when page is either upright or turned so that the top becomes the right side, except for graphs. Fig(s) _____

9. SCALE. 37 CFR 1.84(k)

☐ Scale not large enough to show mechanism without crowding when drawing is reduced in size to two-thirds in reproduction.

☐ Fig(s) _____

☐ Indication such as "actual size" or "scale 1/2" not permitted.

☐ Fig(s) _____

☐ Elements of same view not in proportion to each other.

☐ Fig(s) _____

10. CHARACTER OF LINES, NUMBERS, & LETTERS. 37 CFR 1.84(l)

☐ Lines, numbers & letters not uniformly thick and well defined.

☐ clean, durable, and black (except for color drawings).

☐ Fig(s) _____

11. SHADING. 37 CFR 1.84(m)

☐ Shading used for other than shape of spherical, cylindrical, and conical elements of an object, or for flat parts.

☐ Fig(s) _____

☐ Solid black shading areas not permitted. Fig(s) _____

12. NUMBERS, LETTERS, & REFERENCE CHARACTERS. 37 CFR 1.84(p)

☒ Numbers and reference characters not plain and legible. 37 CFR 1.84(p)(1) Fig(s) 1-2

☐ Numbers and reference characters used in conjunction with brackets, inverted commas, or enclosed within outlines. 37 CFR 1.84(p)(1) Fig(s) _____

☐ Numbers and reference characters not oriented in same direction as the view. 37 CFR 1.84(p)(1) Fig(s) _____

☐ English alphabet not used. 37 CFR 1.84(p)(2)

☐ Fig(s) _____

☐ Numbers, letters, and reference characters do not measure at least .32 cm. (1/8 inch) in height. 37 CFR(p)(3)

☐ Fig(s) _____

13. LEAD LINES. 37 CFR 1.84(q)

☐ Lead lines cross each other. Fig(s) _____

☐ Lead lines missing. Fig(s) _____

☐ Lead lines not as short as possible. Fig(s) _____

14. NUMBERING OF SHEETS OF DRAWINGS. 37 CFR 1.84(t)

☒ Number appears in top margin. Fig(s) 1-3

☐ Number not larger than reference characters.

☐ Fig(s) _____

☐ Sheets not numbered consecutively, and in Arabic numerals, beginning with number 1. Sheet(s) _____

15. NUMBER OF VIEWS. 37 CFR 1.84(u)

☐ Views not numbered consecutively, and in Arabic numerals, beginning with number 1. Fig(s) _____

☐ View numbers not preceded by the abbreviation Fig.

☐ Fig(s) _____

☐ Single view contains a view number and the abbreviation Fig.

☐ Numbers not larger than reference characters.

☐ Fig(s) _____

16. CORRECTIONS. 37 CFR 1.84(w)

☐ Corrections not durable and permanent. Fig(s) _____

17. DESIGN DRAWING. 37 CFR 1.152

☐ Surface shading shown not appropriate. Fig(s) _____

☐ Solid black shading not used for color contrast.

☐ Fig(s) _____

ATTACHMENT TO PAPER NO. (Fig 1-3)

REVIEWER W/S

DATE 6/8/94

03/06/96 MD 10:28 PM




RECEIVED
AUG 23 2004
OFFICE OF PETITIONS

COOPER & DUNHAM

1185 AVENUE OF THE AMERICAS

NEW YORK, N.Y. 10036



Applicant Wybe Martin Kast et al - Client No. 2805
Client Vereenigde File No. 45113 Any TFM
Date February 23, 1996

Kindly acknowledge receipt of the accompanying


AMENDMENT (O.A. 8/23/95)

Certificate of Mailing

Petition Under 37 C.F.R. 1.136(a)

Check for \$ 900.00 for three month extension

Serial No. 08/170,344
Due: February 23, 1996



MAR 1 3 1996

by placing your receiving date stamp hereon and returning to us.

/27/2004

Patent Information Print

ocket No	45113	Application #	08/170344
ountry	United States	Application Dt	04JA1994
ase Type	REGULAR CASE TYPE	Patent No	
elation Type	ORIGINAL OR PATENT CASE	Grant Dt	
iling Type	NATIONAL CASE	Publication #	
iling No		Publication Dt	
ttorney	ROBERT D. KATZ	Assigned	
gent		Expiration Dt	
lient\Division	VEREENIGDE	Conv Type	
urrent Owner	VEREENIGDE	Tax Base Dt	
rev Own		Next Tax Dt	
tatus	Filed	Associate	
irst Filing Dt		Oper Grp	
ub Stat		Ag Ref No	
ub Stat Dt		Verified	N
arent Country	Netherlands	Customer	D4PP
arent Filing Dt		Create Dt	08MR1994
arent No	PCT/NL93/00093	Update Dt	06JL2004
arent Grant Dt		Update Tm	0928
otal Claims		Update User	SML
nd. Claims		Update Type	A

Actions

Action	CHECK DECL./REFUND(if needed)	Comp Dt
Act Due Date	04MR1994	Resp Atty #1
Taken Dt		Resp Atty #2
DeadLn Dt		
Action	INFORMATION DISCLOSURE STATE	Comp Dt
Act Due Date	04AP1994	Resp Atty #1
Taken Dt		Resp Atty #2
DeadLn Dt		
Action	8mo FOREIGN FILING REMINDER	Comp Dt
Act Due Date	04SE1994	Resp Atty #1
Taken Dt		Resp Atty #2
DeadLn Dt		
Action	10mo FOREIGN FILING REMINDE	Comp Dt
Act Due Date	04NO1994	Resp Atty #1
Taken Dt		Resp Atty #2
DeadLn Dt		
Action	11mo FOREIGN FILING REMINDER	Comp Dt
Act Due Date	04DE1994	Resp Atty #1
Taken Dt		Resp Atty #2
DeadLn Dt		
Action	12mo FOREIGN FILING DEADLINE	Comp Dt
Act Due Date	04JA1995	Resp Atty #1
Taken Dt		Resp Atty #2
DeadLn Dt		
Action	6 MONTH RESPONSE DUE	Comp Dt
Act Due Date	04AP1995	Resp Atty #1
Taken Dt	04AP1995	Resp Atty #2
DeadLn Dt		
Action	3 MONTH RESPONSE DUE	Comp Dt
Act Due Date	23NO1995	Resp Atty #1
Taken Dt	23FE1996	Resp Atty #2
DeadLn Dt		
Action	6 MONTH RESPONSE DUE	Comp Dt
Act Due Date	23FE1996	Resp Atty #1
Taken Dt	23FE1996	Resp Atty #2
DeadLn Dt		
Action	STATUS INQUIRY DUE	Comp Dt
Act Due Date	28NO2004	Resp Atty #1
Taken Dt	18JE2004	Resp Atty #2
DeadLn Dt		
Action	PETITION TO REVIVE DUE	Comp Dt
Act Due Date		Resp Atty #1
Taken Dt	28MY2004	Resp Atty #2
DeadLn Dt		

****Inventors****

v Name

MARTIN WYBE KAST

Assigned

****Title****

ptle
PTIDES OF HUMAN PAPILLOMA VIRUS

CLIENT NO 2805

FILE NO.

45113

Ser. No.

APPLICATION OF

WYBE MARTIN KAST
CORNELIS JOSEPH MARIA MELIEF
ALESSANDRO D. SETTE
JOHN C. SIDNEY
FOR

PEPTIDES OF HUMAN PAPILLOMA VIRUS FOR USE
IN HUMAN CELL RESPONSE INDUCING COMPOSITIONS
Filed MARCH 30, 1994 Ser. No. OF/170,344

File No. 45113

Client EREGENICS

FILE NO.

45113

Executed

Date

at

N. P.

REMARKS

CORRES. TO INT'L APPLN.
NO. PCT/NL 93/00093
FILED 4 MAY 1993

ENTIRE interest assigned MARCH 17
1994 to
RISKSUNIVERSITEIT
LEIDEN

Recorded MARCH 30

19 94 Reel 7001 Frame 669

COOPER & DUNHAM
30 ROCKEFELLER PLAZA, NEW YORK, N.Y. 10112

Appn. Ser. No.

Inventor:

Patent No.

→ RAK TFM

VEREENIGDE

CONFIRMATION COPY

OCTROOIBUREAUX

PATENT AND TRADE MARK AGENTS
EUROPEAN PATENT ATTORNEYS

Messrs. Cooper & Dunham
1185 Avenue of the Americas
New York, N.Y. 10036
U.S.A.

Attn. Mr. Thomas F. Moran

Your ref. 45113
Our ref. Ren/92028-310


Re: U.S. patent application Serial No. 08/170,344
"Peptides of Human Papilloma Virus for use in Human
T Cell Response Inducing Compositions" - Wijbe Martin
Kast et al.

Dear Mr. Moran,

In the matter of the above-identified patent application I
kindly request you to send me a copy of the current claims.

Thanking you in advance for your assistance.

Very truly yours,
VEREENIGDE OCTROOIBUREAUX


on behalf of
J. Renes

NvM

Ir Th.A.H.J. Smulders
Mr Drs S.U. Ottevangers
Mr Ir A.W. Prins
Mr Ir J.H.F. Winckels
Mr Drs C.J.J. van Loon
J.A.M.J.H. Vossen
A.A.M. Reijns-Kouwenaar*
Mr Ir F.A. Dietz
Drs M.J. Hatzmann
Ir C.M. Jansen
Ir A.H.K. Tan
Drs J. Renes

Mr Drs W.E.M. ten Cate
Mr Drs W.J. Kruk
F.J. Quanjer, Ltz. b.d.
Drs O. Griebing
Drs H.A.M. Marsman
Ir H.A. Witmans
Ir L.J.J. Jessen

*trade marks and designs

Trade marks and designs
A.A.M. Reijns-Kouwenaar
L.P. Kindt
Mr F.K.B. Carbasius Weber
Mr N.L. Wolfs
Mr P.A. van der Wees

Groningen
Mr Ir A.W. Prins
Ir A.H.K. Tan

Arnhem
Ir C.M. Jansen

Of counsel
Ir J.S.W. van Gennip

Attorney-at-law
Mr Drs S.U. Ottevangers

in association with
Mars & Oostenbroek,
attorneys-at-law

BY FACSIMILE

+1 212 391 0525
Den Haag (The Netherlands)
Nieuwe Parklaan 97

December 10, 1997

RECEIVED
COOPER & DUNHAM

DEC 16 1997

DOCKET CLERK

VEREENIGDE

CONFIRMATION COPY

OCTROOBUREAUX

PATENT AND TRADE MARK AGENTS
EUROPEAN PATENT ATTORNEYS

Messrs. Cooper & Dunham
1185 Avenue of the Americas
New York, N.Y 10036
U.S.A.

Attn. Mr. Thomas F. Moran

Your ref. 45113
Our ref. Ren/92028-310

Re: U.S. patent application Serial No. 08/170,344
"Peptides of Human Papilloma Virus for use in Human
T Cell Response Inducing Compositions" - Wijbe Martin
Kast et al.

Dear Mr. Moran,

With reference to my letter of December 10, 1997 I kindly
request you to send me a copy of the current claims in the
above-referenced application by return.

Thanking you in advance for your assistance.

Very truly yours,
VEREENIGDE OCTROOBUREAUX

J. Renes

NvM

RDK
Ir Th.A.H.J. Smulders
Mr Drs S.U. Ottevangers
Mr Ir A.W. Prins
Mr Ir J.H.F. Winckels
Mr Drs C.J.J. van Loon
J.A.M.J.H. Vossen
A.A.M. Reijns-Kouwenaar*
Mr Ir F.A. Dietz
Drs M.J. Hatzmann
Ir C.M. Jansen
Ir A.H.K. Tan
Drs J. Renes

Mr Drs W.E.M. ten Cate
Mr Drs W.J. Kruk
Drs H.A.M. Marsman
Ir H.A. Witmans
Ir L.J.J. Jessen

*trade marks and designs

Trade marks and designs
A.A.M. Reijns-Kouwenaar
L.P. Kindt
Mr F.K.B. Carbasius Weber
Mr N.L. Wolfs
Mr P.A. van der Wees

Groningen
Mr Ir A.W. Prins
Ir A.H.K. Tan

Arnhem
Ir C.M. Jansen
Ir H.A. Witmans

Of counsel
Ir J.S.W. van Gennip


Attorney-at-law
Mr Drs S.U. Ottevangers

in association with
Mars & Oostenbroek,
attorneys-at-law

BY FACSIMILE

+1 212 391 0525
Den Haag (The Netherlands),
Nieuwe Parklaan 97

January 27, 1998



COOPER & DUNHAM LLP

ATTORNEYS AT LAW

1185 AVENUE OF THE AMERICAS, NEW YORK, NEW YORK 10036

TELEPHONE: (212) 278-0400

CHRISTOPHER C. DUNHAM
NORMAN H. ZIVIN
JOHN P. WHITE
WILLIAM E. PELTON
DONALD S. DOWDEN
PETER J. PHILLIPS
WENDY E. MILLER
ALBERT WAI-KIT CHAN
MARK S. COHEN
MARY ANNE P. TANNER
GEORGE M. MACDONALD
ELIZABETH M. WIECKOWSKI
VICTOR DEVITO
WILLIAM D. DEVAUL
STEPHEN J. LIEB
ADAM M. GOODMAN*
TODD W. EVANS*

IVAN S. KAVRUKOV
PETER D. MURRAY
JAY H. MAIOLI
ROBERT B. G. HOROWITZ
ROBERT D. KATZ
DONNA A. TOBIN
RICHARD S. MILNER
ROBERT T. MALDONADO
PAUL TENG
GERARD M. WISSING
MARY CATHERINE DINUNZIO
RICHARD F. JAWORSKI
PEDRO C. FERNANDEZ
TODD A. HOLMBO
VINCENT A. SIRECI
STEVEN B. STEIN*

FACSIMILE: (212) 391-0525
(212) 391-0526
(212) 391-0630
www.cooperdunham.com

OF COUNSEL
GERALD W. GRIFFIN
JOHN R. GARBER

SCIENTIFIC ADVISORS
JANE M. LOVE, PH. D.
LOCK SEE YU-JAHNES, PH. D.

FOUNDED 1887

January 28, 1998

*BAR ADMISSION PENDING

BY FACSIMILE

Dr. J. Renes
Vereenigde Octrooibureaux
P.O. Box 87930
2508 DH The Hague
Netherlands


Re: Your Ref. Ren/92028-310 - Wybe Martin Kast et al
Peptides of Human Papilloma Virus for Use in
Human T Cell Response Inducing Compositions
Serial No. 08/170,344 filed March 30, 1994
Our Docket 45113

RECEIVED
AUG 23 2004
OFFICE OF PETITIONS

Dear Dr. Renes:

In response to your letter of December 10, 1997, attached please find a retyped version of the pending claims as amended. Please send all further correspondence in this matter to me. Mr. Moran has retired from the practice of law. I look forward to working with you on this matter.

Very truly yours,


Robert D. Katz

RDK:lg
Enclosure

CLAIMS AS OF 1/28/98

25. (Rewritten, canceled claim 1) A peptide comprising an amino acid sequence derived from protein of human papilloma virus (HPV), wherein said amino acid sequence comprises a nonapeptide derived from protein E6 or E7 of HPV 16 or HPV 18 and wherein said nonapeptide has the ability to bind in the grooves on top of the human major histocompatibility complex (MHC) Class I molecule.

2. A peptide according to claim 25, wherein said amino acid sequence is a nonapeptide.

4. A peptide according to claim 25, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1.

5. A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:

AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
KLPQLCTEL (residues 18-26 of HPV16 protein E6) SEQ ID NO:2
QLCTELQTT (residues 21-29 of HPV16 protein E6) SEQ ID NO:3
LCTELQTTI (residues 22-30 of HPV16 protein E6) SEQ ID NO:4
ELQTTIHDI (residues 25-33 of HPV16 protein E6) SEQ ID NO:5
LQTTIHDI (residues 26-34 of HPV16 protein E6) SEQ ID NO:6
TIHDIILEC (residues 29-37 of HPV16 protein E6) SEQ ID NO:7
IHDIILECV (residues 30-38 of HPV16 protein E6) SEQ ID NO:8
CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
FAFRDLCIV (residues 52-60 of HPV16 protein E6) SEQ ID NO:10
KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
PLCDLLIRC (residues 102-110 of HPV16 protein E6) SEQ ID NO:12
TLHEYMLDL (residues 7-15 of HPV16 protein E7) SEQ ID NO:13
YMLDLQPET (residues 11-19 of HPV16 protein E7) SEQ ID NO:14
MLDLQPETT (residues 12-20 of HPV16 protein E7) SEQ ID NO:15
RLCVQSTHV (residues 66-74 of HPV16 protein E7) SEQ ID NO:16
TLEDLLMGT (residues 78-86 of HPV16 protein E7) SEQ ID NO:17
LLMGTLGIV (residues 82-90 of HPV16 protein E7) SEQ ID NO:18
GTLGIVCPI (residues 85-93 of HPV16 protein E7) SEQ ID NO:19 and
TLGIVCPIC (residues 86-94 of HPV16 protein E7) SEQ ID NO:20

a fragment, homolog, isoform, derivative, genetic variant and conservative variant of any one of these amino acid sequences which has the ability to bind to human MHC Class I allele HLA-A2.1.

6. A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV18, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:

KLPDLCTEL (residues 13-21 of HPV18 protein E6) SEQ ID NO:21
SLQDIEITC (residues 24-32 of HPV18 protein E6) SEQ ID NO:22

LQDIEITCV (residues 25-33 of HPV18 protein E6) SEQ ID NO:23
 EITCVYCKT (residues 29-37 of HPV18 protein E6) SEQ ID NO:24
 KTVLELTEV (residues 36-44 of HPV18 protein E6) SEQ ID NO:25
 ELTEVFEFA (residues 40-48 of HPV18 protein E6) SEQ ID NO:26
 FAFKDLFVV (residues 47-55 of HPV18 protein E6) SEQ ID NO:27
 DTLEKLTNT (residues 88-96 of HPV18 protein E6) SEQ ID NO:28
 LTNTGLYNL (residues 93-101 of HPV18 protein E6) SEQ ID NO:29
 TLQDIVLHL (residues 7-15 of HPV18 protein E7) SEQ ID NO:30
 FQQLFLNTL (residues 86-94 of HPV18 protein E7) SEQ ID NO:31
 QLFLNTLSF (residues 88-96 of HPV18 protein E7) SEQ ID NO:32
 LFLNTLSFV (residues 89-97 of HPV18 protein E7) SEQ ID NO:33 and
 LSFVCPWCA (residues 94-102 of HPV18 protein E7) SEQ ID NO:34, and
 a fragment, homolog, isoform, derivative, genetic variant and conservative variant
 of any one of these amino acid sequences which has the ability to bind to human MHC
 Class I allele HLA-A2.1.

7. A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A1.

8. A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 and E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A1 and is selected from the group consisting of:

YRDGNPYAV (residues 61-69 of HPV16 protein E6) SEQ ID NO:35
 WTGRCMSCC (residues 139-147 of HPV16 protein E6) SEQ ID NO:36
 MSCCRSSRT (residues 144-152 of HPV16 protein E6) SEQ ID NO:37
 TTDLYCYEQ (residues 19-27 of HPV16 protein E7) SEQ ID NO:38
 EIDGPAGQA (residues 37-45 of HPV16 protein E7) SEQ ID NO:39 and
 HVDIRTLED (residues 73-81 of HPV16 protein E7), SEQ ID NO:40, and
 a fragment, homolog, isoform, derivative, genetic variant and conservative variant
 of any one of these amino acid sequences which has the ability to bind to human MHC
 Class I allele HLA-A1.

9. A peptide according to claim 25, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A3.2.

10. A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A3.2 and is selected from the group consisting of:

AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
 IILECVYCK (residues 33-41 of HPV16 protein E6) SEQ ID NO:41
 CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
 VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42
 QQLLRREVY (residues 42-50 of HPV16 protein E6) SEQ ID NO:43
 IVYRDGNPY (residues 59-67 of HPV16 protein E6) SEQ ID NO:44
 YAVCDKCLK (residues 67-75 of HPV16 protein E6) SEQ ID NO:45

AVCDKCLKF (residues 68-76 of HPV16 protein E6) SEQ ID NO:46
 VCDKCLKFY (residues 69-77 of HPV16 protein E6) SEQ ID NO:47
 KFYSKISEY (residues 75-83 of HPV16 protein E6) SEQ ID NO:48
 KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
 ISEYRHYCY (residues 80-88 of HPV16 protein E6) SEQ ID NO:49
 RHYCYSLYG (residues 84-92 of HPV16 protein E6) SEQ ID NO:50
 SLYGTTLEQ (residues 89-97 of HPV16 protein E6) SEQ ID NO:51
 TTLEQQYNK (residues 93-101 of HPV16 protein E6) SEQ ID NO:52
 QQYNKPLCD (residues 97-105 of HPV16 protein E6) SEQ ID NO:53
 LIRCINCQK (residues 107-115 of HPV16 protein E6) SEQ ID NO:54
 HLDKKQRFH (residues 125-133 of HPV16 protein E6) SEQ ID NO:55
 CMSSCRSSR (residues 143-151 of HPV16 protein E6) SEQ ID NO:56
 SCCRSSRTR (residues 145-153 of HPV16 protein E6) SEQ ID NO:57
 CCRSSRTRR (residues 146-154 of HPV16 protein E6) SEQ ID NO:58
 HYNIVTFCC (residues 51-59 of HPV16 protein E7) SEQ ID NO:59
 YNIVTFCK (residues 52-60 of HPV16 protein E7) SEQ ID NO:60
 CCKCDSTLR (residues 58-66 of HPV16 protein E7) SEQ ID NO:61 and
 KCDSTLRLC (residues 60-68 of HPV16 protein E7) SEQ ID NO:62,
 and

a fragment, homolog, isoform, derivative, genetic variant and conservative variant
 of any one of these amino acid sequences which has the ability to bind to human MHC
 Class I allele HLA-A3.2.

11. A peptide according to claim 25, wherein said amino acid sequence has the ability to bind
 to human MHC Class I allele HLA-A11.2.

12. A peptide according to claim 25, comprising an amino acid sequence derived from
 protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human
 MHC Class I allele HLA-A11.2 and is selected from the group consisting of:

AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
 HILECVYCK (residues 33-41 of HPV16 protein E6) SEQ ID NO:41
 CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
 VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42
 QQLLRREVY (residues 42-50 of HPV16 protein E6) SEQ ID NO:43
 IVYRDGNPY (residues 59-67 of HPV16 protein E6) SEQ ID NO:44
 YAVCDKCLK (residues 67-75 of HPV16 protein E6) SEQ ID NO:45
 AVCDKCLKF (residues 68-76 of HPV16 protein E6) SEQ ID NO:46
 VCDKCLKFY (residues 69-77 of HPV16 protein E6) SEQ ID NO:47
 KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
 ISEYRHYCY (residues 80-88 of HPV16 protein E6) SEQ ID NO:49
 LIRCINCQK (residues 107-115 of HPV16 protein E6) SEQ ID NO:54
 TGRCMSSCR (residues 140-148 of HPV16 protein E6) SEQ ID NO:63
 CMSSCRSSR (residues 143-151 of HPV16 protein E6) SEQ ID NO:56
 SCCRSSRTR (residues 145-153 of HPV16 protein E6) SEQ ID NO:57
 HYNIVTFCC (residues 51-59 of HPV16 protein E7) SEQ ID NO:59
 YNIVTFCK (residues 52-60 of HPV16 protein E7) SEQ ID NO:60
 CCKCDSTLR (residues 58-66 of HPV16 protein E7) SEQ ID NO:61 and

VCPICSQKP (residues 90-98 of HPV16 protein E7), SEQ ID NO:64
and

a fragment, homolog, isoform, derivative, genetic variant and conservative variant of any one of these amino acid sequences which has the ability to bind to human MHC Class I allele HLA-A11.2.

13. A peptide according to claim 25, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A24.

14. A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A24 and is selected from the group consisting of:

MHQKRTAMF (residues 1-9 of HPV16 protein E6) SEQ ID NO:65
LQTTIHDII (residues 26-34 of HPV16 protein E6) SEQ ID NO:6
VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42
LLRREVYDF (residues 44-52 of HPV16 protein E6) SEQ ID NO:66
VYDFAFRDL (residues 49-57 of HPV16 protein E6) SEQ ID NO:67
PYAVCDKCL (residues 66-74 of HPV16 protein E6) SEQ ID NO:68
KCLKFYSKI (residues 72-80 of HPV16 protein E6) SEQ ID NO:69
EYRHYCYSL (residues 82-90 of HPV16 protein E6) SEQ ID NO:70
HYCYSLYGT (residues 85-93 of HPV16 protein E6) SEQ ID NO:71
CYSLYGTTL (residues 87-95 of HPV16 protein E6) SEQ ID NO:72
RFHNIRGRW (residues 131-139 of HPV16 protein E6) SEQ ID NO:73 and
RAHYNIVTF (residues 49-57 of HPV16 protein E7), SEQ ID NO:74,
and

a fragment, homolog, isoform, derivative, genetic variant and conservative variant of any one of these amino acid sequences which has the ability to bind to human MHC Class I allele HLA-A24.

15. A peptide according to claim 25, having a length of from 9 to 12 amino acids.

16. A pharmaceutical composition containing a prophylactically or therapeutically effective amount for eliciting cellular immune response of a peptide according to claim 25, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.


17. A pharmaceutical composition containing a prophylactically or therapeutically effective amount for eliciting cellular immune response of a peptide according to claim 25 which is capable of inducing a T cell response effective against HPV, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

18. A pharmaceutical composition containing a prophylactically or therapeutically effective amount for eliciting cellular immune response of a peptide according to claim 25 for inducing a HLA Class I-restricted CD8⁺ cytotoxic T cell response effective against HPV, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

RDK

VEREENIGDE

Cooper & Dunham
1185 Avenue of the Americas
New York, N.Y. 10036
USA



Your ref. 45113
Our ref. ME/P20884US00

Den Haag,
January 20, 2004

Re.: Patent Application in the U.S. of America No. 08/170,344
for
of RIJKSUNIVERSITEIT LEIDEN

Could you please supply us with a status report of the above mentioned application as we have not heard from you since January 28, 1998.

Yours faithfully,
VEREENIGDE

A. Rozendaal

Records Department
A. Rozendaal

RECEIVED
AUG 23 2004
OFFICE OF PETITIONS

V313.1



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
--------------------	-------------	-----------------------	---------------------

08/170,344 03/30/94 KAST

W D45113TFM

EXAMINER

MINNIFIELD, N

18M1/0614

COOPER & DUNHAM
30 ROCKEFELLER PLAZA
NEW YORK, NY 10112

ART UNIT	PAPER NUMBER
----------	--------------

16

1802
DATE MAILED:

06/14/96

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

☒ Responsive to communication(s) filed on 2-26-96

☒ This action is FINAL.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 D.C. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

☒ Claim(s) 2, 4-18, 25 is/are pending in the application.

Of the above, claim(s) _____ is/are withdrawn from consideration.

☐ Claim(s) _____ is/are allowed.

☒ Claim(s) 2, 4-18, 25 is/are rejected.

☐ Claim(s) _____ is/are objected to.

☐ Claims _____ are subject to restriction or election requirement.

Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on _____ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been

☐ received.

☐ received in Application No. (Series Code/Serial Number) _____

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

☒ Notice of Reference Cited, PTO-892

☒ Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

— SEE OFFICE ACTION ON THE FOLLOWING PAGES —

RECEIVED
AUG 23 2004
OFFICE OF PETITIONS

Part III DETAILED ACTION

Response to Amendment

15. Applicants' amendment filed February 26, 1996 is acknowledged and has been entered. Claims 1, 19-22, and 24 have been cancelled. Claims 2-8 and 10-18 have been amended. New claim 25 has been added. Claims 2, 4-18, and 25 are now pending in the present application. All prior rejections are withdrawn with the exception of those discussed below.

16. The text of the 35 U.S.C. Code not included in this Office Action can be found in the prior Office Action.

17. The information disclosure statement filed January 4, 1994 fails to comply with 37 CFR § 1.98(a)(3) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the content of the information, of each patent listed that is not in the English language. It has been placed in the application file, but the information referred to therein has not been considered as to the merits. Applicants state (April 17, 1995) that a substitute IDS will be filed, however it has not been received.

The present amendment filed (2-26-96) directed the Examiner to the April 7, 1995 amendment with respect to the content and relevance of the publications referred to in the IDS. The IDS references that have not been considered are EP0375555 and EP0456197. Applicants have not provided an english translation nor a statement of content and relevance of these references in any of the amendments. These references have not been considered as to the merits.

18. The objection to the specification and rejection of claims 2, 4-18 (and now claim 25) under 35 U.S.C. § 112, first paragraph (i.e. lack of an enabling disclosure) is maintained.

Art Unit: 1802

This rejection is maintained for essentially the same reasons as the rejection of claims 1-22 and 24 under this statutory provision, as set forth in the last Office action. Applicants' arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

The specification is objected to under 35 U.S.C. § 112, first paragraph, as failing to provide an adequate written description of the invention and failing to adequately teach how to make and/or use the invention, i.e. failing to provide an enabling disclosure. The disclosure is enabled for nonapeptide sequences from the E6 or E7 genes of HPV16 or HPV18, and MHC Class I molecules as specifically taught in the specification. The specification has not provided sufficient evidence of a method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition. Matlashewski et al. discloses that HPV18 proteins (E6 gene) maybe diagnostically useful since the proteins have been identified in specific human cancers, however the methods as claimed in this invention are not known in the art. Accordingly, amendment of the claims to what is supported in the specification or filing of evidence in the form of a Rule 132 declaration providing factual evidence supporting the broad range claims is suggested.

A disclosure in an application, to be complete, must contain such description and details as to enable any person skilled in the art or science to which it pertains to make and use the invention as of its filing date, *In re Glass*, 181 USPQ 31; 492 F.2d 1228 (CCPA 1974). While the prior art setting may be mentioned in general terms, the essential novelty, the essence of the invention, must be described in such details, including proportions and techniques where necessary, as to enable those persons skilled in the art to make and utilize the invention.

Specific operative embodiments or examples of the invention must be set forth. Examples and description should be of sufficient scope as to justify the scope of the claims. Where the constitution and formula of a compound is stated only as probability and speculation, the disclosure is not sufficient to support claims identifying the compound by

Art Unit: 1802

such composition or formula. A disclosure involving a new chemical compound or composition must teach persons skilled in the art how to make the compound. Incomplete teachings may not be completed by reference to subsequently filed applications.

The instant specification invites the skilled artisan to experiment. The factor which must be considered in determining undue experimentation are set forth in *Ex parte Forman* 230 USPQ 546. The factors include 1) quantity of experimentation necessary, 2) the amount of guidance presented, 3) the presence or absence of working examples, 4) the nature of the invention, 5) the state of the prior art, 6) the predictability of the art and the 7) breath of the claims. With regard to factors three and six, it is noted that there are no working examples or support for in vivo efficacy of the active ingredients in a method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition, or peptides from any HPV that bind to MHC Class I molecules. Such is not seen as sufficient to support the breath of the claims, wherein the scope of the claims encompasses how to prepare a peptide from any of the listed HPV proteins (or any other HPV protein) wherein the peptide binds to any human MHC Class I molecule. It is noted that Law requires that the disclosure of an application shall inform those skilled in the art how to use applicant's alleged discovery, not how to find out how to use it for themselves., see *In re Gardner et al.* 166 USPQ 138 (CCPA 1970).

Applicants have argued that the specification is enabled and have cited Ruppert et al., Kast et al., Feltkamp et al., Vitiello et al., and Ressing et al. as support to demonstrate enablement, however it is noted that the specification must be enabled as of its filing date. Prior art references that were published after Applicants' effective filing date (5-5-92) cannot be used to rebut prima facie case of nonenablement under 35 USC 112. *In re Glass*, 181 USPQ 31; 492 F.2d 1228 (CCPA 1974).

Applicants have argued that it would be unethical to demonstrate HPV treatment in humans, however the Examiner has not suggested such a demonstration. Applicants have not demonstrated treatment of HPV in animal models. With regard to the method of

Art Unit: 1802

prophylactic or therapeutic treatment, it appears that the specification is a paper protocol. The specification does not show any therapy or prophylactic treatment, only in vitro studies; no animal studies using the peptides to demonstrate prophylactic or therapy treatment that would correlate to human efficacy have been set forth in the specification.

Applicants have argued that Kast et al. (1991, PNAS 88:2283-2287 and 1991, Immunol. Letters 30(2):229-232) show that one of skill in the art would readily understand from these references how to make and use the claimed invention. Kast et al. (1991, PNAS) disclose the immunization of synthetic peptides of Sendai virus, not HPV. Further, Kast et al. (1991, Immunol. Letters) does disclose the use of peptide vaccination, however the use of HPV peptides is not discussed. HPV is discussed with regard to using "... cultured human CTL for immunotherapy of virus-induced tumors" (p. 229). Furthermore, the reference discloses that there are several unanswered questions regarding peptide vaccination as a novel immunotherapeutic or preventive approach in man (summary; p. 230, col. 2).

In response to Applicant's argument that Matlashewski et al. does not include certain features of Applicant's invention, the limitations on which the Applicant relies (i.e., peptides that bind in the groove on top of an MHC Class I molecule) are not stated in the claims. Therefore, it is irrelevant whether the reference includes those features or not.

Applicant's arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

Applicants have asserted that as the methods claims directed to methods of prophylactic or therapy treatment of a human have been cancelled that this objection should be eliminated. However, claims (16-18) directed a pharmaceutical composition containing a prophylactically or therapeutically effective amount for eliciting cellular immune response of a peptide and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant are not enabled for the same reasons as methods claims. The claims as presently written indicate or suggest that the 'pharmaceutical composition' would be administered to an animal or human,

Art Unit: 1802

however the specification is not enabled for such administration as previously indicated. Further, such short peptides require immunogenic carriers to ensure an immune response.

The claims also recite fragments, homologs, isoforms, derivatives genetic variants or conservative variants of the amino acid sequences and that these fragments, homologs, isoforms, derivatives genetic variants or conservative variants of the amino acid sequences will bind to the grooves on top of the MHC Class I molecule. The specification discloses that variants and derivatives include any amino acid substitution, deletion, or other processes (p. 17). Since the amino acid sequence of a protein determines its structural and functional properties, predictability of which changes can be tolerated in a protein's amino acid sequence and still retain similar activity/utility requires a knowledge of and guidance with regard to which amino acids in the protein's sequence, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which the proteins' structure relates to its function. However, the problem of predicting protein structure from mere sequence data of a single protein and in turn utilizing predicted structural determinations to ascertain functional aspects of the protein and finally what changes can be tolerated with respect thereto is extremely complex (Bowie et al. 1990; p. 1306; p. 1308) and is well outside the realm of routine experimentation.

While recombinant and mutagenesis techniques are known, it is not routine in the art to screen for multiple substitutions or multiple modifications of other types and the positions within the protein's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining similar activity/utility are limited in protein and the result of such modifications is unpredictable based on the instant disclosure.

The specification does not support the broad scope of the claims which encompass all variants of the protein because the specification does not disclose the following: the general tolerance to modification (substitution, insertion, deletion) and extent of such tolerance; specific positions and regions of the sequence(s) which can be predictably modified and which regions are critical; what variants, if any, can be made which retain the biological activity of the intact protein; and the specification provide essentially no guidance as to which

Art Unit: 1802

of the essentially infinite possible choices is likely to be successful. Further, Houghten et al. teach that changes/modifications (addition, substitution, deletion or inversion) of one or more amino acids in a polypeptide will alter antigenic determinants and therefore effect antibody production (p. 21) as well as antibody binding. Houghten et al. also teach that "...combined effects of multiple changes in an antigenic determinant could result in a loss of [immunological] protection." and "A protein having multiple antigenic sites, multiple point mutations, or accumulated point mutations at key residues could create a new antigen that is precipitously or progressively unrecognizable by any of the antibodies..." (p. 24). Houghten et al. teach that point mutations at one key antigen residue could eliminate the ability of an antibody to recognize this altered antigen (p. 24). It is not always possible to make the derivatives that retain immunodominant regions and immunological activity if the regions have been altered.

Thus, applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed protein in a manner reasonably correlated with the scope of the claims broadly including any number of insertions, deletions or substitutions encompassing a variant, fragment, derivatives, homologs, isoforms etc as presently claimed. The scope of the claims must bear a reasonable correlation with the scope of enablement (In re Fisher, 166 USPQ 19 24 (CCPA 1970)). Without such guidance, the changes which can be made in the protein structure and still maintain activity/utility is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. The sequence of some proteins is highly conserved and one skilled in the art would not expect tolerance to any amino acids modification in such proteins. However, even if it were shown that some modifications could be tolerated in the claimed peptides, for the reasons discussed the claims would still expectedly encompass a significant number of inoperative species which could not be distinguished without undue experimentation. See Amgen, Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F.2d 1200, 18 USPQ2d 1016 (Fed. Cir. 1991) at 18 USPQ2d 1026-1027 and Ex parte Forman, 230 U.S.P.Q. 546 (Bd. Pat. App. & Int. 1986).

Art Unit: 1802

19. Claims 12 and 14 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims are indefinite for being in improper Markush format. The Office recommends the use of the phrase "selected from the group consisting of..." with the use of the conjunction "and" rather than "or" in listing the species. See MPEP 706.03(Y).

This rejection is maintained. It is noted that Applicants attempted to amend these claims with regard to the Markush language, however the instruction for the amendment of these claims is unclear. The line numbers stated in the amendment filed February 26, 1996 are not the same as those in the amendment filed July 18, 1994.

20. The rejection of claims 2, 4, 7, 8, 11, 13, and 15-18 (and now 25) under 35 U.S.C. § 102(b) as anticipated by, or in the alternative, under 35 U.S.C. § 103 as obvious over Schoolnik et al. is maintained. This rejection is maintained for essentially the same reasons as the rejection of claims 1, 2, 4, 7, 8, 11, 13, and 15-22 under this statutory provision, as set forth in the last Office action. Applicants' arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

Schoolnik et al. discloses synthetic peptides from HPV that are useful in the diagnosis and therapy of conditions associated with HPV infection (abstract; p. 9, l. 10-18; claims). Schoolnik et al. teaches the preparation of peptides from HPV16 (E6 and E7) or other HPV proteins useful to raise antibodies for diagnostic, protective (i.e. prophylactic), and therapeutic purposes and vaccines, as well as various mode of administration (p. 3, l. 1-39; p. 5, l. 28-50; p. 4, l. 27 to p. 5, l. 24; p. 7, l. 47 to p. 8, l. 8).

It is noted that the claims recite a peptide comprising an amino acid sequence from a protein of E6 or E7 of HPV 16 or HPV 18.

The teachings of Schoolnik et al. anticipates the claimed invention by disclosing a peptide from a HPV protein wherein the peptide binds to a MHC Class I molecule, and a

Art Unit: 1802

method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition. The compositions and methods disclosed in Schoolnik et al. are believed to inherently possess properties which anticipates the claimed invention or if they are not the same the composition and methods, the HPV peptides (and compositions) and methods of treatment as disclosed by Schoolnik et al. would none the less render the claims obvious because it possesses the components necessary to prepare a peptide from HPV and methods of treatment as claimed in the instant application. Binding of MHC Class I molecules via T-cell activation is an inherent part of the process of generating an immunogenic response in a mammal. Since the Office does not have the facilities for examining and comparing applicants' method for preparation of a HPV peptide and methods of treatment of the prior art, the burden is on applicant to show a novel or unobvious differences between the claimed product and the product of the prior art (i.e., that the peptide, composition, and method of use of the prior art does not possess the same material structural and functional characteristics of the claimed composition and methods of preparation). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

In response to Applicant's argument that Schoolnik et al. does not include certain features of Applicant's invention, the limitations on which the Applicant relies (i.e., peptides have to fit snugly in the groove of HLA Class I molecule; pockets in the groove; specific anchor residues) are not stated in the claims. Therefore, it is irrelevant whether the reference includes those features or not.

It is noted that the use of prior art published after Applicants' effective filing date can not be used rebut rejections.

Applicant's arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

Applicants' comments have been addressed previously. Applicants directed the Examiner to the previous response. It is noted at p. 11 of the previous response that

Art Unit: 1802

Applicants stated "... one was demonstrated by applicants not to have the binding ability to HLA molecule which is a prerequisite to be a CTL epitope...". Evidence to support Applicants' assertion that the prior art does not anticipated or obviate the claimed invention should be submitted in the form of a declaration.

21. The following new rejection has not been necessitated by the amendment.

22. Claims 2, 4-18 and 25 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 25 and its dependent claims are vague and indefinite in the recitation of "comprising" as the use of the open-ended term "comprises" which fails to exclude unrecited steps and leaves the claims open for inclusion of unspecified ingredients, even in major amounts. See In re Horvitz, 168 F 2d 522, 78 U.S.P.Q. 79 (C.C.P.A. 1948) and Ex parte Davis et al., 80 U.S.P.Q. 448 (PTO d. App. 1948). Claim 25 is directed to a peptide comprising an amino acid sequence derived from a HPV protein wherein the sequence comprises a nonapeptide from E6 or E7 of HPV 16 or HPV 18. Claim 9 is indefinite and lacks proper antecedent basis in that the claim depends from claim 1 which has been cancelled.

23. No claims are allowed.

24. Applicant's amendment necessitated the new grounds of rejection. Accordingly, **THIS ACTION IS MADE FINAL**. See M.P.E.P. § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT

Art Unit: 1802


MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

25. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is (703) 305-3394. The examiner can normally be reached on Monday-Thursday from 7:00 AM-4:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (703) 308-4027. The fax phone number for this Group is (703) 305-7939.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

N. M. Minnifield
May 31, 1996


JAMES C. HOUSEL 6/10/96
SUPERVISORY PATENT EXAMINER
GROUP 180

COOPER & DUNHAM LLP
1185 Avenue of the Americas, New York, New York 10036

FACSIMILE TRANSMISSION
Telephone No.: 212-278-0400 / Facsimile No.: 212-391-0526

PLEASE DELIVER THE FOLLOWING PAGES

TO : Dr. J. Renes
COMPANY : Vereenigde Octrooibureaux
FAX NO. : 011-31-70-416-6799
FROM : Robert D. Katz, Esq.

TOTAL NUMBER OF PAGES, INCLUDING COVER PAGE: 15

DATE : March 17, 2004

X CONFIDENTIAL

X URGENT

If this facsimile message has reached you in error, please notify us by collect telephone and return it by the Postal Service, as it may contain attorney privileged and confidential information.

RECEIVED
AUG 9 3 2004
OFFICE OF PETITIONS

MESSAGE:

I enclose the Office Action finally rejecting the application in connection with U.S. Application No. 08/170,344, filed March 30, 1994 (your ref. no. ME/P20884US00). Please send me instructions on how to respond and we will file a response along with a petition to revive the application.

As mentioned we will also need a Terminal Disclaimer, which we can send to you for signature by your client.


IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL SHAKINAH DAVIS AS SOON AS POSSIBLE AT (212) 278-0459.

*Vereenigde
file***Facsimile Transmission**TO: Robert Katz

Ref: 08

FAX: 212 391 0525DATE 3-17-04 pages incl. cover 13From: Helene Stanonik

PLAZA MAILBOXES
2101 CRYSTAL PLAZA ARCADE
ARLINGTON, VA. 22202-4600
PH. (703) 415-0400 FAX (703) 415-0403



-2-

Serial Number: 08/170344

Art Unit: 1802

Part III DETAILED ACTION***Response to Amendment***

15. Applicants' amendment filed February 26, 1996 is acknowledged and has been entered. Claims 1, 19-22, and 24 have been cancelled. Claims 2-8 and 10-18 have been amended. New claim 25 has been added. Claims 2, 4-18, and 25 are now pending in the present application. All prior rejections are withdrawn with the exception of those discussed below.

16. The text of the 35 U.S.C. Code not included in this Office Action can be found in the prior Office Action.

17. The information disclosure statement filed January 4, 1994 fails to comply with 37 CFR § 1.98(a)(3) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the content of the information, of each patent listed that is not in the English language. It has been placed in the application file, but the information referred to therein has not been considered as to the merits. Applicants state (April 17, 1995) that a substitute IDS will be filed, however it has not been received.

The present amendment filed (2-26-96) directed the Examiner to the April 7, 1995 amendment with respect to the content and relevance of the publications referred to in the IDS. The IDS references that have not been considered are EP0375555 and EP0456197. Applicants have not provided an english translation nor a statement of content and relevance of these references in any of the amendments. These references have not been considered as to the merits.

18. The objection to the specification and rejection of claims 2, 4-18 (and now claim 25) under 35 U.S.C. § 112, first paragraph (i.e. lack of an enabling disclosure) is maintained.

Serial Number: 08/170344

Art Unit: 1802

This rejection is maintained for essentially the same reasons as the rejection of claims 1-22 and 24 under this statutory provision, as set forth in the last Office action. Applicants' arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

The specification is objected to under 35 U.S.C. § 112, first paragraph, as failing to provide an adequate written description of the invention and failing to adequately teach how to make and/or use the invention, i.e. failing to provide an enabling disclosure. The disclosure is enabled for nonapeptide sequences from the E6 or E7 genes of HPV16 or HPV18, and MHC Class I molecules as specifically taught in the specification. The specification has not provided sufficient evidence of a method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition. Matlashewski et al. discloses that HPV18 proteins (E6 gene) maybe diagnostically useful since the proteins have been identified in specific human cancers, however the methods as claimed in this invention are not known in the art. Accordingly, amendment of the claims to what is supported in the specification or filing of evidence in the form of a Rule 132 declaration providing factual evidence supporting the broad range claims is suggested.

A disclosure in an application, to be complete, must contain such description and details as to enable any person skilled in the art or science to which it pertains to make and use the invention as of its filing date, *In re Glass*, 181 USPQ 31; 492 F.2d 1228 (CCPA 1974). While the prior art setting may be mentioned in general terms, the essential novelty, the essence of the invention, must be described in such details, including proportions and techniques where necessary, as to enable those persons skilled in the art to make and utilize the invention.

Specific operative embodiments or examples of the invention must be set forth. Examples and description should be of sufficient scope as to justify the scope of the claims. Where the constitution and formula of a compound is stated only as probability and speculation, the disclosure is not sufficient to support claims identifying the compound by

Serial Number: 08/170344

Art Unit: 1802

such composition or formula. A disclosure involving a new chemical compound or composition must teach persons skilled in the art how to make the compound. Incomplete teachings may not be completed by reference to subsequently filed applications.

The instant specification invites the skilled artisan to experiment. The factor which must be considered in determining undue experimentation are set forth in *Ex parte Forman* 230 USPQ 546. The factors include 1) quantity of experimentation necessary, 2) the amount of guidance presented, 3) the presence or absence of working examples, 4) the nature of the invention, 5) the state of the prior art, 6) the predictability of the art and the 7) breath of the claims. With regard to factors three and six, it is noted that there are no working examples or support for in vivo efficacy of the active ingredients in a method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition, or peptides from any HPV that bind to MHC Class I molecules. Such is not seen as sufficient to support the breath of the claims, wherein the scope of the claims encompasses how to prepare a peptide from any of the listed HPV proteins (or any other HPV protein) wherein the peptide binds to any human MHC Class I molecule. It is noted that Law requires that the disclosure of an application shall inform those skilled in the art how to use applicant's alleged discovery, not how to find out how to use it for themselves., see *In re Gardner et al.* 166 USPQ 138 (CCPA 1970).

Applicants have argued that the specification is enabled and have cited Ruppert et al., Kast et al., Feltkamp et al., Vitiello et al., and Rensing et al. as support to demonstrate enablement, however it is noted that the specification must be enabled as of its filing date. Prior art references that were published after Applicants' effective filing date (5-5-92) cannot be used to rebut prima facie case of nonenablement under 35 USC 112. *In re Glass*, 181 USPQ 31; 492 F.2d 1228 (CCPA 1974).

Applicants have argued that it would be unethical to demonstrate HPV treatment in humans, however the Examiner has not suggested such a demonstration. Applicants have not demonstrated treatment of HPV in animal models. With regard to the method of

Serial Number: 08/170344

-5-

Art Unit: 1802

prophylactic or therapeutic treatment, it appears that the specification is a paper protocol. The specification does not show any therapy or prophylactic treatment, only in vitro studies; no animal studies using the peptides to demonstrate prophylactic or therapy treatment that would correlate to human efficacy have been set forth in the specification.

Applicants have argued that Kast et al. (1991, PNAS 88:2283-2287 and 1991, Immunol. Letters 30(2):229-232) show that one of skill in the art would readily understand from these references how to make and use the claimed invention. Kast et al. (1991, PNAS) disclose the immunization of synthetic peptides of Sendai virus, not HPV. Further, Kast et al. (1991, Immunol. Letters) does disclose the use of peptide vaccination, however the use of HPV peptides is not discussed. HPV is discussed with regard to using "... cultured human CTL for immunotherapy of virus-induced tumors" (p. 229). Furthermore, the reference discloses that there are several unanswered questions regarding peptide vaccination as a novel immunotherapeutic or preventive approach in man (summary; p. 230, col. 2).

In response to Applicant's argument that Matlashewski et al. does not include certain features of Applicant's invention, the limitations on which the Applicant relies (i.e., peptides that bind in the groove on top of an MHC Class I molecule) are not stated in the claims. Therefore, it is irrelevant whether the reference includes these features or not.

Applicant's arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

Applicants have asserted that as the methods claims directed to methods of prophylactic or therapy treatment of a human have been cancelled that this objection should be eliminated. However, claims (16-18) directed a pharmaceutical composition containing a prophylactically or therapeutically effective amount for eliciting cellular immune response of a peptide and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant are not enabled for the same reasons as methods claims. The claims as presently written indicate or suggest that the 'pharmaceutical composition' would be administered to an animal or human,

Serial Number: 08/170344

Art Unit: 1802

however the specification is not enabled for such administration as previously indicated. Further, such short peptides require immunogenic carriers to ensure an immune response.

The claims also recite fragments, homologs, isoforms, derivatives genetic variants or conservative variants of the amino acid sequences and that these fragments, homologs, isoforms, derivatives genetic variants or conservative variants of the amino acid sequences will bind to the grooves on top of the MHC Class I molecule. The specification discloses that variants and derivatives include any amino acid substitution, deletion, or other processes (p. 17). Since the amino acid sequence of a protein determines its structural and functional properties, predictability of which changes can be tolerated in a protein's amino acid sequence and still retain similar activity/utility requires a knowledge of and guidance with regard to which amino acids in the protein's sequence, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which the proteins' structure relates to its function. However, the problem of predicting protein structure from mere sequence data of a single protein and in turn utilizing predicted structural determinations to ascertain functional aspects of the protein and finally what changes can be tolerated with respect thereto is extremely complex (Bowie et al. 1990; p. 1306; p. 1308) and is well outside the realm of routine experimentation.

While recombinant and mutagenesis techniques are known, it is not routine in the art to screen for multiple substitutions or multiple modifications of other types and the positions within the protein's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining similar activity/utility are limited in protein and the result of such modifications is unpredictable based on the instant disclosure.

The specification does not support the broad scope of the claims which encompass all variants of the protein because the specification does not disclose the following: the general tolerance to modification (substitution, insertion, deletion) and extent of such tolerance; specific positions and regions of the sequence(s) which can be predictably modified and which regions are critical; what variants, if any, can be made which retain the biological activity of the intact protein; and the specification provide essentially no guidance as to which

Serial Number: 08/170344

Art Unit: 1802

of the essentially infinite possible choices is likely to be successful. Further, Houghten et al. teach that changes/modifications (addition, substitution, deletion or inversion) of one or more amino acids in a polypeptide will alter antigenic determinants and therefore effect antibody production (p. 21) as well as antibody binding. Houghten et al. also teach that "... combined effects of multiple changes in an antigenic determinant could result in a loss of [immunological] protection." and "A protein having multiple antigenic sites, multiple point mutations, or accumulated point mutations at key residues could create a new antigen that is precipitously or progressively unrecognizable by any of the antibodies..." (p. 24). Houghten et al. teach that point mutations at one key antigen residue could eliminate the ability of an antibody to recognize this altered antigen (p. 24). It is not always possible to make the derivatives that retain immunodominant regions and immunological activity if the regions have been altered.

Thus, applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed protein in a manner reasonably correlated with the scope of the claims broadly including any number of insertions, deletions or substitutions encompassing a variant, fragment, derivatives, homologs, isoforms etc as presently claimed. The scope of the claims must bear a reasonable correlation with the scope of enablement (In re Fisher, 166 USPQ 19 24 (CCPA 1970)). Without such guidance, the changes which can be made in the protein structure and still maintain activity/utility is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. The sequence of some proteins is highly conserved and one skilled in the art would not expect tolerance to any amino acids modification in such proteins. However, even if it were shown that some modifications could be tolerated in the claimed peptides, for the reasons discussed the claims would still expectedly encompass a significant number of inoperative species which could not be distinguished without undue experimentation. See Amgen, Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F.2d 1200, 18 USPQ2d 1016 (Fed. Cir. 1991) at 18 USPQ2d 1026-1027 and Ex parte Forman, 230 U.S.P.Q. 546 (Bd. Pat. App. & Int. 1986).

Serial Number: 08/170344

-8-

Art Unit: 1802

19. Claims 12 and 14 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims are indefinite for being in improper Markush format. The Office recommends the use of the phrase "selected from the group consisting of..." with the use of the conjunction "and" rather than "or" in listing the species. See MPEP 706.03(Y).

This rejection is maintained. It is noted that Applicants attempted to amend these claims with regard to the Markush language, however the instruction for the amendment of these claims is unclear. The line numbers stated in the amendment filed February 26, 1996 are not the same as those in the amendment filed July 18, 1994.

20. The rejection of claims 2, 4, 7, 8, 11, 13, and 15-18 (and now 25) under 35 U.S.C. § 102(b) as anticipated by, or in the alternative, under 35 U.S.C. § 103 as obvious over Schoolnik et al. is maintained. This rejection is maintained for essentially the same reasons as the rejection of claims 1, 2, 4, 7, 8, 11, 13, and 15-22 under this statutory provision, as set forth in the last Office action. Applicants' arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

Schoolnik et al. discloses synthetic peptides from HPV that are useful in the diagnosis and therapy of conditions associated with HPV infection (abstract; p. 9, l. 10-18; claims). Schoolnik et al. teaches the preparation of peptides from HPV16 (E6 and E7) or other HPV proteins useful to raise antibodies for diagnostic, protective (i.e. prophylactic), and therapeutic purposes and vaccines, as well as various mode of administration (p. 3, l. 1-39; p. 5, l. 28-50; p. 4, l. 27 to p. 5, l. 24; p. 7, l. 47 to p. 8, l. 8).

It is noted that the claims recite a peptide comprising an amino acid sequence from a protein of E6 or E7 of HPV 16 or HPV 18.

The teachings of Schoolnik et al. anticipates the claimed invention by disclosing a peptide from a HPV protein wherein the peptide binds to a MHC Class I molecule, and a

Serial Number: 08/170344

-9-

Art Unit: 1802

method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition. The compositions and methods disclosed in Schoolnik et al. are believed to inherently possess properties which anticipates the claimed invention or if they are not the same the composition and methods, the HPV peptides (and compositions) and methods of treatment as disclosed by Schoolnik et al. would none the less render the claims obvious because it possesses the components necessary to prepare a peptide from HPV and methods of treatment as claimed in the instant application. Binding of MHC Class I molecules via T-cell activation is an inherent part of the process of generating an immunogenic response in a mammal. Since the Office does not have the facilities for examining and comparing applicants' method for preparation of a HPV peptide and methods of treatment of the prior art, the burden is on applicant to show a novel or unobvious differences between the claimed product and the product of the prior art (i.e., that the peptide, composition, and method of use of the prior art does not possess the same material structural and functional characteristics of the claimed composition and methods of preparation). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

In response to Applicant's argument that Schoolnik et al. does not include certain features of Applicant's invention, the limitations on which the Applicant relies (i.e., peptides have to fit snugly in the groove of HLA Class I molecule; pockets in the groove; specific anchor residues) are not stated in the claims. Therefore, it is irrelevant whether the reference includes those features or not.

It is noted that the use of prior art published after Applicants' effective filing date can not be used rebut rejections.

Applicant's arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

Applicants' comments have been addressed previously. Applicants directed the Examiner to the previous response. It is noted at p. 11 of the previous response that

Serial Number: 08/170344

-10-

Art Unit: 1802

Applicants stated "... one was demonstrated by applicants not to have the binding ability to HLA molecule which is a prerequisite to be a CTL epitope...". Evidence to support Applicants' assertion that the prior art does not anticipated or obviate the claimed invention should be submitted in the form of a declaration.

21. The following new rejection has not been necessitated by the amendment.

22. Claims 2, 4-18 and 25 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 25 and its dependent claims are vague and indefinite in the recitation of "comprising" as the use of the open-ended term "comprises" which fails to exclude unrecited steps and leaves the claims open for inclusion of unspecified ingredients, even in major amounts. See In re Horvitz, 168 F.2d 522, 78 U.S.P.Q. 79 (C.C.P.A. 1948) and Ex parte Davis et al., 80 U.S.P.Q. 448 (PTO d. App. 1948). Claim 25 is directed to a peptide comprising an amino acid sequence derived from a HPV protein wherein the sequence comprises a nonapeptide from E6 or E7 of HPV 16 or HPV 18. Claim 9 is indefinite and lacks proper antecedent basis in that the claim depends from claim 1 which has been cancelled.

23. No claims are allowed.

24. Applicant's amendment necessitated the new grounds of rejection. Accordingly, **THIS ACTION IS MADE FINAL**. See M.P.E.P. § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT

Serial Number: 08/170344

-11-

Art Unit: 1802

MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

25. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is (703) 305-3394. The examiner can normally be reached on Monday-Thursday from 7:00 AM-4:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (703) 308-4027. The fax phone number for this Group is (703) 305-7939.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

N. M. Minnifield
May 31, 1996

James C. Housel
JAMES C. HOUSEL 6/10/96
SUPERVISORY PATENT EXAMINER
GROUP 100

TO SEPARATE, HOLD TOP AND BOTTOM EDGES, SNAP-APART AND DISCARD CARBON

FORM PTO-892
(REV. 3-92)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

SERIAL NO.

GROUP ART UNIT

ATTACHMENT
TO
PAPER
NUMBER

8/170344

1802

16

NOTICE OF REFERENCES CITED

APPLICANT(S)

KAST ETAL.

U.S. PATENT DOCUMENTS

		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
A							
B							
C							
D							
E							
F							
G							
H							
I							
J							
K							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS	PERTINENT SHTS. DWG.	PP. SPEC.
L									
M									
N									
O									
P									
Q									

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

R	Bowie et al. 1990. Science 247: 1306-1310.
S	Doughten et al. 1986. Vaccines 86 pp. 21-25.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
--------------------	-------------	-----------------------	---------------------

08/170,344 03/30/94 KAST

W D45113TFM

EXAMINER
MINNIFIELD, N

18M1/0614

COOPER & DUNHAM
30 ROCKEFELLER PLAZA
NEW YORK, NY 10112

ART UNIT PAPER NUMBER

16

DATE MAILED: 1802

06/14/96

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

☒ Responsive to communication(s) filed on 2-26-96

☒ This action is FINAL.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 D.C. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

- ☒ Claim(s) 2, 4-18, 25 is/are pending in the application.
- Of the above, claim(s) _____ is/are withdrawn from consideration:
- ☐ Claim(s) _____ is/are allowed.
- ☒ Claim(s) 2, 4-18, 25 is/are rejected.
- ☐ Claim(s) _____ is/are objected to.
- ☐ Claims _____ are subject to restriction or election requirement.

Application Papers

- ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- ☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.
- ☐ The specification is objected to by the Examiner.
- ☐ The oath or declaration is objected to, by the Examiner.

Priority under 35 U.S.C. § 119

- ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- ☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
- ☐ received.
- ☐ received in Application No. (Series Code/Serial Number) _____
- ☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

- ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- ☒ Notice of Reference Cited, PTO-892
- ☒ Information Disclosure Statement(s), PTO-1449, Paper No(s). _____
- ☐ Interview Summary, PTO-413
- ☐ Notice of Draftsperson's Patent Drawing Review, PTO-948
- ☐ Notice of Informal Patent Application, PTO-152

- SEE OFFICE ACTION ON THE FOLLOWING PAGES -

770344

Briefed in 180

NL93/00093
APPROVED FOR LICENSE ☐

INITIALS

MAY 19 5 4 5

Date
Received
or
MailedDate
Entered
or
Counted

ABANDONED

1. Application _____ papers.

2. Declaration _____

3. 105 _____

4. 10/10/1008 _____

5. One No Csf _____

6. One No Csf / A _____

7. Responses to 10/10/1008 _____

8. 10/10/1008 _____

9. Raw Sequence Listing (OK) _____

10. Key 3 mod _____

11. One C _____

12. Suppl. Response _____

13. Rejected 3 mod _____

14. Evt. (3) _____

15. One 7 _____

16. Key 3 mod _____

17. Value of Abund _____

18. Power to Input _____

19. _____

20. _____

21. _____

22. _____

23. _____

24. _____

25. _____

26. _____

27. _____

28. _____

29. _____

30. _____

31. _____

32. _____

RECEIVED
JUN 14 1994

GROUP 1800

30 Nov 1994 1800

04 April 1994

02 MAY 1994

5/17/94

10/17/94

10/17/94

10/17/94

10/17/94

9/1/94

4/17/95

4/17/95

5/15/95

8-03-95 8/21

2-21-96 10/17

2-21-96 2/23

6-14-96 6/10

1/23/97

5/10/97

(FRONT)

TOTAL P.14

Confirmation Report - Memory Send

Page : 001
Date & Time: Mar-17-04 15:25
Line 1 : +212 391 0525
Line 2 : +
Machine ID : cooper&dunham

Job number : 771
Date : Mar-17 15:21
To : 01131704166799
Number of pages : 015
Start time : Mar-17 15:21
End time : Mar-17 15:25
Pages sent : 015
Status : OK
Job number : 771

*** SEND SUCCESSFUL ***

COOPER & DUNHAM LLP
1185 Avenue of the Americas, New York, New York 10036
FACSIMILE TRANSMISSION
Telephone No.: 212-278-0400 / Facsimile No.: 212-391-0526

PLEASE DELIVER THE FOLLOWING PAGES

TO : Dr. J. Ranes
COMPANY : Vereenigde Octrooibureaux
FAX NO. : 011-31-70-416-6799
FROM : Robert D. Katz, Esq.

TOTAL NUMBER OF PAGES, INCLUDING COVER PAGE: 15

DATE : March 17, 2004

☒ CONFIDENTIAL

☒ URGENT

If this facsimile message has reached you in error, please notify us by collect telephone and return it by the Postal Service, as it may contain attorney privileged and confidential information.

MESSAGE:

I enclose the Office Action finally rejecting the application in connection with U.S. Application No. 08/170,344, filed March 30, 1994 (your ref. no. ME/P20884US00). Please send me instructions on how to respond and we will file a response along with a petition to revive the application.

As mentioned we will also need a Terminal Disclaimer, which we can send to you for signature by your client.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL SHAKINAH DAVIS AS SOON AS POSSIBLE AT (212) 278-0459.

Shakinah Davis

From: Shakinah Davis
Sent: Monday, March 29, 2004 2:57 PM
To: 'j.renes@vereenigde.nl'
Subject: REMINDER Correspondence from Robert D. Katz

Dear Dr. Renes:

We forwarded the Office Action for U.S. Application No. 08/170,344 (your ref. no. ME/P20884US00; our ref. no. 45113) on March 17, 2004. Please let us know at your earliest convenience how we should proceed.

Robert D. Katz
(c/o Assistant, Shakinah Davis)
COOPER & DUNHAM LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. (212) 278-0400
Fax.(212) 391-0525

3/29/2004

Robert D. Katz

From: Einerhand M. [m.einerhand@vereenigde.nl]
Sent: Thursday, May 13, 2004 11:18 AM
To: Aude Gerspacher
Cc: Robert D. Katz; Elst van der N.
Subject: RE: FW: your ref 45113 our ref ME -20884us00

Dear Bob,

I have just been in contact with the client to inquire about the timing of the response. The situation at this moment is that the licensee has not yet responded. The client assumes that it will not be before next week before we will be able to provide you with instructions.

I discussed the case with a US-agent who also does work for us. He mentioned that there is also a possibility to revive abandoned applications when the abandonment is unavoidable. He suggested that in that case there would be no need to file a terminal disclaimer. What do you think about this opportunity? Is it possible to request revival under this regime in the present case?

Sincerely,

Mark Einerhand

-----Original Message-----

From: KATZ22@aol.com [mailto:KATZ22@aol.com]
Sent: vrijdag 7 mei 2004 15:45
To: m.einerhand@vereenigde.nl
Subject: Re: FW: your ref 45113 our ref ME -20884us00

Mark--Yes, next week will be in time. Please forward to agerspacher@cooperdunham.com, with a copy to me at , and we will get it filed as soon as possible. Thanks. Have a good weekend. Bob

"MMS <unipat>" made the following annotations.

13-05-2004, 17:20:06

 All incoming and outgoing email is scanned to protect against viruses and other malicious content.

The information contained in this communication is confidential and may be legally privileged. It is intended solely for the use of the individual or entity to whom it is addressed and others authorised to receive it. If you are not the intended recipient you are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. VEREENIGDE is neither liable for the proper and complete transmission of the information contained in this communication nor for any delay in its receipt.
 =====

6/4/2004

Shakinah Davis

From: Aude Gerspacher
Sent: Friday, May 14, 2004 10:51 AM
To: 'Einerhand M.'
Cc: Robert D. Katz
Subject: RE: FW: your ref 45113 our ref ME -20884us00

Dear Mark:

Thank you for your e-mail. As far as the timing of filing the petition, the U.S. Patent office requires that once an application becomes inadvertently abandoned, the applicant must act with diligence. The standard for diligence at the Patent Office is one of "reasonable diligence", which "does not require that applicant or his attorney ... drop all other work and concentrate on the particular invention involved". We will file the petition as soon as we receive your instructions.

In addition, there is a provision in the rules for reviving applications for which abandonment was unavoidable. 37 C.F.R 1.137(a) provides that if the delay was *unavoidable*, a petition may be filed to revive the application. Such a petition requires a) the reply required (i.e. the response to the outstanding office action); b) the petition fee; c) a *showing* that the delay was unavoidable; and 4) a Terminal Disclaimer. There is an express requirement for a Terminal Disclaimer. The requirements for filing a petition under this section are actually more stringent as a *showing* (i.e. facts and evidence) must be submitted and be to the satisfaction of the Director reviewing the petition. All that is required for a petition to revive *unintentionally* abandoned applications is a statement asserting the delay was unintentional. In addition, the U.S. Patent Office Manual of Patent Examination Procedures warns that a petition filed for unavoidable delay has less chance of being granted and will inevitably take more time for a decision to be made due to the more stringent "unavoidable" standard. [MPEP 711.03(c)]

I hope this answers your questions and addresses your concerns. Please feel free to contact me if you have additional questions.

Best regards,
Aude

Aude Gerspacher, Esq.
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, NY 10036
Tel: 212-278-0506
Fax: 212-391-0525


CONFIDENTIAL

The information within this e-mail message is intended only for the personal and confidential use of the recipient (s) named above. This message is covered by applicable non-disclosure agreement(s) as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this message in error, please notify us immediately by e-mail, and delete the original message.

-----Original Message-----

From: Einerhand M. [mailto:m.einerhand@vereenigde.nl]
Sent: Thursday, May 13, 2004 11:18 AM

5/19/2004



To: Aude Gerspacher
Cc: Robert D. Katz; Elst van der N.
Subject: RE: FW: your ref 45113 our ref ME -20884us00

Dear Bob,
 I have just been in contact with the client to inquire about the timing of the response. The situation at this moment is that the licensee has not yet responded. The client assumes that it will not be before next week before we will be able to provide you with instructions.

I discussed the case with a US-agent who also does work for us. He mentioned that there is also a possibility to revive abandoned applications when the abandonment is unavoidable. He suggested that in that case there would be no need to file a terminal disclaimer. What do you think about this opportunity? Is it possible to request revival under this regime in the present case?

Sincerely,
 Mark Einerhand

-----Original Message-----

From: KATZ22@aol.com [mailto:KATZ22@aol.com]
Sent: vrijdag 7 mei 2004 15:45
To: m.einerhand@vereenigde.nl
Subject: Re: FW: your ref 45113 our ref ME -20884us00

Mark—Yes, next week will be in time. Please forward to agerspacher@cooperdunham.com, with a copy to me at , and we will get it filed as soon as possible. Thanks. Have a good weekend. Bob

"MMS <unipat>" made the following annotations.

 13-05-2004, 17:20:06

 All incoming and outgoing email is scanned to protect against viruses and other malicious content.


The information contained in this communication is confidential and may be legally privileged. It is intended solely for the use of the individual or entity to whom it is addressed and others authorised to receive it. If you are not the intended recipient you are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. VEREENIGDE is neither liable for the proper and complete transmission of the information contained in this communication nor for any delay in its receipt.

5/19/2004

VEREENIGDE

BY FACSIMILE: +1 212 391 0525
Cooper & Dunham
1185 Avenue of the Americas
New York, N.Y. 10036
USA

Confirmation Copy



Your ref. 45113
Our ref. ME/P20884US00

Den Haag,
June 1, 2004

Re: U.S. patent application No. 08/170,344
in the name of Rijksuniversiteit Leiden

Nieuwe Parklaan 97

P.O. Box 87930
2508 DH Den Haag
The Netherlands

Telephone +31 70 416 67 11
Telefax +31 70 416 67 99

e-mail patent@vereenigde.nl
trademark@vereenigde.nl
legal@vereenigde.nl

www.vereenigde.com

Dear dr. Katz,

The client has approved the draft petition to revive that you provided for their review. Please go forward and file the petition. The signing of the terminal disclaimer by the University will take some time. We will forward you the signed disclaimer upon receipt thereof by us. As discussed on the phone, you will file the petition with an unsigned disclaimer, together with a letter explaining that we will file the signed disclaimer as soon as we have the signatures.

On a different note, the client has requested that we forward a letter to you. The letter, of which a copy is herein enclosed, is self-explanatory.

Sincerely,
VEREENIGDE

M. Einerhand

ne

European and Dutch patent attorneys
* Dutch patent attorney

** European patent attorney and CPA (UK)

J.H.F. Winckels	L.J.J. Jessen
C.J.J. van Loon	K.M.L. Bijvank
F.A. Dietz	B.Ch. Ledeboer
M.J. Hatzmann	
C.M. Jansen	L.J. de Haas
A.H.K. Tan	L.A.C.M. van Wezenbeek
J. Renes	A.P. van Wijk
H.A. Witmans	O.L. Oudshoorn
H.A.M. Marsman	K. Thirlwell**

M.P.W. Einerhand
J.C.C. van Melle
M. van Rooij
F.N. Ferro*
J. de Vries*
F.M. van Bouwelen*
S.T. van Doorn*
M.C. Molling*
L.J. van Grieken-Plooster *

European and Benelux
trademark attorneys

A.A.M. Reijns-Kouenaar

L.P. Kindt
P.A. van der Wees
N.L. Wolfs
M. Driessen
M.J.A. Haegens
M.H. Kamp

Attorneys-at-Law

H. Mars
N.J. Oostenbroek

A.H. de Bosch Kemper-
de Hilster
M.A. van den Hazenkamp

Of counsel
A.W. Prins

~~SEED CAPITAL INVESTMENTS~~

Vereenigde
T.a.v. de heer dr M.P.W. Einerhand
Snouckaertlaan 42
3811 MB AMERSFOORT

per fax: 033 422 7319
confirmation by post

S294.04d / Your ref. ME/P20884US00 / HPV-V US Patent Application No. 08/170,334
18 May 2004

Dear Mr. Einerhand,


We recently received your letter dated 29 April 2004, which included a proposal from Cooper & Dunham for reinstating the above application.

After consultation with our US partner we have come to the conclusion that the Petition to Withdraw the Holding of Abandonment in this case appears to be in order. Please request that Cooper & Dunham proceed. However, as mentioned on several previous occasions, please note that we are still waiting for a detailed explanation from Cooper & Dunham.

Please also be advised that SCI expects to be reimbursed for all expenses and any related costs (including damages) that have been incurred or will be incurred as a result of the abandonment of this application. We would also like to make it very clear that SCI will not pay or reimburse any expenses for the reinstatement of this US application to either Vereenigde or Cooper & Dunham. We kindly ask you to pass this message on to your US partner.

We would appreciate if you would keep us informed on all future developments.

Yours sincerely,
SEED CAPITAL INVESTMENTS (SCI) B.V.



W.J.M. de Vette
Director

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Veröffentlichungsnummer: **0 456 197 A1**

(12)

EUROPÄISCHE PATENTANMELDUNG

(21) Anmeldenummer: 91107423.5

(51) Int. Cl.⁵: **C07K 7/08, C07K 7/10,
A61K 37/02, A61K 39/42,
G01N 33/569**

(22) Anmeldetag: 07.05.91

(30) Priorität: 10.05.90 DE 4015044

(43) Veröffentlichungstag der Anmeldung:
13.11.91 Patentblatt 91/46

(84) Benannte Vertragsstaaten:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Anmelder: **BEHRINGWERKE
Aktiengesellschaft
Postfach 1140
W-3550 Marburg 1(DE)**

(72) Erfinder: **Bleul, Conrad
Römerstrasse 15a
W-6900 Heidelberg(DE)
Erfinder: Gissmann, Lutz, Prof. Dr.
Im Pirolweg 1
W-6908 Wiesloch(DE)
Erfinder: Müller, Martin
Husarenstrasse 14
W-6900 Heidelberg(DE)**

(74) Vertreter: **Becker, Heinrich Karl Engelbert, Dr.
et al
HOECHST AKTIENGESELLSCHAFT Central
Patent Department P.O. Box 80 03 20
W-6230 Frankfurt am Main 80(DE)**

(54) **Seroreaktive Epitope auf Proteinen des menschlichen Papillomavirus (HPV) 18.**

(57) Die Erfindung betrifft seroreaktive Epitope auf Proteinen des menschlichen Papillomavirus HPV18.
Außerdem betrifft die Erfindung Peptide, die Aminosäuresequenzen besitzen, die ganz oder teilweise mit den Sequenzen der seroreaktiven Epitope übereinstimmen und Impfstoffe, die solche Peptide enthalten.

EP 0 456 197 A1

Die Erfindung betrifft Seroreaktive Regionen auf den Proteinen E1, E6 und E7 des menschlichen Papillomavirus (HPV) 18.

Weiterhin betrifft die Erfindung Impfstoffe, die Peptide enthalten, welche Aminosäuresequenzen der seroreaktiven Regionen der genannten Virusproteine umfassen und diagnostische Kits, welche die genannten Peptide enthalten.

HPV18 ist ein spezieller Typ des menschlichen Papillomavirus, der das erste Mal in Proc. Natl. Acad. Sci., USA 80, 3813-3815 (1983) beschrieben wurde.

Die DNA-Sequenz und die Organisation des viralen Genoms von HPV18 wurde in Virology 145, 181-185 (1985) publiziert.

HPV18 induziert nicht nur gutartige Schädigungen des Anogenitaltrakts, sondern auch maligne Tumoren des Uterushalses, des Penis und der Scheide. Zudem findet sich HPV18 jedoch in genitalen Ausschabungen von klinisch symptomlosen Individuen. Bis heute ist über die Immunantwort, die auf eine Infektion durch HPV18 und andere Papillomaviren erfolgt, wenig bekannt.

In ersten Experimenten wurden menschliche Seren von STD-Patienten, von Patienten, die an zervikalen Tumoren leiden und von gesunden Individuen auf die Anwesenheit von Antikörpern, die gegen virale Proteine gerichtet sind, getestet. Diese viralen Proteine wurden als Fusionsproteine, die an verschiedene prokaryotische Peptide über ihren N-Terminus kovalent gebunden waren, exprimiert. Solche Fusionsproteine wurden dann als Antigene in Western-Blot-Experimenten verwendet. Dieser Test ist jedoch relativ langwierig und kompliziert und nur mit großem Aufwand durchzuführen, so daß er nicht für eine quantitative Analyse von großen Mengen menschlichen Serums geeignet erscheint. Außerdem ist dieser Test nicht sehr spezifisch, weil die verschiedenen Papillomavirus-Typen auch im Hinblick auf ihr Proteincore verwandt sind und dadurch eine Kreuzreaktion von Antikörpern mit Proteinen bzw. Fusionsproteinen verschiedener Papillomavirus-Typen nicht ausgeschlossen werden kann.

Die Aufgabe der vorliegenden Erfindung ist deshalb die Identifizierung von viralen Strukturen des HPV18, die als Hilfsmittel in der Prophylaxe, der Diagnose und der Therapie von HPV18-induzierten Krankheiten des Menschen geeignet sind. Das Wissen um solche Strukturen (Proteindomänen) ist eine Voraussetzung für die Etablierung eines Tests mit dem große Mengen menschlichen Blutserums auf Anwesenheit von spezifischen HPV geprüft werden können.

Die vorliegende Erfindung umfaßt insofern ein seroreaktives Epitop auf dem E1-Protein von HPV18 mit der folgenden Aminosäuresequenz

TENSPGERLEVDTLSPRLQEISLNS

sowie seroreaktive Epitope auf dem E6-Protein von HPV18 mit einer der folgenden Aminosäuresequenzen

I. DPTRRPYKLPDLCTELNTSLQDIEITCVYCKT

II. MARFEDPTRRPYKL

III. AACHKCIDFYSRIELRHYSDSVYGDTLEKLT

sowie seroreaktive Epitope auf dem E7-Protein von HPV18 mit einer der folgenden Aminosäuresequenzen

I. VLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQRH und

II. IDGVNHQHLPARR.

Weiterhin umfaßt die Erfindung Peptide, die entweder eine oder mehrere erfindungsgemäße Aminosäuresequenz(en) der oben genannten seroreaktiven Epitope enthalten.

Die Erfindung umfaßt auch Impfstoffe, die auf Peptiden basierten, die eine oder mehrere Aminosäuresequenz(en) der oben genannten seroreaktiven Epitope der Proteine von HPV18 enthalten.

Spezifische Antikörper gegen HPV18 E1-, E6- und E7-Proteine können mit Hilfe eines erfindungsgemäßen diagnostischen Kits in Patientenseren nachgewiesen werden. Dieser Kit enthält die erfindungsgemäßen Peptide.

Im Sinne einer Prophylaxe können auch die spezifischen viralen Proteine, die die seroreaktiven

Regionen enthalten, auch frühzeitig durch polyklonale Antikörper bzw. monoklonale Antikörper, die gegen diese Regionen gerichtet sind, im Blutserum identifiziert werden. Dementsprechend umfaßt diese Erfindung auch einen diagnostischen Kit, der polyklonale oder monoklonale Antikörper enthält, die spezifisch gegen die seroreaktiven Regionen des HPV18 gerichtet sind.

5 Zur Identifizierung der seroreaktiven Epitope wurden folgende voneinander unabhängige Methoden verwendet:

A. Ein Screening einer "Shot Gun"-Expressionsbank: Die im Bakterienplasmidvektor pSP65 klonierte HPV18-DNA wurde mit Ultraschallscherung und anschließender DNase-Behandlung auf eine durchschnittliche Fragmentgröße von 100 Basenpaaren gebracht. Die Enden dieser Fragmente wurden mit T4 DNA-Polymerase aufgefüllt und in den Phagenexpressionsvektor fuse 1 einligiert. Fuse 1 ist von dem Bakteriophagen fd abgeleitet und in Science 228, 1315-1317 (1985) beschrieben. Die Phagen wurden mit Escherichia coli K91 ausplattiert, Replika auf Nitrocellulosefilter abgezogen und die Filter mit geeigneten polyklonalen Kaninchenseren inkubiert. Positive Klone wurden in mehreren Vereinzelungsschritten isoliert und die immunreaktiven Peptidsequenzen durch DNA-Sequenzierung identifiziert.

15 B. Peptidüberlappung

127 überlappende Peptide, die kurzen Stücken der HPV18E6- und -E7-Proteine entsprechen, wurden an Polyethylen-"pins" synthetisiert, wobei die Fmoc-Chemie verwendet wurde (Proc. Natl. Acad. Sci., 82, 178 (1985)). Die Proteinsequenz der E6- und E7-Proteine wurde in 10mere unterteilt, die in 8 Aminosäuren mit dem nächsten Peptid übereinstimmen. Die Peptide wurden in den entsprechenden Antiseren durch ELISA ausgetestet.

Beispiel 1

Derivate des filamentösen Phagen fd wurden benutzt um ein Expressionssystem für HPV18 DNA-Fragmente zu erhalten. Dazu wurde fuse 1 (fd-tet-J6, Science 228, 1315-1317 (1985); Gene 73, 305-318 (1988)) an der einzigen Pvull-Schnittstelle geschnitten. Genomische HPV18 DNA-Fragmente aus einem DNaseI-Verdau nach DNA-Repair wurden mit einer T4-DNA-Ligase blunt-end einligiert. Zur Transformation des fuse 1-Vektors wurde der E. coli Stamm K802 (FgaIK2 galT22 metB1 supE44 hsdR(2); Journal of Molecular Biology 16, 118-133 (1966)) nach dem Verfahren von Hanahan aus Journal of Molecular Biology 30 166, 557-580 (1988) verwendet. Die tet-resistenten Kolonien produzieren Bacteriophagen, die für die Bakterien wegen ihres F-Phänotyps nicht infektiös sind. Um die Phagen auszuplattieren wurde der E. coli Stamm K91 (F⁺, ein Derivat von E. coli K38, Virology 49, 45-60 (1972)) verwendet.

Beispiel 2

35 Ungefähr 50 000 rekombinierte Phagen aus der oben beschriebenen Random-Bank wurden mit 0,2 ml exponentiell wachsenden E. coli K91-Zellen in 3,5 ml 0,5 % Agarose, die 10 mM MgSO₄ enthielt, auf Minimalagarplatten ausplattiert. Replika der Platten wurden auf Nitrocellulosefilter abgezogen und dann 6 h lang bei 37 °C weiter auf frischem Minimalagar inkubiert, um das Signal zu verstärken. Danach wurden die Filter 60 min lang mit 10 % fettarmer Milch in PBS geblockt und über Nacht in 5 % Milch-PBS mit einer Verdünnung von HPV-spezifischen Antisera von 1:100 bis 1:1000 inkubiert. Statt der spezifischen HPV-Antisera können auch monoklonale Antikörper verwendet werden. Die Antisera wurden mit beschallten K91-Zellen präadsorbiert. Die Filter wurden dann 5x gewaschen und zwar 5 min lang in einer PBS/0,1 % Tween 20 und dann 3 h lang bei Raumtemperatur mit Ziegen-anti-Kaninchen-Antikörper oder, im Fall der Verwendung monoklonaler Antikörper, anti-Maus-Peroxidase-Antikörper (1:1000) in 5 % fettarmer Milch inkubiert. Nach Waschen der Filter wurden sie in 50 ml PBS, das 30 mg Diaminobenzidin, 30 µl 1 %iges H₂O₂ und 1,5 ml 1 %iges NiSO₄ enthielt, gefärbt. Danach wurden die Filter 30 min lang in H₂O gewaschen und danach auf Filterpapier getrocknet.

Mit dem polyklonalen Kaninchenserum gegen HPV18 E7 wurden primär 25 Phagen isoliert, von denen sich 18 in den weiteren Aufreinigungsschritten als positiv erwiesen. Anschließend wurden Phagenpartikel in Kultur angezüchtet und Einzelstrang-DNA präpariert.

Beispiel 3

55 Derselbe Ansatz wie in Beispiel 2 wurde auch für HPV18 E6-Protein gewählt. Da das verwendete polyklonale Kaninchenserum Kreuzreaktionen mit nichtviralen Epitopen aufwies, wurde neben der Western-Blot-methode mit spezifischen DNA-Fragmenten geprobt, um unter allen reaktiven Rekombinanten solche mit HPV18 E6-Anteilen zu identifizieren. Aus 70 000 rekombinanten Phagen wurden 15 isoliert und

schließlich sequenziert. Das Epitop HPV18 E6 Nr. 1 wurde so zum Beispiel in der untersuchten Phagenbank insgesamt 10 mal gefunden.

Beispiel 4

5

Präparation von Einzelstrang-DNA aus fuse 1-Rekombinanten

Hierzu wurde eine Vorschrift aus Proc. Natl. Acad. Sci., USA 74, 5463-5467 (1977) verwendet. 50 ml LM wurden mit tet-resistenten E. coli K91-Zellen inkubiert, die das fuse 1-Plasmid trugen und dieser Ansatz wurde 16 h lang bei 37 °C inkubiert. Die Bakterien wurden dann bei 6000 rpm 30 min lang pelletiert. Nach dem Hinzufügen von 2 ml 40 %igem PEG 6000 und 2 ml 5 M Natriumacetat, pH 6,5 zum Überstand wurden die Phagen bei 0 °C 60 min lang präzipitiert und das Präzipitat bei 6000 rpm 60 min lang zentrifugiert. Das Pellet wurde in 0,3 ml TE resuspendiert. Nach zwei Extraktionen mit Phenol wurde die DNA präzipitiert. Ungefähr 25 % der Präparationen wurden dann zur Sequenzierung verwendet.

15

Beispiel 5

Sequenzierung

Zur DNA-Sequenzierung wurde die Standard-USB (United States Biochemicals)-Methode (USB, 1987) verwendet. Der universale Primer wurde durch ein 20mer Oligonucleotid (5'-TCCAGACGTTAGTAAATGAA-3') ersetzt.

Beispiel 6

25

Peptid-Synthese

127 überlappende Peptide, die in kurzen Stücken die ORFs HPV18 E6 und -E7 darstellen, wurden nach der Fmoc-Chemie an Polyethylen-"pins" synthetisiert, wie in Proc. Natl. Acad. Sci. 32, 178 (1985) und Proc. Natl. Acad. Sci. 81, 3998 (1985) beschrieben. Die Polyethylen-"pins", die mit β -Alanin derivatisiert wurden, wurden von CRB England erhalten. Abweichend von oben zitierten Publikationen wurde die Proteinsequenz in Dekapeptide eingeteilt, die mit dem Nachbarpeptid um 8 Aminosäuren überlappen. Die Synthese wurde ausgeführt mit Hilfe der Fmoc-Chemie und in situ-Aktivierung durch BOP (Castro's Reagents) (Tetrahedron Letters, 14, 1219 (1975)). Fmoc-Aminosäurederivate (6 μ mol), BOP und N-Methylmorpholin-Lösung wurden in Polyethyleinsätze (CRB) entsprechend der Peptidsequenz, die synthetisiert werden soll, verteilt. Alle anderen Reaktionen wurden nach dem CRB-Protokoll ausgeführt.

35

Beispiel 7

Die Polyethylen-"pins" wurden nach dem ELISA-Testverfahren mit den oben genannten polyklonalen Kaninchenserum inkubiert, gebundene Antikörper mit Protein-A-Peroxidase nachgewiesen. Ein durch unspezifische Bindungen entstehender Background wurde durch Protein-A-Inkubation ohne ersten Antikörper quantifiziert. Die reaktiven Peptide liegen in Bereichen, die durch das Phagenscreening als seroreaktives Epitop identifiziert wurden.

45

Alle Tests wurden an den Peptiden, die kovalent an die Polyethylen-"pins" gebunden vorliegen und an die sie ursprünglich auch synthetisiert wurden, durchgeführt. Racks mit 96 pins, die in einer solchen Konfiguration fixiert waren, daß sie in die Löcher von Mikrotiter-Platten eingebracht werden konnten, wurden benutzt. Die Inkubation für den ELISA wurde durchgeführt, während die pins in die Löcher hineingetaucht wurden. Die pins wurden mit Methanol und PBS gewaschen und danach mit 0,25 % Gelatine, 0,1 % Tween 20 in PBS 2 h lang bei 37 °C geblockt, gefolgt von einer 1 h Inkubation bei 37 °C mit Seren, die 1:200 bis 1:4000 in 0,125 % Gelatine und 0,05 % Tween 20 verdünnt wurden. Nach einem weiteren Waschschriff mit PBS/0,1 % Tween 20 wurden die pins 1 h lang bei 37 °C mit Protein-A-Peroxidase 1:4000 inkubiert, gefolgt von einem weiteren Waschschriff und Färben mit Tetramethylbenzidin (TMB) 15 min lang. Der Färbeschriff wurde durch Herausziehen der pins aus der Färbelösung und Hinzufügen von 100 μ l einer 0,2 molaren H₂SO₄-Lösung beendet. Die Absorption wurde dann an einem automatischen ELISA-Reader gemessen. Um den Antikörper-Enzym-Komplex nach dem ELISA-Verfahren zu entfernen, wurden die pins für 1 h mit Ultraschall (Wasserbad, 30 W, 48 kHz) bei 60 °C in PBS/1 % SDS/0,1 % β -Mercaptoethanol inkubiert und wurden schließlich mit Methanol gewaschen. Die Effektivität

55

dieser Prozedur wurde mit Hilfe von ELISA unter Verwendung von Protein A/Peroxidase ohne Beteiligung eines primären Serums ausgetestet. Die gleichen Peptide wurden mehr als 40 mal in den folgenden ELISA's getestet.

5 **Tabelle**

Seroreaktives Epitop E1 (HPV18)

10 **bp1193-TENSPLGERLEVDTLSPRLQEISLNS-bp1273**

Seroreaktives Epitop E6 (HPV18)

15 **pb120-DPTRRPYKLPDLCTELNTSLQDIEITCVYCKT-bp215**

MARFEDPTRRPYKL

bp294-AACHKCIDFYSRIELRHYSDSVYGDITLEKT-bp386

20

Seroreaktives Epitop E7 (HPV18)

bp623-VLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQRH-bp763

25

IDGVNHQHLPARR

Patentansprüche

30

1. Seroreaktives Epitop auf dem E1-Protein von HPV18 mit der folgenden Aminosäuresequenz

TENSPLGERLEVDTLSPRLQEISLNS

35

2. Seroreaktive Epitope auf dem E6-Protein von HPV18 mit einer der folgenden Aminosäuresequenzen

40

I. **DPTRRPYKLPDLCTELNTSLQDIEITCVYCKT**

II. **MARFEDPTRRPYKL**

III. **AACHKCIDFYSRIELRHYSDSVYGDITLEKT**

45

3. Seroreaktive Epitope auf dem E7-Protein von HPV18 mit einer der folgenden Aminosäuresequenzen

50

I. **VLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQRH**

II. **IDGVNHQHLPARR.**

55

4. Peptide, dadurch gekennzeichnet, daß sie eines oder mehrere der seroreaktiven Epitope nach den Ansprüchen 1 bis 3 enthalten.

5. Vakzine, dadurch gekennzeichnet, daß sie eines oder mehrere der Peptide nach Anspruch 4 enthalten.

6. Diagnostische Zubereitung für die Identifizierung von spezifischen Antikörpern, die gegen die Proteine E1, E6 oder E7 von HPV18 gerichtet sind, dadurch gekennzeichnet, daß sie eines oder mehrere der Peptide nach Anspruch 4 enthält.
- 5 7. Diagnostische Zubereitung für die Identifizierung von viralen Proteinen in Patientenseren, dadurch gekennzeichnet, daß sie polyklonale oder monoklonale Antikörper mit Spezifität für die Epitope nach Ansprüchen 1 bis 3 und/oder Spezifität für Peptide nach Anspruch 4 enthält.

Patentansprüche für folgenden Vertragsstaat ES

- 10 1. Verfahren zur Herstellung von Impfstoff gegen HPV, dadurch gekennzeichnet, daß eines oder mehrere der Peptide von HPV 18 mit der Aminosäuresequenz

15 **TENSP LGERLEVDT ELS PRLQEISLNS**

des E1-Proteins
20 oder mit den Aminosäuresequenzen

- 25 I. **DPTRRPYKLPDLCTELNTSLQDIEITCVYCKT**
II. **MARFEDPTRRPYKL**
III. **AACHKCIDFYSRIRELRHYSDSVYGDITLEKLT**

30 des E6-Proteins
oder mit den Aminosäuresequenzen

- 35 I. **VLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQRH**
II. **IDGVNHQHLPARR**

40 des E7-Proteins
mit üblichen Adjuvantien und Hilfsstoffen gemischt und für Impfdosen konfektioniert werden.

- 45 2. Verfahren zur Herstellung eines Diagnostikums, dadurch gekennzeichnet, daß eines oder mehrere der Peptide von HPV 18 mit der Aminosäuresequenz

TENSP LGERLEVDT ELS PRLQEISLNS

50 des E1-Proteins
oder mit den Aminosäuresequenzen

55

- I. DPTRRPYKLPDLCTELNTSLQDIEITCVYCKT
II. MARFEDPTRRPYKL
III. AACHKCIDFYSRIRELRHYSDSVYGDITLEKLT

des E6-Proteins

oder mit den Aminosäuresequenzen

- I. VLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQRH
II. IDGVNHQHLPARR

des E7-Proteins

an der Oberfläche eines geeigneten Trägermaterials fixiert wird.

3. Verfahren zur Herstellung eines Diagnostikums, dadurch gekennzeichnet, daß poly- oder monoklonale Antikörper gegen eines oder mehrere der Peptide von HPV 18 mit der Aminosäuresequenz

TENSPIGERLEVDTELSRLQEISLNS

des E1-Proteins

oder mit den Aminosäuresequenzen

- I. DPTRRPYKLPDLCTELNTSLQDIEITCVYCKT
II. MARFEDPTRRPYKL
III. AACHKCIDFYSRIRELRHYSDSVYGDITLEKLT

des E6-Proteins

oder mit den Aminosäuresequenzen

- I. VLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQRH
II. IDGVNHQHLPARR

des E7-Proteins

eingesetzt werden.



Europäisches
Patentamt

EUROPÄISCHER RECHERCHENBERICHT


Nummer der Anmeldung

EP 91 10 7423

EINSCHLÄGIGE DOKUMENTE			
Kategorie	Kennzeichnung des Dokuments mit Angabe, soweit erforderlich, der maßgeblichen Teile	Betrifft Anspruch	KLASSIFIKATION DER ANMELDUNG (Int. Cl.5)
A	EP-A-0 257 754 (STANFORD UNIVERSITY) * Das ganze Dokument, insbesondere Seite 2, Zeilen 10-25; Seite 3; Seite 5, Zeile 25 - Seite 6, Zeile 26 *	1-5	C 07 K 7/08 C 07 K 7/10 A 61 K 37/02 A 61 K 39/42 G 01 N 33/569
A	CHEMICAL ABSTRACTS, Band 107, Nr. 7, 17. August 1987, Seite 191, Zusammenfassung Nr. 53075n, Columbus, Ohio, US; S.T. COLE et al.: "Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products", & J. MOL. BIOL. 1987, 193(4), 599-608 * Zusammenfassung *	1-5	
A	CHEMICAL ABSTRACTS, Band 106, Nr. 1, 5. Januar 1987, Seite 112, Zusammenfassung Nr. 1115k, Columbus, Ohio, US; G. MATLASHEWSKI et al.: "The expression of human papillomavirus type 18 E6 protein in bacteria and the production of anti-E6 antibodies", & J. GEN. VIROL. 1986, 67(9), 1909-16 * Zusammenfassung *	1-5	
Der vorliegende Recherchenbericht wurde für alle Patentansprüche erstellt			
Recherchenort		Abschlußdatum der Recherche	Prüfer
Den Haag		18 August 91	MASTURZO P.
KATEGORIE DER GENANNTEN DOKUMENTE X: von besonderer Bedeutung allein betrachtet Y: von besonderer Bedeutung in Verbindung mit einer anderen Veröffentlichung derselben Kategorie A: technologischer Hintergrund O: nichtschriftliche Offenbarung P: Zwischenliteratur T: der Erfindung zugrunde liegende Theorien oder Grundsätze E: älteres Patentdokument, das jedoch erst am oder nach dem Anmeldedatum veröffentlicht worden ist D: in der Anmeldung angeführtes Dokument L: aus anderen Gründen angeführtes Dokument &: Mitglied der gleichen Patentfamilie, übereinstimmendes Dokument			

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicants : KAST, Wybe Martin et al.
U.S. Serial No. : 08/170,344
U.S. Filing Date : March 30, 1994
For : PEPTIDES OF HUMAN PAPILLOMA VIRUS FOR USE IN
HUMAN T CELL RESPONSE INDUCING COMPOSITIONS



Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF MARK EINERHAND

Sir:

I, Mark Einerhand, hereby declare as follows:

1. I am a registered European Patent Attorney, and a member of the firm of Vereenigde, headquartered in The Hague, The Netherlands. I am a European Patent attorney for the University of Leiden, the assignee of the above-identified application. I am the European Patent attorney responsible for the prosecution of the above-identified application at Vereenigde.
2. In 1994, my firm engaged Cooper & Dunham LLP to file a U.S. patent application for this invention. Mr. Thomas Moran, one of our U.S. correspondents, filed this application on March 30, 1994 and reported its filing to our firm.
3. I am informed that the application underwent examination, and that Office Actions were mailed on October 4, 1994 and August 23, 1995 to which Mr. Moran filed a response on April 4, 1995 and February 23, 1996 respectively.
4. I am further informed that Cooper & Dunham moved its offices from 30 Rockefeller Plaza, New York, New York to 1185 Avenue of the Americas, New York, New

York in late 1994. While we became aware of the change of address sometime in 1994 or 1995, we were unaware that Mr. Moran apparently did not file a change of address notification form for this application. Our foreign correspondents generally would not send us a copy of such a document.

5. I have reviewed our file for this matter, and can state that our firm was unaware that an Office Action was issued in this case on June, 1996, nor were we aware that the United States Patent & Trademark Office issued either an Office Action on June 14, 1996 or a Notice of Abandonment on January 13, 1997. Our file contains no correspondence from Cooper & Dunham during that time period. As mentioned in Mr. Katz's declaration, our firm contacted Cooper & Dunham on December 10, 1997 to ask for a copy of the claims as amended (see Katz Declaration, Ex. 5). We were unaware that a Notice of Abandonment had been mailed by the U.S. Patent and Trademark Office.

6. We first became aware of the possible abandonment when our Records Department on January 20, 2004, sent a status inquiry to Cooper & Dunham to ask about the status of the U.S. application (Ex. A hereto). I am informed that when Cooper & Dunham received our status inquiry, they checked the status of the application on the PTO website, and informed us on February 5, 2004 that the application had gone abandoned in January, 1997 (Ex. B).

7. We sent Mr. Katz of Cooper & Dunham a fax on February 27, 2004 requesting information regarding a possible revival of the application (Exhibit C). In response, Mr. Katz faxed us on February 27, 2004 that he had ordered the file from the USPTO, but that they had thus far not received it (Exhibit D). On around March 8, 2004, we informed the client/investor that the application had become abandoned and that we were investigating the

possibility of reviving the application. On March 17, 2004, we received from Cooper & Dunham a copy of the last Office Action that was issued in this case (Exhibit E). This was reported by us to the client/investor on March 23, 2004 (Exhibit F). On March 30, 2004, we received an email from Cooper & Dunham reminding us that they were awaiting instructions on how to proceed. On around April 5, 2004 we received information from one of the inventors for responding to the Office Action. We sent instructions for responding to the Office Action and an amended set of claims to Cooper & Dunham on April 8, 2004 (Exhibits G and H). On April 21st and 28th, Cooper & Dunham mailed us a draft petition to revive the application, a draft response to the Office Action, a draft request for removal of the finality of the Office Action and a draft terminal disclaimer. These were forwarded to the client/investor on April 29, 2004 (Exhibits I-M). On May 18, 2004, our client informed us that they consulted their licensee and agreed with the proposal for the petition to revive the application and instructed us to inform Cooper & Dunham that they could proceed with the filing of the petition to revive the application (Exhibit N). Since the terminal disclaimer required the signature of the assignee, we contacted Mr. Katz to discuss the filing of the petition to revive the application. After further consultation with the client/investor, we decided not to wait for the signature of the Rijksuniversiteit Leiden, (University of Leiden) but instead to file the petition with an unsigned terminal disclaimer, and a representation that the terminal disclaimer would be filed as soon as received. A written confirmation of this instruction was sent by facsimile on June 1, 2004 (Exhibit O). We received the signed terminal disclaimer on June 30, 2004 (Exhibit P) and forwarded it to Cooper & Dunham on July 1, 2004 (Exhibit Q).

8. On information and belief, and after inquiry, I can state that the personnel at Vereenigde as well as the inventors themselves and the personnel at the assignee University

of Leiden were unaware that the application had become abandoned from January 1997 until February 2004. The delay in filing a response to the June, 1996 Office Action was entirely unintentional, and was due to lack of receipt of the June, 1996 Office Action from Cooper & Dunham LLP. Thus, the delay in filing a response to the June, 1996 Office Action from January 13, 1997 until the filing of a grantable petition was entirely unintentional on the part of my firm, the inventors, the assignee and the investor. Neither the inventors, nor the assignee, nor the investor had any intention or desire to abandon the application. On the contrary, counterparts of the application have been prosecuted in other countries, and the application has been licensed world-wide to an entity that is seeking to commercialize the invention disclosed and claimed in the application. I attach as Exhibit 1 a list showing that applicants have been pursuing the foreign counterparts of this application to issuance throughout the world.

9. The Vereenigde firm, the assignee and the investor acted with reasonable diligence in pursuing revival of the application. After inquiring about the status of the application in January 2004, and learning that the application had become abandoned, we asked Cooper & Dunham LLP to try to determine how the application had gone abandoned, and to see if it could be revived.

10. When we received the copy of the June, 1996 Office Action from Cooper & Dunham LLP, we notified our client, and advised them of the petition to revive procedure, and of the need to file a terminal disclaimer. On information and belief, the assignee/investor had to contact the licensee to inform them of the problem and confirm that they sought to revive the application. Further, the office action was received, and instructions were prepared to enable our U.S. counsel to respond to the June, 1996 Office Action. As soon as they

authorized us to proceed, we notified Cooper & Dunham to file a petition to revive. Cooper & Dunham promptly filed the petition upon receipt of our instructions to do so.

11. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated: August 18, 2004



Mark Einerhand

Den Haag • Groningen • Arnhem • 's-Hertogenbosch • Amersfoort • Nijmegen

Patent Attorneys
Trademark Attorneys
Attorneys-at-Law



VEREENIGDE

Cooper & Dunham
1185 Avenue of the Americas
New York, N.Y. 10036
USA

Nieuwe Parklaan 97

P.O. Box 87930
2508 DH Den Haag
The Netherlands

Telephone +31 70 416 67 11
Telefax +31 70 416 67 99

e-mail patent@vereenigde.nl
trademark@vereenigde.nl
legal@vereenigde.nl

www.vereenigde.com

Your ref. 45113
Our ref. ME/P20884US00

Den Haag,
January 20, 2004

Re.: Patent Application in the U.S. of America No. 08/170,344
for
of RIJKSUNIVERSITEIT LEIDEN

Could you please supply us with a status report of the above mentioned application as we have not heard from you since January 28, 1998.

Yours faithfully,
VEREENIGDE

Records Department
A. Rozendaal

V313.1

Exhibit A

COOPER & DUNHAM LLP
1185 Avenue of the Americas, New York, New York 10036

FACSIMILE TRANSMISSION
Telephone No.: 212-278-0400 / Facsimile No.: 212-391-0526

P208844300

PLEASE DELIVER THE FOLLOWING PAGES

TO : Dr. J. Renes
COMPANY : Vereenigde Octrooibureaux
FAX NO. : 011-31-70-416-6799
FROM : Robert D. Katz, Esq.

ONTVANGEN

06 FEB 2004

AMERSFOORT

TOTAL NUMBER OF PAGES, INCLUDING COVER PAGE: 3

DATE : February 5, 2004

X CONFIDENTIAL

X URGENT

If this facsimile message has reached you in error, please notify us by collect telephone and return it by the Postal Service, as it may contain attorney privileged and confidential information.

MESSAGE:

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL SHAKINAH DAVIS AS SOON AS POSSIBLE AT (212) 278-0459.

LOCATIE:+

ONTV.TIJD 05.02.'04 22:26

Exhibit B

COOPER & DUNHAM LLP

ATTORNEYS AT LAW

1185 AVENUE OF THE AMERICAS, NEW YORK, NEW YORK 10036
TELEPHONE: (212) 278-0400

CHRISTOPHER C. DUNHAM
NORMAN M. ZIVIN
JOHN A. WHITE
WILLIAM S. FELTON
ROBERT D. KATZ
DONNA A. TOSHI
RICHARD S. KILNER
RICHARD F. JAWORSKI
PAUL YONG
PEDRO C. FERNANDEZ
MICHAEL F. MORANO
JASON G. MARIN
KEITH J. BARKAUS
MARVET AGOSTO
ANTHONY V. PLINT
ARIAN A. BARYALAN*
ASHTON J. DEWANEY*
CINDY TANG
RON RILINGSLEY

IVAN S. RAVENHOF
PETER D. MURRAY
JAY H. MAJOU
ROBERT S. S. KORSWITZ
PETER J. PHILLIPS
WENDY E. MILLER
ROBERT T. MALDONADO
ERIC S. KIRCH
ALAN J. MORRISON
GARY J. GRASHNIK
CHRISTINE S. NICHOLS
STAVROS S. LOUKAKOS*
MARIA V. MARUGGI
DEEPRO A. NUNDEE
PAUL S. LIM
AUDE BERGRACHER
JEFFREY C. BISHOP
NARCON BRITHARANT

FACSIMILE: (212) 391-0525
(212) 391-0528
(212) 391-0530

OF COUNSEL
DONALD S. DOWSEN
JOHN R. GARRER
MARR A. FARLEY

SCIENTIFIC ADVISORS
BRIAN J. AMOS, Ph.D.
NICHOLAS F. AUTO, Ph.D.
JOSEPH S. CRYSTAL, Ph.D.
ARMANDO L. BALDONI, M.Phil.
MURIEL M. LIBERTO, Ph.D.
ANNE D. MARINOVIC, Ph.D.
ANTHONY C. RYONG, Ph.D.
JOHN N. RABERMAN, Ph.D.

FOUNDED 1987
www.cooperdunham.com

February 5, 2004

*NEW YORK STATE BAR ADMISSION PENDING
WRITER'S DIRECT DIAL: 212.278.0424
WRITER'S EMAIL: hest2@cooperdunham.com

VIA FACSIMILE

Dr. J. Renes
VEREENIGDE
P.O. Box 87930
2508 DH The Hague
Netherlands

Re: Your prev. ref. Ren/92028-310 - Wybe Martin Kast et al.
Peptides of Human Papilloma Virus for Use in
Human T Cell Response Inducing Compositions
Serial No. 08/170,344 filed March 30, 1994
Your ref. No. ME/P20884US00: Our Docket 45113

Dear Dr. Renes:

In response to your inquiry of January 20, 2004, I have reviewed the file. We are investigating the matter in the Patent Office. I suspect that Mr. Moran never informed the Patent Office that we moved offices, and we never received any correspondence from the Patent Office after our forwarding service expired.

If this turns out to be true, we should be able to revive the application, but will have to file a terminal disclaimer to do so. We will have to disclaim the time period in which the application was unintentionally abandoned.


LOCATIE:+

ONTV.TIJD 05.02.'04 22:26

Dr. J. Renes - VEREENIGDE
February 5, 2004
Page 2

I will let you know as soon as I learn anything further. I apologize on behalf of the firm for this error.

Very truly yours,


Robert D. Katz

RDK/sd

LOCATIE:+

ONTV.T1JD 05.02.'04 22:26



VEREENIGDE

BY FACSIMILE: +1 212 391 0525
Cooper & Dunham
1185 Avenue of the Americas
New York, N.Y. 10036
USA

Nieuwe Parklaan 97

P.O. Box 87930
2508 DH Den Haag
The Netherlands

Telephone +31 70 416 67 11
Telefax +31 70 416 67 99

e-mail patent@vereenigde.nl
trademark@vereenigde.nl
legal@vereenigde.nl

www.vereenigde.com

Your ref. 45113
Our ref. ME/P20884US00

Den Haag,
February 27, 2004

Re: Patent Application in the U.S. of America No. 170844
in the name of RIJKSUNIVERSITEIT LEIDEN

Dear Mr. Katz,

Thank you for your letter of February 5, 2004 in the above-identified patent application.

Could you please inform me whether you have already received word regarding the revival of this application.

Very truly yours,
VEREENIGDE

M. Einerhand

ne

European and Dutch patent attorneys
** Dutch patent attorney*

*** European patent attorney and CPA (UK)*

A.W. Prins
J.E.F. Winckels
C.J.J. van Loon
P.A. Dietz
M.J. Hatzmann
C.M. Jansen
A.H.K. Tan
J. Renes
H.A. Witmans
H.A.M. Maxman

L.J.J. Jansen
K.M.L. Bijvank
B.Ch. Ledebour

L.J. de Kaas
L.A.C.M. van Wezenbeek
A.P. van Wijk
O.L. Oudehoorn
K. Thirivall

M.P.W. Einerhand
J.C.C. van Melle
M. van Rooij
F.N. Feron
J. de Vries
F.M. van Bouweien
S.T. van Doorn
M.C. Molting
L.J. van Orskan-Plooster

European and Benelux
trademark attorneys

A.A.M. Reijns-Kuwnaar

L.P. Kindt
P.A. van der Wees
N.L. Wolfs
M. Driessens
M.J.A. Haegens
M.R. Kamp

Attorneys-at-Law

H. Meem
N.J. Oostenbroek

A.H. de Boesch Kemper-
de Huster
M.A. van den Hazenkamp

COOPER & DUNHAM LLP

ATTORNEYS AT LAW

1125 AVENUE OF THE AMERICAS, NEW YORK, NEW YORK 10036
TELEPHONE: (212) 278-0400

CHRISTOPHER C. DUNHAM
NORMAN R. ZIVIN
JOHN A. WHITE
WILLIAM E. PELTON
ROBERT D. KATZ
DONNA A. TOSIN
RICHARD S. MILNER
RICHARD P. JAWORSKI
PAUL TEND
PEDRO E. FERNANDEZ
MICHAEL P. MORANO
JASON S. MARIN
KATH J. BARKAUS
RAYVEY ASPSTO
ANTHONY V. FLINT
ARIAN A. BARTALAN
ASHTON J. DELANEY
EINSEY YANG
RON BILLINGSLEY

IVAN G. KAVRUMOV
PETER D. MURRAY
JAY K. MAIDLI
ROBERT S. G. HOROWITZ
PETER J. PHILLIPS
WENDY E. MILLER
ROBERT T. MALDONADO
ERIC B. KATZ
ALAN J. MORRISON
GARY J. GERBNIK
CHRISTINE S. NICHLES
SPYROS B. LOUKAKOS
MARIA V. MARUCCI
BSEPRO R. MUKERJEE
PAUL S. LIM
ALICE GERSPACHER
JEFFREY B. SMITH
NARESH SRITHARAN

FACSIMILE: (212) 391-0525
(212) 391-0526
(212) 391-0520

OF COUNSEL
DONALD S. DOWDEN
JOHN R. BARBER
MARK A. FARLEY

SCIENTIFIC ADVISORS
ERIAN J. ANGE, PH.D.
NICHOLAS T. AUTO, PH.D.
JOSEPH B. CRYSTAL, PH.D.
ARMAND L. DABRONI, M. PHIL.
MURIEL M. LEBENT, PH.D.
ANNE C. MARTINOVIC, PH.D.
ANTHONY C. KHONG, PH.D.
JOHN A. HASEMAN, PH.D.

FOUNDED 1957
www.cooperdunham.com

February 27, 2004

*NEW YORK STATE BAR ADMISSION PENDING
WRITER'S DIRECT DIAL: 212.278.0424
WRITER'S EMAIL: fkdz@cooperdunham.com

VIA FACSIMILE

VEREENIGDE
P.O. Box 87930
2508 DH The Hague
Netherlands

Attn: Mark Einerhand


Re: Your prev. ref. Ren/92028-310 - Wybe Martin Kast et al.
Peptides of Human Papilloma Virus for Use in
Human T Cell Response Inducing Compositions
Serial No. 08/170,344 filed March 30, 1994
Your ref. No. ME/P20884US00; Our Docket 45113

Dear Mr. Einerhand:

We have ordered the file in the USPTO, but thus far it has not been located. We have contacted the examiner and she no longer has the file. We will discuss the matter with the examiner. We can reconstruct the file and continue with prosecution from that point.

Once again, on behalf of the firm, we apologize for this error.

Sincerely,


Robert D. Katz

RDK/sd

LOCATION: +2123910525

RX TIME 27.02.'04 22:39

Exhibit D

Veeeniga
file

Facsimile Transmission

TO: Robert Katz




FAX: 212 391 0525

DATE 3-17-04 pages incl. cover 3

From: Helene Stanonik

PLAZA MAILBOXES
2101 CRYSTAL PLAZA ARCADE
ARLINGTON, VA 22202-4600
PH. (703) 415-0400 FAX (703) 415-0403



LOCATION: +2123910525

RX TIME 17.03.'04 21:18

Exhibit B

Serial Number: 08/170344

Art Unit: 1802

-2-

Part III DETAILED ACTION

Response to Amendment

15. Applicants' amendment filed February 26, 1996 is acknowledged and has been entered. Claims 1, 19-22, and 24 have been cancelled. Claims 2-8 and 10-18 have been amended. New claim 25 has been added. Claims 2, 4-18, and 25 are now pending in the present application. All prior rejections are withdrawn with the exception of those discussed below.

16. The text of the 35 U.S.C. Code not included in this Office Action can be found in the prior Office Action.

17. The information disclosure statement filed January 4, 1994 fails to comply with 37 CFR § 1.98(a)(3) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the content of the information, of each patent listed that is not in the English language. It has been placed in the application file, but the information referred to therein has not been considered as to the merits. Applicants state (April 17, 1995) that a substitute IDS will be filed, however it has not been received.

The present amendment filed (2-26-96) directed the Examiner to the April 7, 1995 amendment with respect to the content and relevance of the publications referred to in the IDS. The IDS references that have not been considered are EP0375555 and EP0456197. Applicants have not provided an english translation nor a statement of content and relevance of these references in any of the amendments. These references have not been considered as to the merits.

18. The objection to the specification and rejection of claims 2, 4-18 (and now claim 25) under 35 U.S.C. § 112, first paragraph (i.e. lack of an enabling disclosure) is maintained.

Serial Number: 08/170344

Art Unit 1802

This rejection is maintained for essentially the same reasons as the rejection of claims 1-22 and 24 under this statutory provision, as set forth in the last Office action. Applicants' arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

The specification is objected to under 35 U.S.C. § 112, first paragraph, as failing to provide an adequate written description of the invention and failing to adequately teach how to make and/or use the invention, i.e. failing to provide an enabling disclosure. The disclosure is enabled for nonapeptide sequences from the E6 or E7 genes of HPV16 or HPV18, and MHC Class I molecules as specifically taught in the specification. The specification has not provided sufficient evidence of a method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition. Matlashewski et al. discloses that HPV18 proteins (E6 gene) maybe diagnostically useful since the proteins have been identified in specific human cancers, however the methods as claimed in this invention are not known in the art. Accordingly, amendment of the claims to what is supported in the specification or filing of evidence in the form of a Rule 132 declaration providing factual evidence supporting the broad range claims is suggested.

A disclosure in an application, to be complete, must contain such description and details as to enable any person skilled in the art or science to which it pertains to make and use the invention as of its filing date, In re Glass, 181 USPQ 31; 492 F.2d 1228 (CCPA 1974). While the prior art setting may be mentioned in general terms, the essential novelty, the essence of the invention, must be described in such details, including proportions and techniques where necessary, as to enable those persons skilled in the art to make and utilize the invention.

Specific operative embodiments or examples of the invention must be set forth. Examples and description should be of sufficient scope as to justify the scope of the claims. Where the constitution and formula of a compound is stated only as probability and speculation, the disclosure is not sufficient to support claims identifying the compound by

Serial Number: 08/170344

Art Unit: 1802

such composition or formula. A disclosure involving a new chemical compound or composition must teach persons skilled in the art how to make the compound. Incomplete teachings may not be completed by reference to subsequently filed applications.

The instant specification invites the skilled artisan to experiment. The factor which must be considered in determining undue experimentation are set forth in *Ex parte Forman*, 230 USPQ 546. The factors include 1) quantity of experimentation necessary, 2) the amount of guidance presented, 3) the presence or absence of working examples, 4) the nature of the invention, 5) the state of the prior art, 6) the predictability of the art and the 7) breadth of the claims. With regard to factors three and six, it is noted that there are no working examples or support for in vivo efficacy of the active ingredients in a method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition, or peptides from any HPV that bind to MHC Class I molecules. Such is not seen as sufficient to support the breadth of the claims, wherein the scope of the claims encompasses how to prepare a peptide from any of the listed HPV proteins (or any other HPV protein) wherein the peptide binds to any human MHC Class I molecule. It is noted that Law requires that the disclosure of an application shall inform those skilled in the art how to use applicant's alleged discovery, not how to find out how to use it for themselves., see *In re Gardner et al* 166 USPQ 138 (CCPA 1970).

Applicants have argued that the specification is enabled and have cited Ruppert et al., Kast et al., Feltkamp et al., Vitiello et al., and Rensing et al. as support to demonstrate enablement, however it is noted that the specification must be enabled as of its filing date. Prior art references that were published after Applicants' effective filing date (5-5-92) cannot be used to rebut prima facie case of nonenablement under 35 USC 112. In *re Glass*, 181 USPQ 31; 492 F.2d 1228 (CCPA 1974).

Applicants have argued that it would be unethical to demonstrate HPV treatment in humans, however the Examiner has not suggested such a demonstration. Applicants have not demonstrated treatment of HPV in animal models. With regard to the method of

Serial Number: 08/170344

Art Unit: 1802

prophylactic or therapeutic treatment, it appears that the specification is a paper protocol. The specification does not show any therapy or prophylactic treatment, only in vitro studies; no animal studies using the peptides to demonstrate prophylactic or therapy treatment that would correlate to human efficacy have been set forth in the specification.

Applicants have argued that Kast et al. (1991, PNAS 88:2283-2287 and 1991, Immunol. Letters 30(2):229-232) show that one of skill in the art would readily understand from these references how to make and use the claimed invention. Kast et al. (1991, PNAS) disclose the immunization of synthetic peptides of Sendai virus, not HPV. Further, Kast et al. (1991, Immunol. Letters) does disclose the use of peptide vaccination, however the use of HPV peptides is not discussed. HPV is discussed with regard to using "... cultured human CTL for immunotherapy of virus-induced tumors" (p. 229). Furthermore, the reference discloses that there are several unanswered questions regarding peptide vaccination as a novel immunotherapeutic or preventive approach in man (summary; p. 230, col. 2).

In response to Applicant's argument that Matlashewski et al. does not include certain features of Applicant's invention, the limitations on which the Applicant relies (i.e., peptides that bind in the groove on top of an MHC Class I molecule) are not stated in the claims. Therefore, it is irrelevant whether the reference includes these features or not.

Applicant's arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

Applicants have asserted that as the methods claims directed to methods of prophylactic or therapy treatment of a human have been cancelled that this objection should be eliminated. However, claims (16-18) directed a pharmaceutical composition containing a prophylactically or therapeutically effective amount for eliciting cellular immune response of a peptide and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant are not enabled for the same reasons as methods claims. The claims as presently written indicate or suggest that the 'pharmaceutical composition' would be administered to an animal or human,

Serial Number: 08/170844

Art Unit: 1802

however the specification is not enabled for such administration as previously indicated. Further, such short peptides require immunogenic carriers to ensure an immune response.

The claims also recite fragments, homologs, isoforms, derivatives genetic variants or conservative variants of the amino acid sequences and that these fragments, homologs, isoforms, derivatives genetic variants or conservative variants of the amino acid sequences will bind to the grooves on top of the MHC Class I molecule. The specification discloses that variants and derivatives include any amino acid substitution, deletion, or other processes (p. 17). Since the amino acid sequence of a protein determines its structural and functional properties, predictability of which changes can be tolerated in a protein's amino acid sequence and still retain similar activity/utility requires a knowledge of and guidance with regard to which amino acids in the protein's sequence, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which the proteins' structure relates to its function. However, the problem of predicting protein structure from mere sequence data of a single protein and in turn utilizing predicted structural determinations to ascertain functional aspects of the protein and finally what changes can be tolerated with respect thereto is extremely complex (Bowie et al. 1990; p. 1306; p. 1308) and is well outside the realm of routine experimentation.

While recombinant and mutagenesis techniques are known, it is not routine in the art to screen for multiple substitutions or multiple modifications of other types and the positions within the protein's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining similar activity/utility are limited in protein and the result of such modifications is unpredictable based on the instant disclosure.

The specification does not support the broad scope of the claims which encompass all variants of the protein because the specification does not disclose the following: the general tolerance to modification (substitution, insertion, deletion) and extent of such tolerance; specific positions and regions of the sequence(s) which can be predictably modified and which regions are critical; what variants, if any, can be made which retain the biological activity of the intact protein; and the specification provide essentially no guidance as to which

Serial Number: 08/170344

Art Unit: 1802

of the essentially infinite possible choices is likely to be successful. Further, Houghten et al. teach that changes/modifications (addition, substitution, deletion or inversion) of one or more amino acids in a polypeptide will alter antigenic determinants and therefore effect antibody production (p. 21) as well as antibody binding. Houghten et al. also teach that "... combined effects of multiple changes in an antigenic determinant could result in a loss of [immunological] protection." and "A protein having multiple antigenic sites, multiple point mutations, or accumulated point mutations at key residues could create a new antigen that is precipitously or progressively unrecognizable by any of the antibodies..." (p. 24). Houghten et al. teach that point mutations at one key antigen residue could eliminate the ability of an antibody to recognize this altered antigen (p. 24). It is not always possible to make the derivatives that retain immunodominant regions and immunological activity if the regions have been altered.

Thus, applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed protein in a manner reasonably correlated with the scope of the claims broadly including any number of insertions, deletions or substitutions encompassing a variant, fragment, derivatives, homologs, isoforms etc as presently claimed. The scope of the claims must bear a reasonable correlation with the scope of enablement (In re Fisher, 166 USPQ 19 24 (CCPA 1970)). Without such guidance, the changes which can be made in the protein structure and still maintain activity/utility is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. The sequence of some proteins is highly conserved and one skilled in the art would not expect tolerance to any amino acids modification in such proteins. However, even if it were shown that some modifications could be tolerated in the claimed peptides, for the reasons discussed the claims would still expectably encompass a significant number of inoperative species which could not be distinguished without undue experimentation. See Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F.2d 1200, 18 USPQ2d 1016 (Fed. Cir. 1991) at 18 USPQ2d 1026-1027 and Ex parte Forman, 230 U.S.P.Q. 546 (Bd. Pat. App. & Int. 1986).

Serial Number: 08/170344

Art Unit: 1802

-8-

19. Claims 12 and 14 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims are indefinite for being in improper Markush format. The Office recommends the use of the phrase "selected from the group consisting of..." with the use of the conjunction "and" rather than "or" in listing the species. See MPEP 706.03(Y).

This rejection is maintained. It is noted that Applicants attempted to amend these claims with regard to the Markush language, however the instruction for the amendment of these claims is unclear. The line numbers stated in the amendment filed February 26, 1996 are not the same as those in the amendment filed July 18, 1994.

20. The rejection of claims 2, 4, 7, 8, 11, 13, and 15-18 (and now 25) under 35 U.S.C. § 102(b) as anticipated by, or in the alternative, under 35 U.S.C. § 103 as obvious over Schoolnik et al. is maintained. This rejection is maintained for essentially the same reasons as the rejection of claims 1, 2, 4, 7, 8, 11, 13, and 15-22 under this statutory provision, as set forth in the last Office action. Applicants' arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

Schoolnik et al. discloses synthetic peptides from HPV that are useful in the diagnosis and therapy of conditions associated with HPV infection (abstract; p. 9, l. 10-18; claims). Schoolnik et al. teaches the preparation of peptides from HPV16 (E6 and E7) or other HPV proteins useful to raise antibodies for diagnostic, protective (i.e. prophylactic), and therapeutic purposes and vaccines, as well as various mode of administration (p. 3, l. 1-39; p. 5, l. 28-50; p. 4, l. 27 to p. 5, l. 24; p. 7, l. 47 to p. 8, l. 8).

It is noted that the claims recite a peptide comprising an amino acid sequence from a protein of E6 or E7 of HPV 16 or HPV 18.

The teachings of Schoolnik et al. anticipates the claimed invention by disclosing a peptide from a HPV protein wherein the peptide binds to a MHC Class I molecule, and a

Serial Number: 08/170344

Art Unit 1802

method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases by administering a peptide from HPV proteins in a pharmaceutical composition. The compositions and methods disclosed in Schoolnik et al. are believed to inherently possess properties which anticipate the claimed invention or if they are not the same the composition and methods, the HPV peptides (and compositions) and methods of treatment as disclosed by Schoolnik et al. would none the less render the claims obvious because it possesses the components necessary to prepare a peptide from HPV and methods of treatment as claimed in the instant application. Binding of MHC Class I molecules via T-cell activation is an inherent part of the process of generating an immunogenic response in a mammal. Since the Office does not have the facilities for examining and comparing applicants' method for preparation of a HPV peptide and methods of treatment of the prior art, the burden is on applicant to show a novel or unobvious differences between the claimed product and the product of the prior art (i.e., that the peptide, composition, and method of use of the prior art does not possess the same material structural and functional characteristics of the claimed composition and methods of preparation). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

In response to Applicant's argument that Schoolnik et al. does not include certain features of Applicant's invention, the limitations on which the Applicant relies (i.e., peptides have to fit snugly in the groove of HLA Class I molecule; pockets in the groove; specific anchor residues) are not stated in the claims. Therefore, it is irrelevant whether the reference includes those features or not.

It is noted that the use of prior art published after Applicants' effective filing date can not be used rebut rejections.

Applicant's arguments filed February 26, 1996 have been fully considered but they are not deemed to be persuasive.

Applicants' comments have been addressed previously. Applicants directed the Examiner to the previous response. It is noted at p. 11 of the previous response that

Serial Number: 08/170344

Art Unit: 1802

Applicants stated "... one was demonstrated by applicants not to have the binding ability to HLA molecule which is a prerequisite to be a CTL epitope...". Evidence to support Applicants' assertion that the prior art does not anticipated or obviate the claimed invention should be submitted in the form of a declaration.

21. The following new rejection has not been necessitated by the amendment.

22. Claims 2, 4-18 and 25 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 25 and its dependent claims are vague and indefinite in the recitation of "comprising" as the use of the open-ended term "comprises" which fails to exclude unrecited steps and leaves the claims open for inclusion of unspecified ingredients, even in major amounts. See In re Horvitz, 168 F.2d.522, 78 U.S.P.Q. 79 (C.C.P.A. 1948) and Ex parte Davis et al., 80 U.S.P.Q. 448 (PTO d. App. 1948). Claim 25 is directed to a peptide comprising an amino acid sequence derived from a HPV protein wherein the sequence comprises a nonapeptide from E6 or E7 of HPV 16 or HPV 18. Claim 9 is indefinite and lacks proper antecedent basis in that the claim depends from claim 1 which has been cancelled.

23. No claims are allowed.

24. Applicant's amendment necessitated the new grounds of rejection. Accordingly, **THIS ACTION IS MADE FINAL**. See M.P.E.P. § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT

Serial Number: 08/170344

Art Unit: 1802

MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

25. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is (703) 305-3394. The examiner can normally be reached on Monday-Thursday from 7:00 AM-4:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (703) 308-4027. The fax phone number for this Group is (703) 305-7939.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

N. M. Minnifield
May 31, 1996


JAMES C. HOUSEL 6/10/96
SUPERVISORY PATENT EXAMINER
GROUP 100

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

SERIAL NO.

8/70344

GROUP/ART UNIT

1802

ATTACHMENT
TO
PAPER
NUMBER

16

NOTICE OF REFERENCES CITED

APPLICANT(S)

KAST ETAL.

U.S. PATENT DOCUMENTS

	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
A						
B						
C						
D						
E						
F						
G						
H						
I						
J						
K						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS	PERTINENT SHTS. DWC	PP. SPEC.
L								
M								
N								
O								
P								
Q								

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

R. Bewick et al. 1990. Science 247: 1306-1310.

S. Doughten et al. 1986. Vaccines 86 pp. 21-25.

LOCATION: +2123910525

RX TIME 17.03.'04 21:18



Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
--------------------	-------------	-----------------------	---------------------

08/170,344 03/30/94 KAST

16M1/0614

COOPER & DUNHAM
30 ROCKEFELLER PLAZA
NEW YORK, NY 10112

W D4S113TFM
EXAMINER
MINUTIFIELD, 14

ART UNIT PAPER NUMBER
16

DATE MAILED: 1802

06/14/96

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

2-26-96

Responsive to communication(s) filed on

☒ This action is FINAL.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1636 D.C. 11; 458 O.G. 213.

A 3 month(s), or thirty days, limited statutory period for response to this action is set to expire 3 month(s), or thirty days, whenever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 136). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

- ☒ Claim(s) 2, 4-18, 25 is/are pending in the application.
Of the above, claim(s) _____ is/are withdrawn from consideration:
☐ Claim(s) _____ is/are allowed.
☒ Claim(s) 2, 4-18, 25 is/are rejected.
☐ Claim(s) _____ is/are objected to.
☐ Claims _____ are subject to restriction or election requirement.

Application Papers

- ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-846.
☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.
☐ The specification is objected to by the Examiner.
☐ The oath or declaration is objected to by the Examiner.

only under 35 U.S.C. § 119

- ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some ☐ None of the CERTIFIED copies of the priority documents have been
☐ received.
☐ received in Application No. (Series Code/Serial Number) _____
☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

- ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- ☒ Notice of Reference Cited, PTO-892
☒ Information Disclosure Statement(s), PTO-1449, Paper No(s). _____
☐ Interview Summary, PTO-419
☐ Notice of Draftsperson's Patent Drawing Review, PTO-848
☐ Notice of Informal Patent Application, PTO-152

- SEE OFFICE ACTION ON THE FOLLOWING PAGES -

PTOL-323 (Rev. 10/95)

U.S. GPO: 1995-400-250/45

LOCATION: +2123910525

RX TIME 17.03.'04 21:18

770344

Dr. J. J. J.

ABANDONED

Date
Entered
or
Counted

INITIALS
MAY 98

Date
Received
or
Mailed

RECEIVED
JUN 14 1994
GROUP

30 Nov. 1994 1800
04 April 1994
02 MAY 1994

1. Application papers.

2. Declaration

3. 105

4. Response/ans.

5. *the no. of*

6. *the no. of*

7. *the no. of*

8. *the no. of*

9. Raw Sequence Rating (C.R.)

10. Key Same 3 mod

11. *the no. of*

12. Supply Response

13. *the no. of*

14. *the no. of*

15. *the no. of*

16. *the no. of*

17. *the no. of*

18. *the no. of*

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

the no. of

the no. of

the no. of

the no. of

the no. of

the no. of

the no. of

the no. of

the no. of

the no. of

the no. of

the no. of

VEREENIGDE

PER TELEFAX: 030 294 1526
Seed Capital Investments (SCI) B.V.
Postbus 151
3720 AD Bilthoven

Snouckaertlaan 43
3811 MB Amersfoort

Telefoon 033 422 73 00
Telefax 033 422 73 19

e-mail patent@verenigde.nl
trademark@verenigde.nl
legal@verenigde.nl

www.verenigde.nl

Uw ref.
Onze ref. ME/P20884US00

Amersfoort,
23 maart 2004

Betr.: Octrooiaanvraag in de V.S. van Amerika nr. 08/170,344
"HPV-V"

Geachte heer/mevrouw,

Inzake bovengenoemde octrooiaanvraag zend ik u hierbij de laatste missive van de Amerikaanse Octrooiraad. Mocht u hierover echter vragen hebben, dan verneem ik deze gaarne van u.

Een antwoord kan worden ingediend op of vóór 5 april 2004. Van deze termijn is uitstel te verkrijgen.

Ik verzoek u mij uw instructies, voor het beantwoorden van de openstaande missive, zo spoedig mogelijk te doen toekomen.

Met vriendelijke groet,
VEREENIGDE



M. Einerhand

Bijl.: als genoemd

Cc.: Leids Universitair Medisch Centrum, Prof. Dr. C.J.M. Melief

ne

Europees en Nederlands Octrooigemachtigden

**Nederlandse octrooigemachtigde*

***Europees octrooigemachtigde en CPA (GB)*

Mr Ir J.H.P. Winkels

Mr Drs C.J.J. van Loon

Mr Ir F.A. Dijkstra

Drs M.J. Hatzmann

Ir C.M. Jensen

Ir A.H.K. Tan

Drs J. Renes

Ir E.A. Witmans

Drs H.A.M. Marman

Ir L.J.J. Jensen

Drs K.M.L. Bijvaak

Ir B.Ch. Ledebor

Dr L.J. de Haas

Mr Drs L.A.C.M. van

Wesenberg

Drs A.P. van Wijk

Dr Ir O.L. Oudshoorn

K. Thirwell, B.Sc.

Dr M.P.W. Einerhand

Mr Drs J.C.C. van Melle

Ir M. van Rooij

Mr Ir F.N. Parro

Ir J. de Vries

Dr Ir F.M. van Bouwelen

Drs S.T. van Doorn

Ir M.C. Molting

Drs L.J. van Orlanen-Plooster

Europees en Benelux

Merkengemachtigden

A.A.M. Reijns-Kouwenaar

L.P. Kindt

Mr P.A. van der Woude

Mr N.L. Wolff

Mr M. Driessens

Mr M.J.A. Haegens

Mr M.H. Kamp

Advocaten

Mr H. Mays

Mr N.J. Oostenbroek

Mr A.H. de Boer Kemper-

de Hilster

Mr M.A. van den Hezenkamp

Adviseurs

Mr Ir A.W. Prins

Elst van der N.

From: Einerhand M.
Sent: donderdag 8 april 2004 19:02
To: 'sdavis@cooperdunham.com'
Cc: Elst van der N.
Subject: your ref 45113 our ref ME -20884us00

Dear mr Katz accompanying please find a discussion peace for drafting a response to the office action in the case identified above.

Please review the letter and provide me with your comments and suggestions for moving forward in this case. I have also included comments from the inventor relief on the office action.

Sincerely,

Mark Einerhand



039 Einerhand.doc



Concept antwoord
op Office act...



VEREENIGDE

Address

Nieuwe Parklaan 97

P.O. Box 87930
2508 DH Den Haag
The Netherlands

Telephone +31 70 416 67 11
Telefax +31 70 416 67 99

e-mail patent@vereenigde.nl
trademark@vereenigde.nl
legal@vereenigde.nl

www.vereenigde.com

Your ref. yourref
Our ref. ourref

Den Haag,
date

Re:

Dear mr. Katz,

This is in response to the Office Action that you faxed us on March 17, 2004. I would like to ask your opinion on the following matters.

The Office Action was signed by the supervisory patent examiner James Housel on June 10, 1996. You mentioned on the phone that the patent application became abandoned as result of not responding to this Office Action. I presume therefore that the application became abandoned in December 1996. You mentioned that you would provide us with details as to what events led to the abandonment. However, we have as yet not received this information. We urge you again to provide us with the information as soon as possible.

In the meantime, the client wishes to revive the application. Considering the interest of the applicant in this matter and the fact that the application is licensed I request that you vigorously pursue the actions to be taken in this file.

The Office Action is final, implying that we have limited possibilities to argue the patentability of the claims. However, from your colleague mr. Gershtik I learned that it should be possible to remove the finality of the Office Action under rule 1.129. In view of this possibility I suggest that we pursue the claims listed in the appendix.

You will notice that this claim set differs from the last claim set only in that claims 17 and 18 have been cancelled. We propose this strategy in view of the fact that whereas all claims were rejected under 35 U.S.C. § 112, first paragraph (lack of an enabling

European and Dutch patent attorneys

* Dutch patent attorney

** European patent attorney and CPA (UK)

J.H.P. Winckels
C.J.J. van Lenn
F.A. Diets
M.J. Hattemer
C.M. Jansen
A.H.K. Tan
J. Bence
B.A. Wilmans
H.A.M. Meerman

L.J.J. Jesse
K.M.L. Bijvank
B.Ch. Ledebour

L.J. de Haas
L.A.G.M. van Weerenbroek
A.P. van Wijk
O.L. Oudeboorn
K. Thielwell**

M.P.W. Eijerhand
J.C.C. van Melle

M. van Rooij
F.N. Ferro*
J. de Vries*
F.M. van Bouwelein*
S.T. van Doorn*
M.C. Melling*
I.J. van Orlcken-Ploester*

**European and Benelux
trademark attorneys**

A.A.M. Reijne-Kouwenaar

L.P. Kindt
P.A. van der Wee
N.L. Wolff
M. Driessen
M.J.A. Hoogen
M.H. Kamp

Attorneys-at-Law

H. Mura
N.J. Oostenbrink

A.H. de Bosch Kemper-
de Hilster
M.A. van den Haeckhamp

Of counsel:
A.W. Prins

Page 2
Your ref. yourref
Our ref. ourref
Date date

Patent Attorneys
Trademark Attorneys
Attorneys-at-Law



disclosure), the arguments of the examiner are solely based on the pharmaceutical composition claims. For this reason it is suggested that we cancel two of the three pharmaceutical composition claims and provide detailed argumentation for enablement of the remaining pharmaceutical composition claim. As mentioned above, the peptide claims are formally rejected. However, the examiner provides no specific arguments against the peptide claim of 25 other than the sentence on page 3 wherein it is said that the disclosure is enabled for nonapeptide sequences derived from the E6 or E7 genes of HPV16 or HPV18, and MHC Class I molecules specifically taught in the specification. Could we limit our argumentation on the peptide claims to a discussion of the sentence on page 5, third paragraph, where the examiner states that the wording "peptides that bind in the groove on an MHC class I molecule" is not present in the claims? Claim 25 appears to contain this requirement.

The rejection of the pharmaceutical claims is quite extensive but seems to boil down to the now cancelled claims 17 and 18. The broadest pharmaceutical claim 16 is in my view defensible. There are two possibilities that I would like to put forward for your review. The first option is to leave the claim as it is. The other option is to cancel the phrase "a prophylactically or therapeutically effective amount" and replace it with "an effective amount". The argument for enablement is that peptides that bind to MHC-I are always capable of eliciting a cellular immune response of the peptide when present in an effective amount. That is the way the immune system works, it mounts an immune response to peptides that are presented in the context of MHC-I. Whether the immune response is sufficient to be effective against HPV (the requirement of claims 17 and 18) is in this strategy no longer a question as we do not require such effectiveness in our claims. If you can support this approach I can obtain art that underlines these arguments from the inventors.

The examiner objects to the phrase "fragments, homologs, isoforms, derivatives, genetic variants or conservative variants" in claims 5, 6, 8, 10, 12 and 14. I suggest that we cancel this phrase and replace it with the phrase "or a variant of any one of these amino acid sequences differing by one conservative amino acid substitution". Basis for this amendment can be found on page 17, lines 5-12 and example 4: page 31, lines 26-34 and table IX to XIII on pages 32-35. The examples show that such peptides were generated in the application and are effective in binding to MHC-class I molecules.

Please take care of the minor amendment of claims 12 and 14, writing the selection in the proper markush format. Apparently the examiner could not properly identify which "or" was to be replaced by an "and"

With respect to Schoolnik et al, it appears as if the examiner mixes up antibody immunity and cellular immunity. These two types of immunity are generated through different systems. For cellular immunity to be developed against a peptide it is

Page 3
Your ref yourref
Our ref ourref
Date date

Patent Attorneys
Trademark Attorneys
Attorneys-at-Law



VEREENIGDE

essential that the peptide is presented in the context of MHC class I. Schoolnik provides at best a means for developing a humeral response.



Appendix

Claims

25. (Rewritten, cancelled claim 1) A peptide comprising an amino acid sequence derived from protein of human papilloma virus (HPV), wherein said amino acid sequence comprises a nonapeptide derived from protein E6 or E7 of HPV or HPV 18 and wherein said nonapeptide has the ability to bind in the grooves on top of the human major histocompatibility complex (MHC) Class I molecule.

2. A peptide according to claim 25, wherein said amino acid sequence is a nonapeptide.

4. A peptide according to claim 25, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1.

5. A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:

AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
KLPQLCTEL (residues 18-26 of HPV16 protein E6) SEQ ID NO:2
QLCTELQTT (residues 21-29 of HPV16 protein E6) SEQ ID NO:3
LCTELQTTI (residues 22-30 of HPV16 protein E6) SEQ ID NO:4
ELQTTIHDI (residues 25-33 of HPV16 protein E6) SEQ ID NO:5
LQTTIHDI (residues 26-34 of HPV16 protein E6) SEQ ID NO:6
TIHDILEC (residues 29-37 of HPV16 protein E6) SEQ ID NO:7
IHDILECV (residues 30-38 of HPV16 protein E6) SEQ ID NO:8
CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
FAFRDLCIV (residues 52-60 of HPV16 protein E6) SEQ ID NO:10
KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
PLCDLLIRC (residues 102-110 of HPV16 protein E6) SEQ ID NO:12
TLHEYMLDL (residues 7-15 of HPV16 protein E7) SEQ ID NO:13
YMLDLQPET (residues 11-19 of HPV16 protein E7) SEQ ID NO:14
MLDLQPETT (residues 12-20 of HPV16 protein E7) SEQ ID NO:15
RLCVQSTHV (residues 66-74 of HPV16 protein E7) SEQ ID NO:16
TLEDLLMGT (residues 78-86 of HPV16 protein E7) SEQ ID NO:17
LLMGTLGIV (residues 82-90 of HPV16 protein E7) SEQ ID NO:18



GTLGIVCPI (residues 85-93 of HPV16 protein E7) SEQ ID NO:19 and
TLGIVCPIC (residues 86-94 of HPV16 protein E7) SEQ ID NO:20

or a variant of any one of these amino acid sequences differing by
one conservative amino acid substitution which has the ability to bind to human MHC
Class I allele HLA-A2.1.

6. A peptide according to claim 25, comprising an amino acid sequence derived
from protein E6 or E7 of HPV18, wherein said amino acid sequence has the ability to
bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting
of:

KLPDLCTEL (residues 13-21 of HPV18 protein E6) SEQ ID NO:21
SLQDIETTC (residues 24-32 of HPV18 protein E6) SEQ ID NO:22
LQDIETTCV (residues 25-33 of HPV18 protein E6) SEQ ID NO:23
EITCVYCKT (residues 29-37 of HPV18 protein E6) SEQ ID NO:24
KTVLELTEV (residues 36-44 of HPV18 protein E6) SEQ ID NO:25
ELTEVFEEA (residues 40-48 of HPV18 protein E6) SEQ ID NO:26
FAFKDLFVV (residues 47-55 of HPV18 protein E6) SEQ ID NO:27
DTLEKLTNT (residues 88-96 of HPV18 protein E6) SEQ ID NO:28
LTNTGLYNL (residues 93-101 of HPV18 protein E6) SEQ ID NO:29
TLQDIVLHL (residues 7-15 of HPV18 protein E7) SEQ ID NO:30
FQQLFLNTL (residues 86-94 of HPV18 protein E7) SEQ ID NO:31
QLFLNTLSF (residues 88-96 of HPV18 protein E7) SEQ ID NO:32
LFLNTLSFV (residues 89-97 of HPV18 protein E7) SEQ ID NO:33 and
LSFVCPWCA (residues 94-102 of HPV18 protein E7) SEQ ID NO:34, and

or a variant of any one of these amino acid sequences differing by
one conservative amino acid substitution which has the ability to bind to human MHC
Class I allele HLA-A2.1.

7. A peptide according to claim 25, comprising an amino acid sequence derived
from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to
bind to human MHC Class I allele HLA-A1.

8. A peptide according to claim 25, comprising an amino acid sequence derived
from protein E6 and E7 of HPV16, wherein said amino acid sequence has the ability to
bind to human MHC Class I allele HLA-A1 and is selected from the group consisting of:

YRDGNPYAV (residues 61-69 of HPV16 protein E6) SEQ ID NO:35
WTGRCMSCC (residues 139-147 of HPV16 protein E6) SEQ ID NO:36
MSCCRSSRT (residues 144-152 of HPV16 protein E6) SEQ ID NO:37
TTDLYCYEQ (residues 19-27 of HPV16 protein E7) SEQ ID NO:38
EIDGPAGQA (residues 37-45 of HPV16 protein E7) SEQ ID NO:39 and
HVDIRTLED (residues 73-81 of HPV16 protein E7) SEQ ID NO:40, and



or a variant of any one of these amino acid sequences differing by one conservative amino acid substitution which has the ability to bind to human MHC Class I allele HLA-A3.2.

9. A peptide according to claim 25, wherein said amino acid sequence has the ability to bind to human to human MHC Class I allele HLA-A3.2.

10. A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A3.2 and is selected from the group consisting of:

AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
IILECVYCK (residues 33-41 of HPV16 protein E6) SEQ ID NO:41
CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42
QQLLRREVY (residues 42-50 of HPV16 protein E6) SEQ ID NO:43
IVYRDGNPY (residues 59-67 of HPV16 protein E6) SEQ ID NO:44
YAVCDKCLK (residues 67-75 of HPV16 protein E6) SEQ ID NO:45
AVCDKCLKF (residues 68-76 of HPV16 protein E6) SEQ ID NO:46
VCDKCLKFY (residues 69-77 of HPV16 protein E6) SEQ ID NO:47
KFYSKISEY (residues 75-83 of HPV16 protein E6) SEQ ID NO:48
KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
ISEYRHYCY (residues 80-88 of HPV16 protein E6) SEQ ID NO:49
RHYCYSLYG (residues 84-92 of HPV16 protein E6) SEQ ID NO:50
SLYGTTLLEQ (residues 89-97 of HPV16 protein E6) SEQ ID NO:51
TTLEQQYNK (residues 93-101 of HPV16 protein E6) SEQ ID NO:52
QQYNKPLCD (residues 97-105 of HPV16 protein E6) SEQ ID NO:53
LIRCINCQK (residues 107-115 of HPV16 protein E6) SEQ ID NO:54
HLDKKQRFH (residues 125-133 of HPV16 protein E6) SEQ ID NO:55
CMSCCRSSR (residues 143-151 of HPV16 protein E6) SEQ ID NO:56
SCCRSSRTR (residues 145-153 of HPV16 protein E6) SEQ ID NO:57
CCRSSRTRR (residues 146-154 of HPV16 protein E6) SEQ ID NO:58
HYNIVTFCC (residues 51-59 of HPV16 protein E7) SEQ ID NO:59
YNIVTFCK (residues 52-60 of HPV16 protein E7) SEQ ID NO:60
CCKCDSTLR (residues 58-66 of HPV16 protein E7) SEQ ID NO:61 and
KCDSTLRLC (residues 60-68 of HPV16 protein E7) SEQ ID NO:62, and

or a variant of any one of these amino acid sequences differing by one conservative amino acid substitution which has the ability to bind to human MHC Class I allele HLA-A11.2.

11. A peptide according to claim 25, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A11.2.



12. A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A11.2 and is selected from the group consisting of:

AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
IILECVYCK (residues 33-41 of HPV16 protein E6) SEQ ID NO:41
CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42
QQLLRREVV (residues 42-50 of HPV16 protein E6) SEQ ID NO:43
IVYRDGNPY (residues 59-67 of HPV16 protein E6) SEQ ID NO:44
YAVCDKCLK (residues 67-75 of HPV16 protein E6) SEQ ID NO:45
AVCDKCLKF (residues 68-76 of HPV16 protein E6) SEQ ID NO:46
VCDKCLKFY (residues 69-77 of HPV16 protein E6) SEQ ID NO:47
KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
ISEYRHYCY (residues 80-88 of HPV16 protein E6) SEQ ID NO:49
LIRCINCQK (residues 107-115 of HPV16 protein E6) SEQ ID NO:54
TGRCMSCCR (residues 140-148 of HPV16 protein E6) SEQ ID NO:63
CMSCCRSSR (residues 143-151 of HPV16 protein E6) SEQ ID NO:56
SCCRSSRTR (residues 145-153 of HPV16 protein E6) SEQ ID NO:57
HYNIVTFCC (residues 51-59 of HPV16 protein E7) SEQ ID NO:59
YNIVTFCKK (residues 52-60 of HPV16 protein E7) SEQ ID NO:60
CCKCDSTLR (residues 58-66 of HPV16 protein E7) SEQ ID NO:61 and
VCPICSQKP (residues 90-98 of HPV16 protein E7) SEQ ID NO:64 and

or a variant of any one of these amino acid sequences differing by one conservative amino acid substitution which has the ability to bind to human MHC Class I allele HLA-A11.2.

13. A peptide according to claim 25, wherein said amino acid sequence to bind to human MHC Class I allele HLA-A24.

14. A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A24 and is selected from the group consisting of:

MHQKRTAMF (residues 1-9 of HPV16 protein E6) SEQ ID NO:65
LQTTIHDII (residues 26-34 of HPV16 protein E6) SEQ ID NO:6
VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42
LLRREVVYDF (residues 44-52 of HPV16 protein E6) SEQ ID NO:66
VYDFAFRDL (residues 49-57 of HPV16 protein E6) SEQ ID NO:67
PYAVCDKCL (residues 66-74 of HPV16 protein E6) SEQ ID NO:68



KCLKFYISKI (residues 72-80 of HPV16 protein E6) SEQ ID NO:69
EYRHYCYSL (residues 82-90 of HPV16 protein E6) SEQ ID NO:70
HYCYSLYGT (residues 85-93 of HPV16 protein E6) SEQ ID NO:71
CYSLYGTTL (residues 87-95 of HPV16 protein E6) SEQ ID NO:72
RFHNIRGRW (residues 131-139 of HPV16 protein E6) SEQ ID NO:73 and
RAHYNIVTF (residues 49-57 of HPV16 protein E7) SEQ ID NO:74, and

or a variant of any one of these amino acid sequences differing by one conservative amino acid substitution which has the ability to bind to human MHC Class I allele HLA-A24.

15. A peptide according to claim 25, having a length of from 9 to 12 amino acids.

16. A pharmaceutical composition containing a prophylactically or therapeutically effective amount for eliciting cellular immune response of a peptide according to claim 25, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.



VEREENIGDE

Seed Capital Investments (SCI) B.V.
Postbus 151
3720 AD Bilthoven

Attn. Mr. W.J.M. de Vette

Nieuwe Parklaan 97

P.O. Box 87930
2508 DH Den Haag
The Netherlands

Telephone +31 70 416 67 11
Telefax +31 70 416 67 99

e-mail patent@vereenigde.nl
trademark@vereenigde.nl
legal@vereenigde.nl

www.vereenigde.com

Your ref.
Our ref. **ME/P20884US00**

Den Haag,
April 29, 2004

Re: **U.S. patent application No. 08/170,344**
"HPV-V"

Dear Mr. De Vette,

I have enclosed the proposal from Cooper & Dunham for reinstating application number 08/170,344. The proposal encompasses four items, the petition to revive, the response to the Office Action, a request to withdraw the finality of the Office Action and a terminal disclaimer. I have given a short description of the documents together with some comments on substantive response to the Office Action below.

The petition to revive contains the statement that the abandonment of the application was unintentional. The statement does not elaborate on the circumstances that have led to the abandonment. As discussed in our telephone conversation of today, Vereenigde will send a reminder to Cooper & Dunham that we are still waiting for an explanation of the events that have led to the abandonment. I noticed that the petition requires the payment of a fee. The proposal did not come with an explanation that Cooper & Dunham will pay this fee. I will point them to the fact that we expect that any costs associated with the revival will be taken care of by Cooper & Dunham.

The proposal further contains a request to remove the finality of the Office Action. The request will, according to Cooper & Dunham, have the effect that we will have at least one more opportunity to argue patentability of the claims and/or file amendments.

European and Dutch patent attorneys

** Dutch patent attorney*

*** European patent attorney and CPA (UK)*

J.H.F. Winkels
C.J.J. van Loon
F.A. Distz
M.J. Hatzmann
C.M. Janssen
A.H.K. Ten
J. Remes
H.A. Wismans
H.A.M. Meerman

L.J.J. Jessen
K.M.L. Blijwink
B.Ch. Ledsboer
L.J. de Haas
L.A.C.M. van Wezenbeek
A.P. van Wijk
O.L. Oudeheurn
K. Thierwell

M.P.W. Eisebrand
J.C.C. van Meile
M. van Rooij
F.N. Puzos
J. de Vries
F.M. van Bouwman
B.T. van Doorn
M.C. Molting
L.J. van Gricke-Mooster

*European and Benelux
trademark attorneys*

A.A.M. Reijns-Kouwenaar

L.P. Kindt
P.A. van der Wou
N.L. Wolfs
M. Driessen
M.J.A. Haepens
M.H. Kamp

Attorneys-at-Law

H. Marn
N.J. Oostenbroek
A.H. de Bosch Kemper-
de Hiltter
M.A. van den Hasenkamp
Of counsel
A.W. Prins

Page 2
Your ref.
Our ref. ME/P20884US00
Date April 29, 2004

Patent Attorneys
Trademark Attorneys
Attorneys-at-Law



VEREENIGDE

The enclosed terminal disclaimer is necessary to disclaim the period of abandonment.

The response to the Office Action is more or less in line with the strategy that we discussed earlier. The amendments to the claims have been kept to a minimum. A first amendment is concerned with the pharmaceutical composition claims 16-18. A large part of the objections of the examiner is concerned with these claims. The examiner is of the opinion that the specification does not support the breadth of the claims because it lacks working examples or support for *in vivo* efficacy of the active ingredients. The suggested amendment is intended to circumvent this objection of the examiner in that such efficacy is no longer a part of the claims. This is done by deleting claims 17 and 18 and broadening claim 16 such that a prophylactically or therapeutically effective amount is no longer required but instead requires only an amount effective in obtaining a cellular immune response. In my estimation this amendment should be sufficient to remove the lack of support rejection against claim 16, as to my best knowledge any peptide capable of binding to MHC-I, is able to elicit such a cellular immune response when provided in sufficient amounts to a human carrying the specific MHC-I molecule.

A further amendment is in claims 5, 6, 8, 10, 12, and 14 and is concerned with the deletion of the phrase "fragments, homologues, isoforms, derivatives, genetic variants or conservative variants" and replacing it with the phrase "or a variant of any one of these amino acid sequences differing by one conservative amino acid substitution".

This amendment is instigated by the experience that it is difficult to convince examiners of the patentability of the deleted subject matter, in the absence of support in the specification. Moreover, fragments of the nona-peptides will more than likely not be effective, whereas isoforms are already included in the structural formula of the sequences. The sentence replacing the deletion covers peptides that deviate by one conservative amino acid from the depicted peptide. Example 4 shows peptides comprising a replacement of a cysteine.

A further amendment deals with a correction of improper language of claims 12 to 14.

Considering that the present situation is exceptional we will independently and at our own expense obtain a second opinion from a US patent attorney with respect to the actions to be taken in this case. Particularly we will request clarification of the, as yet, conflicting opinions maintained by the lawyers of the licensee and Cooper & Dunham as to the required declarations for requesting revival of the application.

Page 3
Your ref
Our ref ME/P20884US00
Date April 29, 2004

Patent Attorneys
Trademark Attorneys
Attorneys-at-Law



VEREENIGDE

Please do not hesitate to contact me if you have questions regarding the actions to be taken or the proposal from Cooper & Dunham.

Sincerely,
VEREENIGDE

Mark Einerhand

Encl: Draft Petition to revive
Draft Response to Office Action
Draft Request for removal of the finality of the Office Action
Draft Terminal Disclaimer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wybe Martin Kast et al.
Serial No. : 08/170,344 Examiner: N. Minnifield
Filed : March 30, 1994
For : PEPTIDES OF HUMAN PAPILLOMA VIRUS FOR USE IN
HUMAN T CELL RESPONSE INDUCING COMPOSITIONS

1185 Avenue of the Americas
New York, NY 10036
April 20, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

**COMMUNICATION REQUESTING
WITHDRAWAL OF FINALITY UNDER 37 C.F.R. §1.129(a)**

This Communication is submitted pursuant to the provisions of 37 C.F.R. §1.129(a) to request withdrawal of the finality of the June 14, 1996 Final Office Action issued by the U.S. Patent and Trademark Office in connection with the above-identified application. Applicants request consideration of the First Submission Under 37 C.F.R. § 1.129(a) and Amendment in Response to June 14, 1996 Final Office Action attached hereto as **Exhibit A**.

The subject application has been pending for at least two years as of June 8, 1995, taking into account reference made to earlier filed applications under 35 U.S.C. §§120, 121, and 365(c).

Under 37 C.F.R. §1.129(a), applicants in an application that has been pending for at least two years as of June 8, 1995, taking into account any reference made in such application to any earlier filed application under 35 U.S.C. §§120, 121 and 365(c), are entitled to have the finality of a final rejection withdrawn and a submission entered and considered on the merits twice after final rejection if the submission and the fee set forth in 37 C.F.R. §1.17(r) are filed prior to the filing of an appeal brief and

Applicants: Wybe Martin Kast et al.
Serial No.: 08/170,344
Filed: March 30, 1994
Page 2

prior to abandonment of the application.

The fee for a large entity under 37 C.F.R. §1.17(r) for consideration and entry of a first submission after a final rejection is SEVEN-HUNDRED AND SEVENTY DOLLARS (\$770.00) and a check for TWO THOUSAND ONE HUNDRED DOLLARS (\$2,100.00) which includes this amount is enclosed.

Applicants respectfully request, pursuant to 37 C.F.R. §1.129(a), to have the finality of the June 14, 1996 Final Office Action withdrawn and to have their first submission entered and considered on the merits in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided.

No fee, other than the \$770.00 fee under 37 C.F.R. §1.17(r) is deemed necessary in connection with the filing of this Communication. However, if any additional fee is required, authorization is given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Robert D. Katz
Reg. No. 30,141

Date

Robert D. Katz, Esq.
Registration No. 30,141
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, NY 10036
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wybe Martin Kast et al.
Serial No. : 08/170,344 Examiner: N. Minnifield
Filed : March 30, 1994
For : PEPTIDES OF HUMAN PAPILLOMA VIRUS FOR USE IN HUMAN
T CELL RESPONSE INDUCING COMPOSITIONS

1185 Avenue of the Americas
New York, NY 10036
April 20, 2004

Office of Petitions
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

**PETITION TO REVIVE UNINTENTIONALLY
ABANDONED APPLICATION UNDER 37 C.F.R. §1.137(b)**

This petition is made in response to the January 23, 1997 Notice of Abandonment issued in connection with the above-identified application. Applicants understand that no reply to the June 14, 1996 Final Office was filed resulting in abandonment.

Applicants hereby petition to revive the subject abandoned application pursuant to 37 C.F.R. §1.137(b). A grantable petition under this paragraph must be accompanied by (1) the reply required to the outstanding Office action or notice, unless previously filed; (2) the petition fee as set forth in §1.17(m); (3) a statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to this paragraph was unintentional; and (4) any terminal disclaimer required pursuant to 37 C.F.R. §1.137(d).

In satisfaction of the requirements for a grantable petition under 37 C.F.R. §1.137(b), applicants have enclosed as **Exhibit A** the required reply to the June 14, 1996 Final

Applicants: Wybe Martin Kast et al.
Serial No.: 08/170,344
Filed: March 30, 1994
Page 2

Office Action issued in connection with this application. Applicants submit that the entire delay in filing this reply from the due date for the reply until the filing of this petition was unintentional. The fee to revive an unintentionally abandoned application required under 37 C.F.R. §1.137(b) is ONE THOUSAND THREE HUNDRED THIRTY DOLLARS (\$1330.00) and a check for TWO THOUSAND ONE HUNDRED DOLLARS (\$2,100.00) which includes this amount is enclosed.

In addition, applicants submit as **Exhibit B** a terminal disclaimer as required under 37 C.F.R. §1.137(d) in connection with the filing of this petition.

No fee, other than the enclosed \$1330.00, is deemed necessary in connection with the filing of this Petition. However, if any other fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Robert D. Katz
Reg. No. 30,141

Date

Robert D. Katz, Esq.
Registration No. 30,141
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, NY 10036
(212) 278-0400

Dkt. 45113/RDK/AG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wybe Martin Kast et al.
Serial No. : 08/170,344 Examiner: N. Minnifield
Filed : March 30, 1994
For : PEPTIDES OF HUMAN PAPILLOMA VIRUS FOR USE IN HUMAN
T CELL RESPONSE INDUCING COMPOSITIONS

1185 Avenue of the Americas
New York, NY 10036
April 21, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT IN RESPONSE TO JUNE 14, 1996 FINAL OFFICE ACTION

This Amendment is submitted in response to a June 14, 1996 Final Office Action Issued by the United States Patent and Trademark Office in connection with the above-identified application. This Response forms part of a Petition to Revive an Unintentionally Abandoned Application under 37 C.F.R. §1.137(b). Applicants also file herewith a Communication Requesting Withdrawal of Finality under 37 C.F.R. §1.129(a). Revival of the application and examination of the present response is respectfully requested.

Claim amendments may be found beginning on page 2.

Remarks may be found beginning on page 10.

Please amend the subject application as follows:

Applicants: Wybe Martin Kast et al.
Serial No.: 08/170,344
Filed: March 30, 1994
Page 2

Amendments to the claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (canceled)
2. (previously presented) A peptide according to claim 25, wherein said amino acid sequence is a nonapeptide.
3. (canceled)
4. (previously presented) A peptide according to claim 25, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1.
5. (amended) A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:

AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
KLPQLCTEL (residues 18-26 of HPV16 protein E6) SEQ ID NO:2
QLCTELQTT (residues 21-29 of HPV16 protein E6) SEQ ID NO:3
LCTELQTTI (residues 22-30 of HPV16 protein E6) SEQ ID NO:4
ELQTTIHD I (residues 25-33 of HPV16 protein E6) SEQ ID NO:5
LQTTIHDII (residues 26-34 of HPV16 protein E6) SEQ ID NO:6

TIHDIILEC (residues 29-37 of HPV16 protein E6) SEQ ID NO:7
IHDIIIECV (residues 30-38 of HPV16 protein E6) SEQ ID NO:8
CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
FAFRDLCIV (residues 52-60 of HPV16 protein E6) SEQ ID NO:10
KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
PLCDLLIRC (residues 102-110 of HPV16 protein E6) SEQ ID NO:12
TLHEYMLDL (residues 7-15 of HPV16 protein E7) SEQ ID NO:13
YMLDLQPET (residues 11-19 of HPV16 protein E7) SEQ ID NO:14
MLDLQPETT (residues 12-20 of HPV16 protein E7) SEQ ID NO:15
RLCVQSTHV (residues 66-74 of HPV16 protein E7) SEQ ID NO:16
TLEDLLMGT (residues 78-86 of HPV16 protein E7) SEQ ID NO:17
LLMGTLGIV (residues 82-90 of HPV16 protein E7) SEQ ID NO:18
GTLGIVCPI (residues 85-93 of HPV16 protein E7) SEQ ID NO:19
TLGIVCPIC (residues 86-94 of HPV16 protein E7) SEQ ID NO:20 and
a fragment, homolog, isoform, derivative, genetic variant or conservative
variant of any one of these amino acid sequences differing by one
conservative amino acid substitution which has the ability to bind to
human MHC Class I allele HLA-A2.1.

6. (amended) A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV18, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:

KLPDLCTEL (residues 13-21 of HPV18 protein E6) SEQ ID NO:21
SLQDIEITC (residues 24-32 of HPV18 protein E6) SEQ ID NO:22
LQDIEITCV (residues 25-33 of HPV18 protein E6) SEQ ID NO:23
EITCVYCKT (residues 29-37 of HPV18 protein E6) SEQ ID NO:24

KTVLELTEV (residues 36-44 of HPV18 protein E6) SEQ ID NO:25
ELTEVFEFA (residues 40-48 of HPV18 protein E6) SEQ ID NO:26
FAFKDLFVV (residues 47-55 of HPV18 protein E6) SEQ ID NO:27
DTLEKLTNT (residues 88-96 of HPV18 protein E6) SEQ ID NO:28
LTNTGLYNL (residues 93-101 of HPV18 protein E6) SEQ ID NO:29
TLQDIVLHL (residues 7-15 of HPV18 protein E7) SEQ ID NO:30
FQQLFLNTL (residues 86-94 of HPV18 protein E7) SEQ ID NO:31
QLFLNTLSF (residues 88-96 of HPV18 protein E7) SEQ ID NO:32
LFLNTLSFV (residues 89-97 of HPV18 protein E7) SEQ ID NO:33
LSFVCPWCA (residues 94-102 of HPV18 protein E7) SEQ ID NO:34 and
a fragment, homolog, isoform, derivative, genetic variant or conservative
variant of any one of these amino acid sequences differing by one
conservative amino acid substitution which has the ability to bind to
human MHC Class I allele HLA-A2.1.

7. (previously presented) A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A1.
8. (amended) A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 and E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A1 and is selected from the group consisting of:

YRDGNPYAV (residues 61-69 of HPV16 protein E6) SEQ ID NO:35
WTGRCMSCC (residues 139-147 of HPV16 protein E6) SEQ ID NO:36
MSCCRSSRT (residues 144-152 of HPV16 protein E6) SEQ ID NO:37
TTDLYCYEQ (residues 19-27 of HPV16 protein E7) SEQ ID NO:38

EIDGPAGQA (residues 37-45 of HPV16 protein E7) SEQ ID NO:39
HVDIRTLED (residues 73-81 of HPV16 protein E7) SEQ ID NO:40 and
~~a fragment, homolog, isoform, derivative, genetic variant or conservative~~
variant of any one of these amino acid sequences differing by one
conservative amino acid substitution which has the ability to bind to
human MHC Class I allele HLA-A3.2.

9. (previously presented) A peptide according to claim 25, wherein said amino acid sequence has the ability to bind to human to human MHC Class I allele HLA-A3.2.
10. (amended) A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A3.2 and is selected from the group consisting of:

AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
IILECVYCK (residues 33-41 of HPV16 protein E6) SEQ ID NO:41
CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42
QQLLRREVY (residues 42-50 of HPV16 protein E6) SEQ ID NO:43
IVYRDGNPY (residues 59-67 of HPV16 protein E6) SEQ ID NO:44
YAVCDKCLK (residues 67-75 of HPV16 protein E6) SEQ ID NO:45
AVCDKCLKF (residues 68-76 of HPV16 protein E6) SEQ ID NO:46
VCDKCLKFY (residues 69-77 of HPV16 protein E6) SEQ ID NO:47
KFYSKISEY (residues 75-83 of HPV16 protein E6) SEQ ID NO:48
KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
ISEYRHYCY (residues 80-88 of HPV16 protein E6) SEQ ID NO:49

RHYCYSLYG (residues 84-92 of HPV16 protein E6) SEQ ID NO:50
SLYGTTLEQ (residues 89-97 of HPV16 protein E6) SEQ ID NO:51
TTLEQQYNK (residues 93-101 of HPV16 protein E6) SEQ ID NO:52
QQYNKPLCD (residues 97-105 of HPV16 protein E6) SEQ ID NO:53
LIRCINCQK (residues 107-115 of HPV16 protein E6) SEQ ID NO:54
HLDKKQRFH (residues 125-133 of HPV16 protein E6) SEQ ID NO:55
CMSCCRSSR (residues 143-151 of HPV16 protein E6) SEQ ID NO:56
SCCRSSRTR (residues 145-153 of HPV16 protein E6) SEQ ID NO:57
CCRSSRTRR (residues 146-154 of HPV16 protein E6) SEQ ID NO:58
HYNIVTFCC (residues 51-59 of HPV16 protein E7) SEQ ID NO:59
YNIVTFCK (residues 52-60 of HPV16 protein E7) SEQ ID NO:60
CCKCDSTLR (residues 58-66 of HPV16 protein E7) SEQ ID NO:61
KCDSTLRLC (residues 60-68 of HPV16 protein E7) SEQ ID NO:62 and
a fragment, homolog, isoform, derivative, genetic variant or conservative
variant of any one of these amino acid sequences differing by one
conservative amino acid substitution which has the ability to bind to
human MHC Class I allele HLA-A11.2.

11. (previously presented) A peptide according to claim 25, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A11.2.
12. (amended) A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A11.2 and is selected from the group consisting of:

AMFQDPQER (residues 7-15 of HPV16 protein E6) SEQ ID NO:1
IILECVYCK (residues 33-41 of HPV16 protein E6) SEQ ID NO:41

Applicants: Wybe Martin Kast et al.

Serial No.: 08/170,344

Filed: March 30, 1994

Page 7

CVYCKQQLL (residues 37-45 of HPV16 protein E6) SEQ ID NO:9
VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42
QQLLRREVY (residues 42-50 of HPV16 protein E6) SEQ ID NO:43
IVYRDGNPY (residues 59-67 of HPV16 protein E6) SEQ ID NO:44
YAVCDKCLK (residues 67-75 of HPV16 protein E6) SEQ ID NO:45
AVCDKCLKF (residues 68-76 of HPV16 protein E6) SEQ ID NO:46
VCDKCLKFY (residues 69-77 of HPV16 protein E6) SEQ ID NO:47
KISEYRHYC (residues 79-87 of HPV16 protein E6) SEQ ID NO:11
ISEYRHYCY (residues 80-88 of HPV16 protein E6) SEQ ID NO:49
LIRCINCQK (residues 107-115 of HPV16 protein E6) SEQ ID NO:54
TGRCMSCCR (residues 140-148 of HPV16 protein E6) SEQ ID NO:63
CMSSCRSSR (residues 143-151 of HPV16 protein E6) SEQ ID NO:56
SSCRSSRTR (residues 145-153 of HPV16 protein E6) SEQ ID NO:57
HYNIVTFCC (residues 51-59 of HPV16 protein E7) SEQ ID NO:59
YNIVTFCKK (residues 52-60 of HPV16 protein E7) SEQ ID NO:60
CCKCDSTLR (residues 58-66 of HPV16 protein E7) SEQ ID NO:61
VCPICSQKP (residues 90-98 of HPV16 protein E7) SEQ ID NO:64 and
a fragment, homolog, isoform, derivative, genetic variant or conservative
variant of any one of these amino acid sequences differing by one
conservative amino acid substitution which has the ability to bind to
human MHC Class I allele HLA-A11.2.

13. (previously presented) A peptide according to claim 25, wherein said amino acid sequence to bind to human MHC Class I allele HLA-A24.
14. (amended) A peptide according to claim 25, comprising an amino acid sequence derived from protein E6 or E7 of HPV16, wherein said amino acid sequence has

the ability to bind to human MHC Class I allele HLA-A24 and is selected from the group consisting of:

MHQKRTAMF (residues 1-9 of HPV16 protein E6) SEQ ID NO:65
LQTTIHDI (residues 26-34 of HPV16 protein E6) SEQ ID NO:6
VYCKQQLLR (residues 38-46 of HPV16 protein E6) SEQ ID NO:42:
LLRREVVDF (residues 44-52 of HPV16 protein E6) SEQ ID NO:66
VYDFAFRDL (residues 49-57 of HPV16 protein E6) SEQ ID NO:67
PYAVCDKCL (residues 66-74 of HPV16 protein E6) SEQ ID NO:68
KCLKFYSKI (residues 72-80 of HPV16 protein E6) SEQ ID NO:69
EYRHYCYSL (residues 82-90 of HPV16 protein E6) SEQ ID NO:70
HYCYSLYGT (residues 85-93 of HPV16 protein E6) SEQ ID NO:71
CYSLYGTTL (residues 87-95 of HPV16 protein E6) SEQ ID NO:72
RFHNIRGRW (residues 131-139 of HPV16 protein E6) SEQ ID NO:73
RAHYNIVTF (residues 49-57 of HPV16 protein E7) SEQ ID NO:74 and
a fragment, homolog, isoform, derivative, genetic variant or conservative
variant of any one of these amino acid sequences differing by one
conservative amino acid substitution which has the ability to bind to
human MHC Class I allele HLA-A24.

15. (previously presented) A peptide according to claim 25, having a length of from 9 to 12 amino acids.
16. (amended) A pharmaceutical composition containing ~~a prophylactically or therapeutically~~ an effective amount for eliciting cellular immune response of a peptide according to claim 25, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

Applicants: Wybe Martin Kast et al.

Serial No.: 08/170,344

Filed: March 30, 1994

Page 9

17-24. (canceled)

25. (previously presented) A peptide comprising an amino acid sequence derived from protein of human papilloma virus (HPV), wherein said amino acid sequence comprises a nonapeptide derived from protein E6 or E7 of HPV or HPV 18 and wherein said nonapeptide has the ability to bind in the grooves on top of the human major histocompatibility complex (MHC) Class I molecule.

Applicants: Wybe Martin Kast et al.
Serial No.: 08/170,344
Filed: March 30, 1994
Page 10

REMARKS

Claims 2, 4-18 and 25 are pending and under examination in the subject application. By this Amendment, applicants have amended claims 5, 6, 8, 10, 12, 14 and 16 and have canceled claims 17 and 18. Accordingly, claims 2, 4-16 and 25 will be pending and under examination in the subject application upon entry of this Amendment. In view of the remarks below, applicants maintain that the Examiner's rejections have been overcome, and respectfully request that they be withdrawn.

Formalities

The Examiner states that the information disclosure statement filed January 4, 1994 fails to comply with 37 C.F.R. §1.98(a)(3) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in §1.56(c) most knowledgeable about the content of the information, of each patent listed that is not in the English language. Specifically, the Examiner states that references EP0375555 and EP0456197 have not been considered as to the merits.

In response, (statements of relevance)

Accordingly, applicants submit that the requirements of 37 C.F.R. §1.98(a)(3) have been met and request that the Examiner withdraw the objection, consider the references, and make them of record in this application.

Rejection under 35 U.S.C. §112, first paragraph

The Examiner rejected claims 2, 4-18 and 25 under 35 U.S.C. §112, first paragraph, as allegedly containing subject matter which was not described in the specification in such

Applicants: Wybe Martin Kast et al.
Serial No.: 08/170,344
Filed: March 30, 1994
Page 11

a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. As the Examiner's concedes on page 3 of the June 14, 1996 Office Action, the disclosure is enabled for the subject matter as provided in claim 25, i.e. "for nonapeptide sequences from E6 and E7 genes of HPV16 or HPV18, and MHC-I class molecules as specifically taught in the specification." Therefore, applicants understand the instant rejection to be to the pharmaceutical composition claims, i.e. claims 16-18.

In response, applicants respectfully traverse the Examiner's rejection. The test for enablement is whether one skilled in the art could, at the time of the invention, make and use the claimed invention based on the disclosure and the information known in the art without undue experimentation. Applicants maintain that the claimed invention satisfies the test for enablement, and that the Examiner has not set forth sufficient grounds for concluding otherwise.

The subject invention encompasses peptides comprising an amino acid sequence derived from protein of human papilloma virus (HPV), wherein the amino acid sequence comprises a nonapeptide derived from protein E6 or E7 of HPV or HPV 18 and wherein the nonapeptide has the ability to bind in the grooves on top of the human major histocompatibility complex (MHC) Class I molecule, as well as pharmaceutical compositions comprising this nonapeptide. This invention is based, at least in part, on applicants' discovery of exact HLA class I binding peptides of HPV16 and HPV18 with CTL inducing properties.

In support of the rejection, the Examiner states that the specification does not provide sufficient evidence of a method of prophylactic or therapeutic treatment of a human with cervical carcinoma or other HPV related diseases. The Examiner further alleges that although applicants have cancelled the rejected method claims, the pharmaceutical

Applicants: Wybe Martin Kast et al.
Serial No.: 08/170,344
Filed: March 30, 1994
Page 12

composition claims as written suggest the composition would be administered to a subject.

In response, but without conceding the correctness of the Examiner's rejection, applicants note that pharmaceutical composition claims 17 and 18 have been cancelled, thereby rendering the rejection to these claims moot. Applicants further note that the remaining pharmaceutical composition claim 16 has been amended to recite "an effective amount," rather than "prophylactically or therapeutically effective amount." Applicants maintain that peptides that bind to MHC-I are by definition capable of eliciting a cellular response when present. This is inherent in the workings of the immune system and well known to one skilled in the pertinent art. An immune response is automatically triggered upon presentation of a peptide by MHC-I. Accordingly, claim 16 as amended does not require a prophylactic or therapeutic effect, thereby obviating the Examiner's rejection.

The Examiner further states that the scope of claims reciting "a fragment, homolog, isoforms, derivative, genetic variant or conservative variant" is not supported by the specification as it does not disclose the general tolerance to and extent of modification, specific positions and regions of the sequence(s) which can be predictably modified, the critical regions and what variants can be made that retain the biological activity of the intact protein. In response, but without conceding the correctness of the Examiner's rejection, applicants note that claims 5, 6, 8, 10, 12 and 14 have been amended thereby obviating the Examiner's rejection.

Accordingly, applicants maintain that the specification coupled with the information known in the art clearly enables one skilled in the art to practice the claimed invention. In view of these remarks, applicants maintain that claims 2, 4-16 and 25 satisfy the

Applicants: Wybe Martin Kast et al.
Serial No.: 08/170,344
Filed: March 30, 1994
Page 13

requirements of 35 U.S.C. §112, first paragraph, and submit that the rejection can be withdrawn.

Rejection under 35 U.S.C. §112, second paragraph

The Examiner rejected claims 12 and 14 under 35 U.S.C. §112, second paragraph, as allegedly indefinite for failing to particularly point out and distinctly claim the subject matter which applicants regard as the invention. Specifically, the Examiner alleges that the claims are indefinite for being in improper Markush format.

In response, but without conceding the correctness of the Examiner's rejection, applicants note that claims 12 and 14 as amended recite the proper Markush format using the suggested phrase "selected from the group consisting of" and with the conjunction "and". Accordingly, applicants maintain that amended claims 12 and 14 particularly point out and distinctly claim the subject matter of the invention.

In view of these remarks, applicants maintain that claims 12 and 14 satisfy the requirements of 35 U.S.C. §112, second paragraph, and request that the rejection be withdrawn.

Rejection under 35 U.S.C. §102(b) and §103

The Examiner rejected claims 2, 4, 7-8, 11, 13, 15-18 and 25 under 35 U.S.C. §102(b) as allegedly anticipated by or under 35 U.S.C. §103 as allegedly obvious over Schoolnik. Specifically, the Examiner alleges that the peptides and compositions of the subject invention are disclosed in Schoolnik.

Applicants: Wybe Martin Kast et al.
Serial No.: 08/170,344
Filed: March 30, 1994
Page 14

Applicants respectfully traverse the Examiner's rejection, and respectfully disagree with the Examiner's interpretation of the teachings of Schoolnik. Schoolnik teaches HPV16 E6 and E7 peptides and HPV proteins which may be used to raise antibodies for diagnostic and therapeutic purposes. The subject invention, on the other hand, provides peptides comprising an amino acid sequence derived from protein of human papilloma virus (HPV), wherein the amino acid sequence comprises a nonapeptide derived from protein E6 or E7 of HPV or HPV 18, and wherein the nonapeptide has the ability to bind in the grooves on top of the human major histocompatibility complex (MHC) Class I molecule, as well as pharmaceutical compositions comprising this nonapeptide. These features are recited in the claims. As stated above, the basis for this invention is applicants' discovery of HLA class I binding peptides of HPV16 and HPV18 with CTL inducing properties. Schoolnik does not disclose peptides comprising the claimed sequences combined with the claimed features of the peptides. In addition, Schoolnik does not disclose peptides which bind to the MHC Class I molecule or that are cytotoxic to T lymphocyte epitopes. Schoolnik discloses peptides which would induce a B-cell response, not a CTL response. In fact, Schoolnik does not disclose any of the peptides claimed in the instant invention.

Moreover, as mentioned above, the subject invention provides for inducing an immune response through T-cell mediated immunity. No antibodies are contemplated in this invention, only peptides presented to MHC-I to elicit an immune response have been envisaged. Schoolnik merely discusses the raising of antibodies to viral proteins, but does not illicit an immune response. The antibodies raised would presumably be used as a therapy to HPV related diseases. The T-cell mediated response and the antibody response are separate and distinct types of immunity. Schoolnik does not address, contemplate or suggest the T-cell mediated immunity through the presentation of the claimed peptides by MHC-I to illicit an immune response as is claimed in the subject invention. Accordingly, applicants maintain that amended claims 2, 4, 7-8, 11, 13, 15-

Applicants: Wybe Martin Kast et al.

Serial No.: 08/170,344

Filed: March 30, 1994

Page 15

16 and 25 define an invention patentable over the cited reference, and submit that the cited reference fails to set forth either a case of anticipation or a prima facie case of obviousness. The reference therefore cannot be said to anticipate or render obvious the claimed invention. In view of these remarks, applicants maintain that claims 2, 4, 7, 8, 11, 13, 15, 16 and 25 are patentable over Schoolnik, and that the rejections under 35 U.S.C. §102(b) and §103 should be withdrawn.

Conclusion

For the reasons set forth herein, applicants respectfully request that the Examiner reconsider and withdraw the rejections, and earnestly solicit allowance of the pending claims.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: Wybe Martin Kast et al.
Serial No.: 08/170,344
Filed: March 30, 1994
Page 16

No fee is deemed necessary in connection with this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Robert D. Katz
Reg. No. 30,141

Date

Robert D. Katz, Esq.
Registration No. 30,141
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, NY 10036
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wybe Martin Kast et al.
Serial No. : 08/170,344 Examiner: N. Minnifield
Filed : March 30, 1994
For : PEPTIDES OF HUMAN PAPILLOMA VIRUS FOR USE IN HUMAN
T CELL RESPONSE INDUCING COMPOSITIONS

1185 Avenue of the Americas
New York, NY 10036

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Petitioner, Rijksuniversiteit Leiden, a state university organized and existing under the laws of the Netherlands, and engaged in business at Stationweg 46, 2312 AV Leiden, The Netherlands, the assignee of record of the entire right, title and interest in and to the above-identified application by virtue of an assignment from Wybe Martin Kast, Cornelis Joseph Maria Melief, Alessandro D. Sette and John C. Sidney, recorded with the United States Patent and Trademark Office on March 30, 1994 at reel 7001/frame0668, hereby disclaims the terminal portion of the statutory term of any patent granted on the subject application equivalent to the lesser of (a) the period of abandonment of the application, or (b) the period extending beyond twenty years from the date on which the application for the patent was filed in the United States or, if the application contains specific reference to an earlier filed application(s) under 35 U.S.C. §120, §121 or §365(c), from the date on which the earliest such application was filed. This disclaimer also applies to any patent granted on an application filed before June 8, 1995, that contains a specific reference under 35 U.S.C. §120, §121 or §365(c) to the

Applicants: Wybe Martin Kast et al.

Serial No.: 08/170,344

Filed: March 30, 1994

Page 2

above identified application. This disclaimer is binding upon the grantee, its successors or assigns.

I certify that I have reviewed the above-identified assignment and that, to the best of my knowledge and belief, Rijksuniversiteit Leiden has right, title and interest in and to the subject application. I further certify that I am authorized to sign this Terminal Disclaimer on behalf of Rijksuniversiteit Leiden.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Rijksuniversiteit Leiden

Date: _____

By: _____ (signature)

_____ (printed name)

~~SEED CAPITAL INVESTMENTS~~

ONTVANGEN

19 MEI 2004

AMERSFOORT

Vereenigde
T.a.v. de heer dr M.P.W. Einerhand
Snouckaertlaan 42
3811 MB AMERSFOORT

per fax: 033 422 7319
confirmation by post

S294.04d / Your ref. ME/P20884US00 / HPV-V US Patent Application No. 08/170,334
18 May 2004

Dear Mr. Einerhand,

We recently received your letter dated 29 April 2004, which included a proposal from Cooper & Dunham for reinstating the above application.

After consultation with our US partner we have come to the conclusion that the Petition to Withdraw the Holding of Abandonment in this case appears to be in order. Please request that Cooper & Dunham proceed. However, as mentioned on several previous occasions, please note that we that we are still waiting for a detailed explanation from Cooper & Dunham.

Please also be advised that SCI expects to be reimbursed for all expenses and any related costs (including damages) that have been incurred or will be incurred as a result of the abandonment of this application. We would also like to make it very clear that SCI will not pay or reimburse any expenses for the reinstatement of this US application to either Vereenigde or Cooper & Dunham. We kindly ask you to pass this message on to your US partner.

We would appreciate if you would keep us informed on all future developments.

Yours sincerely,
SEED CAPITAL INVESTMENTS (SCI) B.V.



W.J.M. de Vette
Director

P.O. Box 151
3720 AD Bilthoven
the Netherlands
Tel. +31 (0)30 299 5247

Prof. Bronckhorstlaan 25
3723 MB Bilthoven
the Netherlands
Fax. +31 (0)30 294 1828

Seed Capital Investments (SCI) B.V.
ABN-Amro Bank 45.40.13.785 KvK Utrecht 20091339
Seed Capital Investments-2 (SCI-2) B.V.
ABN-Amro Bank 45.25.88.869 KvK Utrecht 30128809

Exhibit N

VEREENIGDE

BY FACSIMILE: +1 212 391 0525
Cooper & Dunham
1185 Avenue of the Americas
New York, N.Y. 10036
USA

Nieuwe Parklaan 97

P.O. Box 87930
2508 DH Den Haag
The Netherlands

Telephone +31 70 416 67 11
Telefax +31 70 416 67 99

e-mail patent@verenigde.nl
trademark@verenigde.nl
legal@verenigde.nl

www.verenigde.com

Your ref. 45113
Our ref. ME/P20884US00

Den Haag,
June 1, 2004

Re: U.S. patent application No. 08/170,344
in the name of Rijksuniversiteit Leiden

Dear dr. Katz,

The client has approved the draft petition to revive that you provided for their review. Please go forward and file the petition. The signing of the terminal disclaimer by the University will take some time. We will forward you the signed disclaimer upon receipt thereof by us. As discussed on the phone, you will file the petition with an unsigned disclaimer, together with a letter explaining that we will file the signed disclaimer as soon as we have the signatures.

On a different note, the client has requested that we forward a letter to you. The letter, of which a copy is herein enclosed, is self-explanatory.

Sincerely,
VEREENIGDE

M. Einerhand

ne

European and Dutch patent attorneys

* Dutch patent attorney

** European patent attorney and CPA (UK)

J.H.F. Winckels
C.J.J. van Loon
F.A. Diers
M.J. Hartmann
C.M. Janßen
A.H.K. Tan
J. Rentes
H.A. Wibmans
H.A.M. Mareman

L.J.J. Jansen
R.M.L. Bijvank
B.Ch. Ledebor
L.J. de Haas
L.A.C.M. van Wezenbeek
A.P. van Wijk
O.L. Oudshoorn
K. Thielwoll**

M.P.W. Einerhand
J.G.C. van Melle
M. van Rooij
F.N. Ferro*
J. de Vries*
F.M. van Bouwelen*
S.T. van Doorn*
M.C. Molting*
L.J. van Orselen-Plooster *

European and Benelux
trademark attorneys

A.A.M. Ruijs-Kouwenaar

L.P. Kindt
P.A. van der Wem
N.L. Wolfs
M. Driessen
M.J.A. Haegens
M.H. Kamp

Attorneys-at-Law

H. Mars
N.J. Oostenbroek

A.H. de Haach Kemper
de Hilster
M.A. van den Hazenkamp

Of counsel
A.W. Prins



LEIDS UNIVERSITAIR MEDISCH CENTRUM

ONTVANGEN

30 JUN 2004

AMERSFOORT

afdeling Raad van Bestuur
pos:zone H-01-Q
Mw. Y. Bleeksma

aan Verenigde
T.a.v. de heer M. Einerhand
adres Snouckaertlaan 42
3811 MB Amersfoort

telefoon 071 526 2704 fax 071 524 8125
e-mail y.bleeksma@lumc.nl
onze referentie 42164/
uw referentie ME/P20884US00

datum 29 juni 2004
onderwerp Terminal disclaimer inz. octrooiaanvraag

Geachte heer Einerhand,

Bijgaand ontvangt u een getekend exemplaar van de Terminal Disclaimer inz. octrooiaanvraag in de VS nr. 08/170,344 'HPV-V' retour.

Met vriendelijke groet,


Mw. Y. Bleeksma
managementassistente

Bijlage(n): Getekend exemplaar Terminal Disclaimer



Dkt. 45113/RDK/AG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wybe Martin Kast et al.
Serial No. : 08/170,344 Examiner: N. Minnifield
Filed : March 30, 1994
For : PEPTIDES OF HUMAN PAPILLOMA VIRUS FOR USE IN HUMAN
T CELL RESPONSE INDUCING COMPOSITIONS

1185 Avenue of the Americas
New York, NY 10036

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Petitioner, Rijksuniversiteit Leiden, a state university organized and existing under the laws of the Netherlands, and engaged in business at Stationweg 46, 2312 AV Leiden, The Netherlands, the assignee of record of the entire right, title and interest in and to the above-identified application by virtue of an assignment from Wybe Martin Kast, Cornelis Joseph Maria Melief, Alessandro D. Sette and John C. Sidney, recorded with the United States Patent and Trademark Office on March 30, 1994 at reel 7001/frame0868, hereby disclaims the terminal portion of the statutory term of any patent granted on the subject application equivalent to the lesser of (a) the period of abandonment of the application, or (b) the period extending beyond twenty years from the date on which the application for the patent was filed in the United States or, if the application contains specific reference to an earlier filed application(s) under 35 U.S.C. §120, §121 or §365(c), from the date on which the earliest such application was filed. This disclaimer also applies to any patent granted on an application filed before June 8, 1995, that contains a specific reference under 35 U.S.C. §120, §121 or §365(c) to the



VEREENIGDE

BY FACSIMILE: +1 212 391 0525
Cooper & Dunham
1185 Avenue of the Americas
New York, N.Y. 10036
USA

Nieuwe Parklaan 97

P.O. Box 87930
2508 DH Den Haag
The Netherlands

Telephone +31 70 416 67 11
Telefax +31 70 416 67 99

e-mail patent@vereenigde.nl
trademark@vereenigde.nl
legal@vereenigde.nl

www.vereenigde.com

Attn. Mr. Robert D. Katz

Your ref. 45113
Our ref. ME/P20884US00

Den Haag,
July 1, 2004

Re: U.S. patent application No. 08/170,344
in the name of Rijksuniversiteit Leiden

Dear Mr. Katz,

Thank you for your facsimile of June 23, 2004 in the matter of the above-identified patent application.

Please find enclosed the signed terminal disclaimer.

Should you have any questions or need additional information, please do not hesitate to contact me.

Very truly yours,
VEREENIGDE

M. Einerhand

Encl.: as mentioned

ne

European and Dutch patent attorneys

** Dutch patent attorney*

*** European patent attorney and CPA (UK)*

J.H.F. Winkels
C.J.J. van Loon
P.A. Dietz
M.J. Hatzmann
C.M. Jansen
A.H.K. Tap
J. Reben
H.A. Wisman
H.A.M. Maxman

L.J.J. Jensen
K.M.L. Bijvank
B.Ch. Ledebur

L.J. de Haas
L.A.C.M. van Wezenbeek
A.P. van Wijk
O.L. Oudshoorn
K. Thielwell**

M.P.W. Eiberhand
J.C.C. van Melle
M. van Rooij
F.N. Ferro*
J. de Vries*
F.M. van Boven*
S.T. van Doorn*
M.C. Molliet*
I.J. van Grunke-Plooster*

*European and Benelux
trademark attorneys*

A.A.M. Reijns-Kouwenaar

L.P. Kindt
P.A. van der Ween
N.L. Wolfs
M.J.A. Haegens
M.H. Kamp

Attorneys-at-Law

H. Mars
N.J. Oostenbroek

A.J. de Bouch Kamper-
de Hilster
M.A. van den Hazenkamp

Of counsel
A.W. Prins

Exhibit Q

Dkt. 45113/RDK/AG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wybe Martin Kast et al.
Serial No. : 08/170,344 Examiner: N. Minnifield
Filed : March 30, 1994
For : PEPTIDES OF HUMAN PAPILLOMA VIRUS FOR USE IN HUMAN
T CELL RESPONSE INDUCING COMPOSITIONS

1185 Avenue of the Americas
New York, NY 10036

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Petitioner, Rijksuniversiteit Leiden, a state university organized and existing under the laws of the Netherlands, and engaged in business at Stationweg 46, 2312 AV Leiden, The Netherlands, the assignee of record of the entire right, title and interest in and to the above-identified application by virtue of an assignment from Wybe Martin Kast, Cornelis Joseph Maria Melief, Alessandro D. Sette and John C. Sidney, recorded with the United States Patent and Trademark Office on March 30, 1994 at reel 7001/frame0868, hereby disclaims the terminal portion of the statutory term of any patent granted on the subject application equivalent to the lesser of (a) the period of abandonment of the application, or (b) the period extending beyond twenty years from the date on which the application for the patent was filed in the United States or, if the application contains specific reference to an earlier filed application(s) under 35 U.S.C. §120, §121 or §365(c), from the date on which the earliest such application was filed. This disclaimer also applies to any patent granted on an application filed before June 8, 1995, that contains a specific reference under 35 U.S.C. §120, §121 or §365(c) to the

Applicants: Wybe Martin Kast et al.

Serial No.: 08/170,344

Filed: March 30, 1994

Page 2

above identified application. This disclaimer is binding upon the grantee, its successors or assigns.

I certify that I have reviewed the above-identified assignment and that, to the best of my knowledge and belief, Rijksuniversiteit Leiden has right, title and interest in and to the subject application. I further certify that I am authorized to sign this Terminal Disclaimer on behalf of Rijksuniversiteit Leiden.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Rijksuniversiteit Leiden

Date: 16/12/2024

By: [Signature] (signature)
HJ WELCHER. (printed name)

[illegible]

EXHIBIT 1

Overview of details regarding the status overview of family EP Pat. No.
0 593 754 / PCT/NL98/00093 in the name of
Rijksuniversiteit Leiden, as of August 17, 2004

Family : inventor(s)	Owner (Licensee)	Countries	Application /patent No.	Filing Date (Priority Date)	Status Grant Date
HPV-V :Kast, Wybe Martin Melief, Cornelia Joseph Maria Sette, Alessandro D. Sidney, John C.	Rijks- universiteit Leiden	AU	675794	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	30-12-1996
		CA	2,112,798	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	Pending
		IL	105554	29-04-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	18-11-1999
		JP	5-519145	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	Pending
		MX	213898	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	25-04-2003
		NZ	253330	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	09-10-1996
		US	08/170,344	04-05-1193 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	abandoned, re- instatement initiated
		ZA	93/3135	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	29-04-1994

		ATEP	E207495	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	24-10-2001
		BEEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	24-10-2001
		CHEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		DEEP	69330988.1	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		DKEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		EPOO	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		ESEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		FREP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		GBEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		GREP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001

		IEEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		ITEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		LUEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		MCEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		NLEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		PTEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001
		SEEP	0593754	04-05-1993 (05-05-1992) (10-12-1992) (01-02-1993) (05-03-1993)	12-10-2001

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.